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Abstract 
Polypeptide Nucleic Acids, PNAs, are analogues of DNA and have the potential to bind to 
DNA by base-pairing and hence act as therapeutic agents. Amino acids carrying 
heterocycles in their side-chains are valid targets as natural products and as components of 
these potential therapeutic agents (PNAs) for use in living organisms. The aim of this 
investigation was to synthesise a range of heterocyclic amino acids, that could be used in 
the formation of PNAs. The proteinogenic amino acids, serine and cysteine and the 
unnatural amino acids, homocysteine, 2,3-diaminopropionic acid and 2,4-diaminobutyric 
acid, have been used in the formation of said heterocyclic amino acids via a C-X bond 
(where X=C, S, 0 or N) in a linker chain. 
It was decided to approach the synthesis of heterocyclic amino acids by way of a linker 
approach, joining the ready-formed heterocycJe with an amino acid. Once the amino acids 
had been suitably protected several different methods were attempted in order to form 
heterocyclic amino acids. To form a carbon-carbon (X=C) bond in the Iinker chain, radical 
and organocuprate conjugate addition reactions and hydroboration and metathesis coupling 
were attempted. The formation of a linker containing a carbon-heteroatom bond (X=S, 0 
or N) was investigated using a substitution approach. 
Where X=C, radical and organocuprate conjugate addition onto a methylene oxazolidinone 
amino acid template with N-(w-haloalkyl) heterocycle derivatives (prepared by Mitsunobu 
coupling or phase transfer catalysis) produced none of the desired products. There was 
evidence of reduced product indicating that radicals had been formed, and evidence also of 
Iithiumlhalogen exchange, leading to a number of undesired side reactions. The 
hydroboration and metathesis coupling reactions, again using a methylene oxazolidinone 
amino acid template, this time with N-vinyl heterocycle derivatives, also proved fruitless, 
possibly be due to steric factors. 
Far greater success was had with formation of C-X bonds by substitution where X=S, 0 or 
N. The substitution reactions involved heteroatoms on the amino acids side chains reacting 
with N-(haloalkyl) heterocycJe derivatives. Yields of the reactions involving cysteine were 
over 60% in many of the cases and new heterocycJic amino acids were prepared by this 
method. 
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1. Introduction 
1.1 Aim of Research 
Amino acids carrying heterocycIes in their side-chains are valid synthetic targets as natural 
products and as components of potential therapeutic agents for use in living organisms. 
Heterocyclic amino acids, as in Figure 1.1, can also be used in the formation of the 
prospective therapeutic agents Polypeptide Nucleic Acids, PNAs, hence how these amino 
acids are made is of great importance. The aim of the investigation reported in this thesis 
was to synthesise a range ofheterocyclic amino acids, which could be used in the formation 
ofPNAs. 
( )n 
~O 
H N OH 
2 
Figure 1.1 Heterocyclic Amino Acid (X=heteroatom or Carbon) 
1.2 Amino Acids 
As the name suggests an amino acid possesses both a carboxyl and an amino group 
attached to the same carbon atom. O!-Amino acids have the general formula, 
RCH(NH1)COOH, where R=H or an organic group possibly containing a heteroatom.1 It is 
I 
the R group that determines the properties of the amino acid2 and hence what makes them 
potential therapeutic agents. For this investigation onlya-amino acids have been used and 
the configuration of theO!amino acids (L or D) can play an important role in the formation 
of a potential therapeutic agent. l In proteins, the amino acids have the L-configuration, 
corresponding to (S) in all but cysteine. 
If the R group contains a heterocycle, any heterocycle could be used to form a synthetic 
amino acid, but in nature there are only two heterocycles found in proteinogenic amino 
acids (imidazole in histidine and indole in tryptophan). Amongst non-proteinogenic amino 
acids particular (but not exclusive) interest is in the five main heterocycles found in nucleic 
acids, and their incorporation into amino acids. 
1.3 Nucleic Acids 
A nucleic acid is an organic compound found in all living cells that consists of a chain of 
nucleotides, which are themselves made of a purine or pyrimidine base linked to a 
phosphorylated ribose sugar.3 These bases are shown in Figure 1.2. 
NH2 0 
,5 0 0 (iN~ H'~N H, :J H,y N I ~ 
oJ...-N I 
N I N I 
HNAN N oJ...-N oAN N ~ 2 I I I I 
H H H H H 
Adenine Guanine Cytosine Uracil Thymine 
Figure 1.2 The Five Naturally Occurring Nucleobases 
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Nucleic Acids as Therapeutic Agents 
3' -Deoxy-2',3' -didehydrothymidine is a well lmown and promising candidate for AIDS 
chemotherapy and further investigations into 2',3' -didehehydro-2',3' -dideoxynucleosides 
has led to further research involving other nucleobases.4 The 3'-deoxy-2',3'-
didehydrothymidine and precursor to other 2',3'-didehydro-2',3'-dideoxynucleosides are 
shown in Figure 1.3. There are several other nucleosides and nucleoside analogues which 
have potential for use as therapeutic agents. 
Figure 1.3 
o 
I NH 
R1 R2 
R3=protecting group 
R2 = Bror H 
R1 = Bror H 
3' -deoxy-2' ,3' -didehydrothymidine and 
2' - or 3' -bromo-3' -deoxy-2',3' -didehydrouridine 
1.4 Heterocyclic Amino Acids as Natural Products 
One reason heterocyclic amino acids are of interest is because of the number of them in 
natural products. The earliest of these isolated by Gmelin: N-thyminyl-L-alanine from a 
type of rose and called willardiine after the rose.5 These naturally occurring heterocyclic 
amino acids have been successfully synthesised with yields up to 78%.6 
3 
Another couple of more recent heterocyclic examples are given below: 
Baldwin et al. have investigated a number of non-proteinogenic a-amino acids based 
around the a-amino acid L-lathyrine (Figure 1.4).7 
Figure 1.4 L-Lathyrine and other a-Amino Acids Based on this System 
Young et al. have also investigated the use of pyroglutamic acid derivatives (Figure 1.5) as 
possibilities in the treatment of illnesses such as Alzheimers, epilepsy and ischaemia.8 
H H 
ctt~ C02tBu N, NHBoc N 0 
I 
H 
Figure 1.5 Pyrazine/Glutamic Acid Derivative 
Further examples ofheterocyclic amino acids are given later in this chapter. 
4 
Sialyl Oligosaccharides. 
HO 
HO 
Figure 1.6 CMP-sialic acid 
Although not a heterocyclic amino acid this shows heterocycIes attached to a system that is 
similar to those PNAs are designed to mimic. Cytidine 5' -monophosphate-sialic acid 
(CMP-sialic acid) (Figure 1.6) links to the ends of glycoconjugates to form sialyl 
oligonucIeotides which play an important role in cell differentiation, immune responses to 
bacterial and viral infections and other cell recognition events.9 The inhibitors of 
sialyltransferases, that transfer sialic acid from CMP-sialic acid to galactose or other 
residues of oligosaccharides, would be excellent candidates as anti-inflammatory agents, 
anti-metasastic agents and agents for therapy of auto-immune diseases (Figure 1.7). 
HO 
Figure 1.7 Mimetics of sialic acid 
5 
It has also been noted that, in the area of therapeutics, protein backbones have been 
modified like that of ketoamides lO -NH-CO-CO- and in PNA research as described in 
greater detail later. 
Pyrrole-Imidazole Polyamides - Distamycin 
An example of where heterocyc1es have been used within the backbone similar to that of 
PNA is Distamycin, a natural product that contains three N-methylpyrrole amino acids and 
binds in the minor groove of DNA. This natural compound inhibits DNA-dependent 
processes but is of limited use because of its toxicity. I Distamycin analogues have 
therefore been of great interest as therapeutic agents. The base distamycin molecule is 
shown in Figure 1.8 and some of the variations shown in Figure 1.9. 
o \ 
o~ H ~ \~ "~~N~~O J
HN~NH 0 
I ~y 
NH2 H 
Figure 1.8 Distamycin 
I 0 (,N~ 
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Pyrrole Imidazole 
I 0 (,N~ 
: J-!< : 
:~ OH 
Hydroxypyrrole 
Figure 1.9 Distamycin and its Derivatives 
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1.5 Peptides and Peptide Bonds 
The bond between an et-amino nitrogen and et-carboxyl carbon atom is known as a peptide 
bond and is formed with the loss of water (Figure 1.10). The linking of several amino acids 
by such peptide bonds produces a (poly)peptide; long polypeptide chains are known as 
proteins, and may function as enzymes. 
1 ,OH 
H2N' If 
o ! -H20 
H 
N 
R 
o 
OH 
Figure 1.10 Peptide or Polypeptide 
A large number of smaIIer peptides that occur naturaIIy are thought to be the by-products of 
enzymatic reactions on proteins by tissue autolysis, bacterial action and digestive 
processes. lI Other naturaIIy occurring peptides have a clearer physiological role as 
coenzymes, hormones or antibiotics. 
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1.5.1 Polypeptide Nucleic Acid 
It becomes obvious why heterocyclic amino acids are of such interest when PNA and DNA 
are compared as in Figure 1.11. 
o~=) 
B~ > 
PNATypeI NH 
(Polypeptide/amide o=<' 
nucleic acid) 0 > 
B->-> 
/NH 
Figure 1.11 Comparison of DNA and PNA 
/ 
HN B~O 
alpha-PNA 0::> 
B~O 
O==) 
DNA consists of a chain of ribose sugars with negatively charged phosphates and either 
purine or pyrimidine bases as side-chains. Amino acid derived chains with nucleic acid 
bases in their side-chains are monomers for the man-made analogous chain PNA with one 
major difference between this chain and the DNA chain, PNA contains an electrically 
neutral backbone where the phosphodiester backbone has been replaced by a polyamide or 
peptide backbone. 
The first PNA macromolecules that were investigated over 40 years ago comprised of 
glycine and 1,2-diaminoethane with N-acyl side chains.12.13.14 Since then, PNA 
investigation has been split into two main categories; Type I and Type II. 15 
8 
PNA type I consists ofN-(aminoalkyl)amino acid units with the nuc1eobases attached to the 
nitrogen in the backbone, the first of these, the N-(aminoethyl)glycine backbone, is shown 
in Figure 1.11; PNA type II consists of amino acid residues carrying the nuc1eobase in their 
side chain, again shown in Figure 1.11 as ex-PNA, these amino acid residues can be 
interspersed with simple amino acids (e.g. glycine (illustrated) or valine) to give the correct 
length between each nuc1eobase or pseudonucleobase for bonding to DNA or RNA. IS 
PNAs containing heterocyc1es that are not naturally occurring have also been investigated 
previously, for example, adenine has been replace by 2,6-diaminopurine and this has been 
shown to enhance the PNAs tendency to hybridise, possibly due to its stronger pairing with 
thymine through three hydrogen bonds. ls 
PNAs are analogues of DNA and have the potential to bind to DNA by base-pairing (Figure 
1.12). 
A·:::·· T ~ ~'Gl 
C"'~ ~. 
_",C rt 
G":-··· ........ ~ 
• .-:. A )-0' 
T'- .A~ 
Protein pNA DNA 
Figure 1.12 PNA-DNA base pairing (ref: Pseudo-Peptides in Drug Discovery, Ed. P.E. 
Nielsen, Wiley-VCH, (2004) 154) 
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They form a novel class of therapeutic agents as nucleic acids store and copy information 
within a living organism therefore information can be transferred to DNA using the 
synthetic nucleic acid chain, PNA.16•17 In essence heterocyclic amino acids can induce 
biological activity when incorporated into peptides or peptide like structures. 
1.5.2 DNA 
DNA is usually found in the body in the form ofa double helix (Figure 1.13). 
Figure 1.13 The Double helix formation of DNA. (ref: KJ.McConnell, D.L.Beveridge, 
DNA structure: What's in Charge?, J. Mol. BioI, (2000) 304, 803). 
Two factors play a part in this "dimer" formation. One is regioselectivity, which manifests 
itself in DNA as shape complementarity; the two strands of DNA can come together like 
puzzle pieces: when the sequencing is not right then it will be very unlikely that the two 
10 
strands in question will fit together. The other is that of hydrogen bonding, which in the 
case of DNA, is specific between pairs of bases and these are known as Watson-Crick base 
pairs (Figure 1.14). 
Cytosine-Guanine Thymine-Adenine 
Figure 1.14 Watson-Crick base pairing 
The insertion of molecules into the DNA system to disrupt the DNA sequence and to insert 
another molecule to either gather information from the DNA strand, or containing different 
information in a therapeutic manner, can be investigated with the use of PNA, which can 
contain both the spatial and polar properties necessary to form a PNAlDNA duplex. 
PNA-DNA recognition again takes place by Watson-Crick base pairing18 and it seems the 
DNA-PNA is more thermally stable than that of DNA-DNA and the rate of hybridisation is 
at least as fast as that of DNA-DNA duplex formation, possibly faster due to the lack of 
electrostatic repulsion between PNA and DNA. It is also possible that introduction of 
positive charges in PNA may improve the stability. In one study,! 9 the -0-(P02-)-0-
linkers of DNA are replaced by -NH-C(=NH2l-NH- or -NH-C(=S+CH3)-NH-linkers in the 
PNA backbone. These Iinkers have shown increased hybridisation association rates, 
suggesting potential utility in diagnostics, biomolecular probes and antisense/antigene 
therapeutics. 
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To assist in the binding, specificity and uptake into cells, the insertion of stereogenic 
centres has been suggested.2o The investigation into this has shown that the introduction of 
chiral centres into the PNA backbone does not alter the tendency of PNA and duplexes to 
form P-helixes but can limit the ability of PNA to form other conformations and increases 
the recognition selectivity?O The structure of a standard PNA-DNA duplex is that of a P-
helix, this has the same specificity and selectivity as a DNA-DNA duplex but not exactly 
the same shape. 
Incorporation of chirality or placing conformational constraints into PNA may also be 
important in discrimination ofPNA-DNA bonding.19 The base has often been appended to 
nitrogen in the chain (Figure 1.11), giving it no chirality, so that a way of introducing 
chirality is by linking the base to a carbon atom in the PNA backbone. It has been shown 
that the chiral PNA, oxy-peptide nucleic acid (OPNA) (Figure 1.15), does bind to 
complementary DNA and PNA strands21 and it was noted once again that the hybridisation 
with DNA was greater than that with PNA and was demonstrated by strand replacement of 
PNA-OPNA to DNA-OPNA. 
Figure 1.15 Chirality in PNA (In this case OPNA) 
With OPNA chirality has been introduced, and this is the same for Qi-PNAs as shown in 
Figure 1.11. It is necessary for this chirality to be present and hence the amino acids that 
are to be used in this investigation will also impart chirality into the molecule. The 
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a-aminooxy acids are considered as {'l-peptide mimics, and can be built up into OPNA's and 
can be made from a-amino acids. 
The molecular mechanism for binding-induced gene expression of PNA will have 
implications for the gene therapy in humans. Abnormal gene expression has been linked to 
many age related diseases and others such as cancer, several drugs have been developed to 
induce gene expression, but none so far have induced specific genes.22 
1.6 Applications of PNA 
In living organisms and the environment there are a number of natural products containing 
amino acids: an example of their use by a living organism is that of mediation by amino 
acids of synaptic excitation. The use of PNAs in living organisms has also been in gene 
therapeutics23 as an agent for antisense and antigene applications in cell culture24.2S,26 due to 
their high chemical and biological stability. 
Peptides are able to adopt well defined and controlled secondary structures which can in 
theory be used as scaffolds to place and orientate pharmacophores and create new 
molecules with interesting biological activities, hence the interest in building helical 
compounds with PNA. 
Although 'naked' PNAs have been shown to down-regulate receptor activities upon 
injection of the PNAs into the brains of rats and hence into nerve cells,24 the main problem 
in these cases is the inefficient uptake of PNA into cells, which is combated in a number of 
ways as explained later. From studies with mice24 it has been shown that PNA has been 
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able to reach the target DNA within the cell and it is possible that targeting the nucleus of a 
cell with PNA is not as compromised as suggested by in vitro experiments, and so PNA 
investigation is worthwhile. 
Human Telomerase 
The inhibition of human telomerase activity is another example involving PNA, in which 
PNA is targeted to the RNA component of the enzyme?7 Telomeres are guanine-rich 
regions of DNA located at the ends of eukaryotic chromosomes and are essential for 
preserving the stability of the genome and cell viability by preventing aberrant 
recombination and degradation of DNA. These te\omeres, which have a telomeric 
sequence in human DNA of (TTAGGG)n, are maintained by telomerase, an RNA 
dependent DNA polymerase. In healthy tissue these regions show little or no activity and 
the interest in them is because telomerase activity has been detected in tumour biopsies. 
Although the RNA telomerase region has been shown as a target for inhibition by antisense 
oligonucleotides, PNA was found to be a more effective antisense inhibitor of telomerase 
and the inhibition of human te\omerase activity has been demonstrated using specific PNA 
recognition. The studies have shown that it is possible to enhance the inhibitory properties 
of relatively short PNAs by the use of a peptide fragment and the use of a cationic peptide 
has probably contributed to inhibition by increasing the stability of the complexes formed 
between PNA and the RNA region. 
14 
HIV Protein Inhibition 
HIV is unfortunately a well known and widespread virus which has seen a large amount of 
investigation over the years.l One method for the treatment for people suffering from HIV 
could involve the use of PNAs. The disruption of the HIV -1 virus replication has been 
investigated by the use of a macromolecule, which incorporates a PNA-type backbone as 
shown in Figure 1.16. The molecule works by blocking the interaction of the HIV-l 
protein with RNA. The tests have proven that this will work at nanomolecular 
concentrations and the problem of cell delivery has been broached by the use of a partly 
naturally occurring compound. 
Figure 1.16 Macromolecule Inhibitor to HlV-l virus 
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Gene Inhibition and Activation 
Gene expression can be activated or inhibited by the presence of PNA. PNA binds to a 
wide range of DNA sites with high affinity and will competitively displace DNA from its 
double helix. In this way it is potentially useful in the treatment of cancer as shown by 
cultured and in vivo studies of cancerous kidney cells.zs Polyamides can also be used with 
RNA and target viral genes normally transcribed by RNA polymerase. This has been 
shown in human blood lymphocytes where treatment with two polyamides in combination 
. inhibited viral replication by 99%. 
The human T-cell leukaemia virus has also been studied and the promoter of the virus 
inhibited. The polyamide is targeted to a sequence that is also recognised by bacterial 
gyrase and hence this inhibited the gyrase catalysed cleavage of the DNA. 
PNA investigation 
PNA can also be used in an investigative way. An investigation of the substrate specificity 
of helicases29 involved PNAs being 'sent in' to substitute for one strand of DNA to see if 
specific enzymelDNA interactions were necessary for the unraveIling of the DNA helix. 
The chemical, biological and genetic properties of DNA are obviously important for the 
development of new PNAs. It has been noticed that the structure of PNA-DNA 
intermediates is via Watson-Crick base pairing as shown by the parameters for PNAlDNA-
PNA triplexes.3o One method for the investigation of gene sequencing is by the invasion of 
16 
a DNA strand by PNA as a tool in genetic diagnostics.31 Genome sequencing has revealed 
the identities of many genes that encode proteins whose functions are unknown?5 
Oligonucleotide mimics and PNAs are used as synthetic tools to inhibit gene expression at 
these sites. 25,32 The advantage of PNAs is that their uncharged neutral backbone does not 
inhibit their hybridisation as there is no interstrand electrostatic repulsion, which means 
there can be high affinity between PNA and either DNA or RNA. 
1.6.1 Mechanism and Methods for PNA Invasion 
When a PNA molecule replaces one of the DNA strands in double stranded DNA it does so 
by strand invasion with the displaced DNA strand forming a D-Ioop structure at the PNA 
binding site?2 This D-Ioop is comparable in size to the length of PNA that has invaded 
(Figure 1.17). 
D-loop 
PNA 
DNA 
Figure 1.17 D-Ioop formation 
Alternatively two PNAs insert into DNA and both sides of the double stranded DNA can 
become bound (Figure 1.18). 
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DNA double duplex 
_~(i 111111111i"\,-__ /_ 
I I I I I I 
\.!I 
I I I I I I _ Base pair bonding 
IIIIIII~ 
pcPNA strands 
Figure 1.18 Invasion ofPNA into DNA double duplex 
For the invasion of the PNA molecule, experiments have shown that the molecule needs to 
be at least a l2mer in length and for sequence-specific binding they need to be longer, at 
least a l4mer?2 
Cellular Delivery 
The cellular delivery of PNAs into cells is an important factor, if they cannot be put into 
cells for therapeutic use then they cannot be of value as antisense or antigene agents. It is 
the pseudopeptide backbone of PNA that makes it stable in biological fluids, as it is not 
degraded by nucleases or peptidases (or other cellular enzymes) and gives PNA-DNA 
duplexes their thermal stability.)) The uptake of a drug containing PNA may be limited by 
biological barriers, since they are polar molecules which diffuse poorly though the lipid 
bilayer of cells.· 
It is also the backbone that makes it difficult to get PNA into the nucleus of a cell. This is 
due to the high salt concentration and pH dependency of PNA as demonstrated in several 
investigations where formation of the PNA-DNA duplex has been slow.)) 
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Despite this PNA has been heavily investigated as it improves hybridisation characteristics 
of DNA and RNA. Initial studies into PNA were in cell-free environments and showed 
promising inhibition of transcriptional and translational processes. The investigation into 
the potential of PNA as a gene therapeutic has however been hampered by its poor uptake 
into cells, the problem being that PNA is a large hydrophilic molecule that does not cross 
lipid membranes easily. A variety of cellular delivery systems have been developed to aid 
in the investigation and use of PNAs within a cellular system. 
Unmodified PNAs can be delivered into a cell by a number of methods,33 the first and 
simplest chemical method to perform is that of microinjection. The PNA in injected 
directly into the cell nucleus and although this is an excellent tool for assessing the validity 
of PNA as an anti sense agent, it is a laborious technique that can only be applied to small-
scale experimental set-ups. 
Electroporation is a more feasible method for the transfer of PNA, which has shown good 
results in the inhibition of telomerase. 
19 
PNAlDNAfLipid 
PNA 
Plasmid 
Figure 1.19 Introduction ofPNA into cells. 
Inhibitor 
Activity 
Co-transfection with DNA allows the PNA to transfect the cell as it is hybridised to 
partially complementary DNA in the presence of cationic lipids (Figure 1.19) and this 
method has produced some promising results.26 It is also possible to permeabilise the cell 
by the use of streptolycin-O to make the cell permeable to PNA. Another, possibly toxic, 
method is to use very high concentrations of PNA which encourages a limited uptake, this 
has shown promising results but the advantages of this method are probably outweighed by 
the disadvantages. 
PNA can also be modified chemically by some kind of conjugation technique.33 The 
conjugation of PNA to a lipophilic moiety, adamantyl-acetic acid or triphenylphosphonium 
ion, was done to promote PNA transfection by the use of cationic Iiposomes. This method 
has produced varying results and is unreliable since it is not possible to predict which type 
of cells the conjugate will be able to enter. Another method of conjugation has been used 
to some effect and it is that of conjugation to peptides. These so-called 'Trojan' peptides 
are a class of largely amphiphilic cationic/hydrophobic peptides that have been reported to 
have the ability to transport molecules across the cells membrane and show great potential 
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in the development of PNA-based antibiotics. Conjugation of PNAs to ceIl-specific 
receptor ligands has less potential and where PNA did target the desired ceIls there was 
little or no effect of PNA as in some cases the PNA was exclusively found in the vesicular 
compartments and not in the nucleus. Cationic ,6-peptides derived from HIV -I proteins 
have been reported to permeate through the ceIl membrane and to mediate the transport of 
peptides, 'proteins and oligo-DNAs into target ceIls.1 Arginine-rich amino acid residues 
have also undergone ceIlular uptake, and these arginine-rich compounds can be used to 
carry therapeutic agents with them with some flexibility in terms of side chain composition. 
Also PNAlDNA chimeras have been shown to form more stable duplexes with DNA, 
possibly due to lack of electrostatic repulsion, and have helped to combat difficulty with 
strand invasion.30.31.34 
An investigation involving the testing of 18 antisense PNAs with a number of target genes 
and at a number of positions has shown that only one PNA in only one site on the DNA 
chain is necessary to cause an effect; an example of this is that of the significant inhibition 
of luciferase activity by one PNA at the extreme 5' -end of DNA, which blocked 80% of 
activity when delivered to cells as a PNA-DNA-Lipid complex. This luciferase 
investigation has also shown that if the DNA-PNA duplex is too stable for the PNA to be 
released when inside the ceIl or if the DNA-PNA duplex is too weak for the PNA to make it 
inside the ceIl. then inhibition or activity cannot occur. 
Some other examples of problems and targets, possibly treatable by PNA, and how it has 
been delivered into the cell are: 
Human Prostate Cancer / Telomerase - 15mer PNA - Cationic Liposomes; 
Lymphoma / RNA - 15mer PNA - Electroporation; 
E. Coli / Ribosomal RNA - 1 0-15mer PNA - Direct Delivery. 
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PNAlDNA stability 
The helical structures of DNA and PNA are very similar, as shown in Figure 1.20, below: 
a h c 
Figure 1.20 Comparison of DNA and PNA Duplexes Pseudo Peptides (ref: S. Sen, L. 
Nilsson, J. Am. Chem. Soc., (1998) 120,619-631) 
The stability of PNA-DNA duplexes may rely on the strength of the interresidue hydrogen 
bonding35 within the PNA units as these stabilise the helical PNA strand when in this 
conformation (Figure 1.21), but this has been disputed by other investigators.3o This is a 
perfect example of how PNA still requires a large amount of investigation. 
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Figure 1.21 H-bonding in PNA 
It has been noted that DNA-PNA and RNA-PNA duplexes are thennally more stable than 
their DNNRNA-DNAlRNA counterparts. Due to the flexibility ofPNA it is more able to 
confonnationally adapt to the more rigid DNA or RNA.24 It is this lack of confonnational 
and configurational restraints that has led to the postulation that the binding occurs in an 
orientation dependent manner and PNA can bind to DNA from both the 3' and 5' ends of 
theDNA.32 
One variation in the PNA backbone that has been tried is that of placing a methyl group on 
the nitrogen in order to test the structure-activity relationships. With the methyl group on 
the second nitrogen there is no possibility of intraresidue hydrogen bonding and this 
changes the hydrophilicity and hydration properties. It was demonstrated that PNA 
duplexes can accommodate up to -30% ofN-methyl substitutions in the backbone without 
a major loss in stability.36 
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Conformational heterogeneity between chains can arise due to alternative conformations 
possessing similar energies. This is where constraints on the backbone become necessary 
to form homogeneity between conformations. 
PNA Structure 
PNAs have been looked at in a number of different variations to try to solve the problems 
of solubility and ambiguity, mainly involving a different range of molecules in the 
backbone chain of the PNA. Investigations by a number of groupS32.37.38.39 have shown that 
PNAlDNA binding can be enhanced or controlled by: 
1) Inserting some kind of fixed chirality into the molecule. The chirality of the chain is 
dependent on the configuration of the stereogenic centre on the amino acid, in naturally 
occurring amino acids this is the L-configuration. 
2) Having some kind of charge in either the side chain or the main chain. The type of 
charge can help the solubility of the PNA molecule and is in line with the relatively low 
solubility of some uncharged PNAs.40 
3) The pH of the environment the of the PNA strand. The binding rate is fastest in a 
slightly acidic environment with specificity being at its greatest around neutral and in some 
cases slightly basic pH. 
4) The electrostatic and ionic strengths of the PNA. The molecular dynamics of the 
PNAlDNA system have been studied and have shown stability in the DNAlPNA duplex41 
which does not always contain a j3-helix structure. This is most likely to be due to the 
electrostatically different backbone in PNA. It was also noted in this publication that 
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PNAlPNA duplexes did maintain a stable and we11-defined double helix formation, 
showing the base pairings themselves are sufficient to form a stable double helix structure. 
5) The temperature of the system. 
6) The hydrogen - bonding of the system. 
7) The rigidity of the backbone itself (Figure 1.22).42 
> Rigid backbone Aminocyc\opentylglycylthymine monomer 
Figure 1.22 Formation of monomer for PNA containing a rigid backbone 
8) The concentration of PNA. It has also been noted that for the formation of PNAlDNA 
the best rate is obtained by using two PNA molecules for every one DNA.39 It would 
clearly be better if this could be decreased for financial and product formation reasons. 
Structural Variations 
As far as variants in the main chain is concerned it has been found that a-PNAs have 
shown better solubility than some other earlier PNAs, so further investigation into this is 
justified. Previous investigations into PNAlDNA interactions43,44,45 have also involved, not 
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just the five naturally occurring nucleobases, but variations on a theme, such as PNA 
containing 2,6-diaminopurines and 2-thiouracils (Figure 1.23). 
Interaction of a) Adenine and Thiouracil and b) Diaminopurine and Uracil 
Interaction showing c) the sterie clash of the Diaminopurine and Thiouracil 
Figure 1.23 Pseudocomplementary PNAs43,44,45 
These specific PNAs have been given the name pseudocomplementary PNAs and have 
been shown to work in a similar way to PNA and in some cases the pseudo-Watson-Crick 
pairings have greater strength than the natural pairings. These investigations have been 
successful for duplex-DNA invasion under low ionic concentrations, in cells however the 
ionic concentration will be greater and hence could potentially cause a problem for use in 
'real life' , as investigations have shown that PNA strand invasion is inhibited by NaCl.32 
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1.6.2 Formation ofPNA Monomers 
PNA type I monomers have been made in a number of different ways, depending on the 
type ofPNA that is being made. 
/'.. ,NH BocHN' "'-" 2 
i) CH,CHCOOCH" 
CH)CN, reflux, 20h 
ii) BCH,COOPfp, 
Et,N, DMF, 20h 
iii) NaOH(aq). toM 
i) CICH,COOH 
ii) MeOH, HCI 
Hi) P·N02PC6HP2pBoc, 
HplDioxane, pH 10 
iv) BCH,COOH, DhbtOH, 
BocHN~NH2 DeC, DMF/CH,ct, 
v)NaOH,MeOH,lh 
i) Th)TIline, MeOH 
NaOH. reflux, 45h 
ii) 2M NaOH, HCI(aq) 
iii) BocNHCH2CH2NHC~COOC2H5' 
~COOR DMF/CH,ct" DhbtOH, DCC; 3h 
iv) 2M NaOH in MeOH, 1 h or 
I M LiOH in THF. 45m 
Where B=thyminyJ or N'-(Z)-cytosyJ 
Figure 1.24 Methods of making PNA type I monomers46 
In Figure 1.24 three different ideas for PNA are shown, the first is that of an extra carbon in 
what will become the backbone of PNA, the second contains two additional carbons and 
the third contains an additional carbon within the side chain. These have been investigated 
in the formation of a DNA duplex, but it was found that the original PNA formed the best 
duplex, with this area still being open to further investigation.46 
A lot of the methods of synthesis are derived from pyrimidine and purine alkylation 
chemistry. 
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/ NaH.DMF 
1~ 
BocHN COiCH3), 
~ K,C03. DMF 
NJC:N ~ I 
N ~NH H 2 
NJC:N ~ I 
N ~NH f 2 
. Ju 
BocHN C02tBu 
Figure 1.25 Method of making PNA type II monomer 
One method for monomers used for PNA type II involved the use of halogens on the amino 
acid side chains for linkage to the heterocycIes as shown in Figure 1.25. This will be 
discussed further in Chapter 2. 
In the investigation described in this thesis linkage of the heterocycle to the amino acid will 
be looked at via a heteroatom as well as an all carbon chain. One method previously 
reported where the linkage chains contain a heteroatom is the use of iodine-promoted 
nucIeosidation between an O-methylthiornethyl ether of serine and a heterocyc!e,47 as 
shown in Figure 1.26. 
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/ 
S-
0---./ 
12, 3A mol sieves, 
THF,RT f FmocHN C02Sn 0yN.yNHSOC 
"" . (NJ ~----------- 0 
TMSO'Y,/JN~ NHBoc f 
11 FmocHN C02Sn N .0 
Figure 1.26 Iodine Promoted Reaction Scheme47 
1.7 Heterocyclic Amino Acid Synthesis 
There are various potential methods of forming heterocyclic amino acids and the methods 
used in this investigation have been detailed in the Results and Discussion section of this 
report. Methods for the formation of a C-C bond between the amino acid and the 
heterocycle can include: a glycine enolate approach; a radical approach; or a Mitsunobu 
approach.48,49.50 Other methods involving the formation of the heterocylic ring whilst on 
the amino acid are also viable (e.g. Diels-alder reactions, etc) but these have not been 
studied in this investigation. It is also possible to use a heteroatom within the chain joining 
the heterocycle and the amino acid. 
The same basic structure for a heterocyclic amino acid has been the target for each of the 
bonding methods used, and this is shown below in Figure 1.27: 
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o 
N 
~)n 
~C02H where X=C,S,O or N 
H2N 
Figure 1.27 Heterocyclic Amino Acid 
1.8 Protection of the Amino Acid 
Before any reaction involving the bringing together of the amino acid and the heterocyc1e 
can take place there must be protection of some of the vulnerable groups. 
In this investigation the proteinogenic amino acids serine, cysteine and homocysteine, and 
the unnatural amino acids 2,3-diaminopropionic acid and 2,4-diaminobutyric acid have 
been used, and hence have required protection from any undesired side reactions. A 
selection of possible protection methods is given below. 
a-Amino Protection:S1.S2 
Alkoxycarbonyl protection - amino groups are easily converted to alkoxycarbonylamino 
derivatives: 
Benzyloxycarbonyl (Z, C6HsCH20CO-) - removed under acidic conditions; 
t-Butoxycarbonyl (Boc, qCHl)l)OCO-) - easy to add using base, easily removed by TFA; 
2-(4-Biphenyl)isopropoxycarbonyl (Spoc, (C6HS)2CHCH(CHl)OCO-) - more acidic, can be 
removed by catalytic hydrolysis; 
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9-Fluorenylmethoxycarbonyl (Fmoc, CI3HgCH20CO-) - cleaved by piperidinelDMF; 
Triphenylmethyl (Trt, (C6HS)3CO- ) - direct tritylation of amino acids using the chloride; 
2-Nitrophenylsulphenyl (Nps, C6HS(N02)S-). 
a-Carboxy Protection:SI .S2 
Esterification 
Methyl and ethyl esters - not affected by HBr, AcOH, TFA, catalytic hydrogenolysis, 
thiols, amines or organic solvents, can be removed by saponification or hydrazinolysis; 
Benzyl esters - formed from 4-toluenesulfonic acid and benzyl alcohol, easier to cleave due 
to steric factors and conjugation; 
t-Butyl esters - stable in free base form, inert to electrophilic and nucleophilic attack; 
Phenyl esters - useful where acid sensitive groups are present, removed by catalytic 
hydrogenolysis. 
For the investigations involving a carbon-carbon linkage, the protection of the two moieties 
was facilitated in one case by the formation of an oxazolidinone system as shown in 
Figure 1.28. 
• 
Figure 1.28 OxazoIidinone Protection of Amino Acid 
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This involved an internal esterification to protect the carbonyl group and benzyl 
chloroformate to protect the amino moiety by forming an alkoxycarbonyl. 
In other cases involving a carbon-heteroatom linage, protection was by Boc protection of 
the amino group and simple ethyl ester protection of the acid as shown in Figure 1.29. 
~XHn _____________ • ~XHn 
H2N eOOH BocHN eOOMe/Et 
Figure 1.29 Boc/Ester Protection of Amino Acid 
The actual procedures used and the reasoning behind them are explained in detail in the 
Results and Discussion and the Experimental sections of this thesis. 
The amino acid is not the only compound that needs to be protected. In some cases the 
heterocycles also need protection as some had more than one reactive centre (in this 
investigation this was a nitrogen). This other reactive centre was either protected by Boc or 
a benzoyl group. The reaction to attach a haloalkyl group to the heterocycle (to become the 
linkage in the side chain) was done under Mitsunobu conditions. Further details of this are 
discussed and detailed in the Results and Discussion and the Experimental sections. 
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2 Results and Discussion 
2.1 Heterocyclic Amino Acid Formation 
This project has been to investigate heterocyclic amino acid fonnation by fonning a C-X 
bond (where X= C, S, 0, N) in the chain linking the amino acid backbone to the intact 
heterocycIe. The linkage strategies are introduced below. 
There are many methods that could be used to fonn heterocyclic amino acids by this 
strategy, for example: radical or organocuprate conjugate addition, hydroboration or 
metathesis coupling, substitution and Mitsunobu reactions or glycine enolate approaches. 
These are all alternatives to building up the heterocyclic ring from a functionalised amino 
acid side chain. 
2.1.1 The Formation of Heterocyclic Amino Acids 
There are a number of ways in which heterocyclic amino acids have been made in the past 
and some methods have involved heterocyclic ring fonnation on the amino acid side chain 
(e.g. Diels-Alder reactions, etc). These methods have not been covered in this thesis as it 
was decided that the research would focus on methods of fonning the linkage between a 
prefonned heterocycIe and the amino acid units. Previous research into this area includes a 
glycine enolate approach, the Mitsunobu approach53 and a radical approach. 
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2.1.1.1 Glycine Enolate Approach 
This approach uses specifically glycine as the amino acid component of the heterocyclic 
amino acid and the heterocycle adds with the complete side chain. 
The use of a glycine enolate has been explored previously by Seebach and Fritzi,54.55 shown 
below in Figure 2.1a, and by Myers et al.56,57 and in our group by Berthelot and Jones58 
with a pseudoephedrine-based method as shown in Figure 2.1b. 
a) 
- + Cl H,N"-,/CO,Me 
MeNH,IEIOH --1 .xe 0 --1 .xe 
Pivaldehyde. ~y LDAlTHF. ~yo 
PhCOCI n_~ / N Electrophile, RX CH\\ N "'R Resolution ~ \ 
o - o 
b) LDA, 0 o C;:H, 0 ~l, 0 C;:H, 0 NaOH,(Boc)20 Jl ,NHR' V0~~NH'----' VV~JYNH, or • HO' '( 
OH CH OH CH, R H20, reflux R 
, R'= H orBoc 
R=Base 
Figure 2.1 a and b Alkylation of enolate 
The drawback with this method, so far investigated, is the poor e.e. values and due to 
competition between substitution and elimination in haloalkylnucleobases under strongly 
basic conditions, amino acids with nucleobases in the side chain could not be formed. 
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2.1.1.2 Mitsunobn Approach 
This approach is to the opposite extreme and links an amino acid with a complete side 
chain to the heterocycle. Serine (or another amino acid containing an alcohol group in the 
side chain) is reacted with a pyrimidine/purine base under Mitsunobu conditions to give the 
corresponding heterocycIic amino acid. This has been reported by Kuwahara5o•s9 and 
Altrnann et a1.48•60 for serine-based derivatives used in two different PNA structures as in 
Figures 2.2 and 2.3. 
OH (_.. 0 DEAD, Ph,P, THF 
BOCHN~O~OR --------. 
N-benzoylthymine 
or 
N-benzoyluracil 
Oyl ~ 0 K, A 
R=CH, 43%, 74% 
0yNyO H 46%,80% 
R~Nl 0 
BOCHN~O~OR 
Figure 2.2 Use of Mitsunobu reaction in the fonnation ofheterocyclic amino acids 
2 
6
0H ~ DEAD, Ph3P, THF R~N"-:::: 0 Also for 
.. O~ ----.-. l.jl adenine 75% 
BocN" OC(CH3)3 N-benzoylthyrnine 6~O 
.. oJ 
BocN" OC(CH ) 
63% 33 
Figure 2.3 Other PNA preparations 
35 
One limitation with the Mitsunobu approach is the availability of suitable hydroxyl-
functionalised side chains, with serine as the usual amino acid source for these reactions. 
2.2 Heterocyclic Amino Acids for this Investigation 
After looking at previous research, it was decided to focus on bond forming methodology 
where part of the side chain is situated on the amino acid moiety and part on the 
heterocyc1e. 
For ease of explanation the methods investigated have been split into two separate groups: 
C-C bond formation and C-S/OIN bond formation. 
2.2.1 Carbon-Carbon Bond Formation 
The first step for this research was to synthesise a chiral amino acid template suitable for a 
range of carbon-carbon bond forming reactions. An oxazolidinone as a substrate for 
conjugate addition and various coupling procedures was selected, its synthesis being shown 
in Figures 2.4 and 2.5.58 
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~O ~~ 
SMe 1-3 ZNy ~Ny ~C02H 4 • 9:1 • • tBu tBu 82% 
~O ~~ H2N 
ZNV ZNV 
tBu 
I. NaOH, 5 min 
2. tBuCHO, Hexane, Reflux, 24 h 
3. Benzyl chloroformate, DCM, oDe / RT, 36 h 
then NaHCOJ(aq), 4 h 
4. Acetonitrile, Oxone in Water 
tBu 
Figure 2.4 (2S,4R)-3-Benzyloxycarbonyl-2-tert-butyl-4-methyleneoxazolidin-5-one 
and (2R, 4R) isomer 
The amino acid derivative (R)-S-methylcysteine was stirred with sodium hydroxide 
solution to give the corresponding carboxylate salt. After evaporating to dryness, the salt 
was suspended in hexane with 2,2-dimethylpropanal and refluxed with Dean-Stark water 
removal to form a Schiff base at the amino moiety. The Schiff base then underwent 
cyclisation promoted by addition of benzyl chloroformate to acylate the imine nitrogen 
atom, hence protecting both the amino and acid moieties of the amino acid. This protection 
resulted in the formation of two diastereoisomers that could be distinguished by NMR 
spectroscopy but were difficult to separate using column chromatography. Both isomers 
were cleaned of excess benzyl chloroformate using an extraction procedure and then 
oxidised to the sulfones. Oxidation was achieved by adding an aqueous solution of Oxone® 
to a solution of the diastereoisomers in acetonitrile. Problems initially occurred at this 
stage, possibly due to the presence of residual benzyl alcohol formed from the benzyl 
chloroformate. This was resolved by removing the alcohol under vacuum at a raised 
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temperature for a longer time than previously thought necessary. The sulfone 
diastereoisomers were easier to separate at this stage using column chromatography on 
silica gel to give the major syn-isomer as a pale yellow liquid. This was not easy to 
crystallise using solvents, but it was serendipitously discovered that crystals were formed 
by leaving the product in the refrigerator for a few nights after removal of the solvents. The 
ratio of the two diastereoisomers could be determined by measuring the integrals of the 
S02Me signals in the 'H NMR spectrum, which occurred at /) 2.87ppm for the minor anti 
isomer and /) 3.11 ppm for the major syn isomer and by comparison of the masses of the 
diastereoisomers after column chromatography (the isomers being shown in Figure 2.4). 
The two isomers were distinguished by running n.O.e's of the pure isomers at the H-2 and 
H-4 frequencies. The ratio of the two isomers was found to be around 9:1 (syn:anti). 
Figure 2.5 
DBU, 
dry DCM, 
2.5 h 
• 
Oxazolidinone template 
66% 
The elimination of the sulfone moiety to generate the desired double bond, needed for the 
proposed carbon-carbon bond forming reactions, was instigated using the strong hindered 
base, DBU, which was added dropwise to a solution of the syn-sulfone in dry DeM. This 
gave a relatively clean product, shown in Figure 2.5, which was further purified by filtering 
through a short column of silica gel. It was clear that the elimination reaction had taken 
place due to the disappearance of the proton NMR signal at 0 3.11ppm (S02Me protons). 
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Again the product proved difficult to crystallise, but the clear liquid formed clear crystals of 
(2S)-3-Benzyloxycarbonyl-2-tert-butyl-4-methyleneoxazolidin-5-one (the oxazolidinone 
template) when it was left in the refrigerator for a few nights. The overall yield, based on 
the starting S-methy1cysteine derivative, for this sequence of reactions, was good at 54%. 
Use of Oxazolidinone Template 
As explained briefly in the introduction, the linkage between the amino acid and the 
heterocycle can contain only carbons or a heteroatom and the oxazolidinone was used for 
the all-carbon approaches. 
There are many different methods that may be used for C-C bond formation, and several of 
these have been looked at in this investigation. Each method is introduced before the 
discussion of the results for each method tried. 
2.3 Radical Reactions 
The first step in a radical chain reaction is always that of initiation, i.e. the formation of the 
radical for use in the reaction. There several ways in which a radical reaction can be 
initiated for use in synthesis.51 ,61 
The first (and most common) is by thermolysis. Several compounds containing weak 
bonds can be broken down using heat to form a free radical initiator. Three main ones are 
di-t-butyl peroxide at 140°C, azobisisobutyronitrite (AIBN) at 90°C and t-butyl hyponitrite 
at 50°C. The initiator radical performs an atom abstraction on the reaction substrate to 
generate a chain carrier radical. 
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The second way to initiate a radical reaction is by photolysis. UV or visible light carries 
enough energy to break some bonds, with the type of bond in question determining the 
amount of energy that the light must have to break it. 
Another way is by radiolysis. High energy electromagnetic radiation with a and 13 particles 
can promote a chemical change by ionisation. This method is often too energetic for 
selective synthesis. 
Once a radical reaction has been initiated, the carrier radicals in the reaction can also react 
in different ways.51.61 The proposal on this occasion is conjugate addition to the 
oxazolidinone template followed by H abstraction to continue the chain reaction, to give the 
addition product as in Figure 2.6. 
\ 
I 
LiOH, 
THFIH,o 
• 
Figure 2.6 
Radical 
Reaction 
The planned reaction pathway for the formation of heterocyc1ic amino acids 
via radical conjugate addition 
For this investigation the radical procedure was carried out in a similar way for each 
reaction. This involved the use of AIBN to form a radical by thermolysis which in turn 
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goes on to fonn a tributyl tin radical from BU3SnH, either added directly or fonned in situ 
The proposed full pathway to amino acids is shown in Figure 2.6, with the addition product 
then being deprotected to give the heterocyc1ic amino acid. 
For the radical reactions it was necessary to have a good leaving group, a halogen (e.g. 
iodine), at the position the radical fonnation was required, therefore iodoalkyl derivatives 
of the heterocyc1es were the most desirable. The simplest method available was that of 
Mitsunobu coupling to fonn the bromoalkyl derivative using a bromoalcohol, followed by 
halide exchange. The iodide fonnation could not be perfonned directly as the desired 
iodoalcohols were not readily available. 
2.3.1 N-iodoalkyl derivatives 
N3-Benzoyluracil 
1) rl 
CI~ 
o 
F)TiCline,llcetoniUile 
2) Kzeo" 
Dioxane, water 
• 
Figure 2.7 Benzoyl Protection of Uracil 
The first heterocycle to be derivatised for addition to the oxazolidinone template by a 
radical reaction was uracil. Uracil contains two nitrogen atoms in the molecule which are 
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open to alkylation by the Mitsunobu method. The nitrogen atom at the NI position is 
slightly more reactive than that at the N3 position, but since this difference is small it was 
necessary to protect at the N3 position (Figure 2.7) to only allow the Mitsunobu reaction to 
occur at the NI position and prevent any 'undesired side reactions. 
Uracil was suspended in a solution of acetonitrile/pyridine (5:1 v/v) with benzoyl chloride 
being added drop wise at O°C due to the exothermic reaction. After 2 h the suspension had 
disappeared to give an orange solution. This was checked by IH NMR spectroscopy, which 
showed a change from 2 NH peaks in theol0.5ppm region to a single peak, and by mass 
spectrometry and confirmed to be the Nl-benzoyluracil, so the solution was left to stir 
overnight to form Nl,N3-dibenzoyluracil. This was again confirmed by IH NMR 
spectroscopy which now showed no NH peaks in the 0 lO.5ppm region. The dibenzoylated 
compound proved difficult to separate from the pyridine solvent even after extensive use of 
the rotary evaporator under reduced pressure. DCM and water were added to the 'slush' 
which produced a white suspension that was filtered off to give the dibenzoylated product 
as the solid component. 
The NI benzoyl group was preferentially removed by hydrolysis using potassium carbonate 
in water/dioxane (1:1 v/v) to give the desired N3-benzoyluracil product in 72% yield 
(Figure 2.7). 
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N3-Benzoyl-Nl-(2-bromoethyl)uracil 
I"" "" o 1.& 
1 N 1 N N~O DIAD,Ph,P,' NAo 
8 Dioxane ~ 
Br 
Figure 2.8 Bromoethyluracil 
(j 
JNXO 
--'-lA 
~ 0 
NaI, 
Acetone 
For the first reaction to form a haloalkylheterocyc1e, it was decided to derivatise the 
protected uracil with a haloethyl chain. A bromoethyl group was added to N3-
benzoyluracil at the NI position under Mitsunobu conditions, as shown in Figure 2.8. 
N3-Benzoyluracil, 2-bromoethanol and triphenylphosphine (TPP) were stirred in dry 
dioxane with DIAD added dropwise over I h at -5°C, just above the freezing temperature 
of dioxane. The mixture was allowed to warm to room temperature and was stirred 
overnight to give a yellow solution. The solvent was then removed under reduced pressure 
and the desired NI-alkylated product was purified using column chromatography. The first 
attempt gave a low yield of 27% and this was attributed to the solvent not being sufficiently 
dry. Indeed a second attempt with more stringently dried dioxane gave a yield of 95% for 
the desired product, N3-benzoyl-NI-(2-bromoethyl)uracil, and further reactions after this 
gave reproducible yields in the high 80's at least. 
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N3-benzoylated-Nl-(2-iodoethyl) uracil 
To fonn the iodoethyl derivative rather than the bromoethyl derivative a simple halogen 
exchange is needed and the so-called Finkelstein reaction was utilised, which takes 
advantage of NaI being soluble in acetone whereas NaBr is less soluble. The halogen 
exchange from the bromo to the iodoalkyl was orchestrated by reluxing the bromoalkyl 
derivative in dry acetone with dry NaI. This gave the desired N3-benzoyl-Nl-(2-
iodoethyl)uracil in a yield of 71 % (Figure 2.8). For this reaction it proved very important 
to ensure that the solvent was completely dry or else the yields were severely reduced, as in 
the first attempt which gave a yield of 36% where the acetone was only distilled once. For 
all the Finkelstein reactions after this the acetone solvent was either distilled twice, or 
anhydrous acetone bought fresh from the suppliers was used and either of these gave the 
higher yields of around 71%. 
Nl-(2-Bromoethyl)benzimidazole 
The N-alkylation reactions were also perfonned using benzimidazole as this heterocycle 
has a similar structure to purines but does not need protection. 
Figure 2.9 
Bromoethanol, 
Dioxane 
• cc'-'::: N-, ~ N 
\ 
Br 
N 1-(2-Bromoethyl)benzimidazole 
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Although the uracil derivative is useful for looking at the reactions where a natural 
heterocycle is present, it was decided that it would be easier for the initial test reactions for 
coupling to an amino acid, to use a heterocyc1e that does not need protection, but has a 
similar structure, such as benzimidazole. Any methods that prove fruitful for the 
benzimidazole derivative could also be used for the uracil and the other naturally occurring 
heterocycles. 
Benzimidazole was bromoalkylated under Mitsunobu conditions, shown in Figure 2.9. The 
benzimidazole, 2-bromoethanol and TPP were stirred in dry dioxane with DIAD being 
added dropwise over 1 h. After being left to stir at room temperature overnight the solvent 
was removed under reduced pressure. The crude product was purified by column 
chromatography to give Nl-(2-bromoethyl)benzimidazole with a yield of 98%. 
Nl-(2-Iodoethyl)benzimidazole 
NaI, 
Acetone (dry) 
• 
Figure 2.10 Nl-(2-Iodoethyl)benzimidazole 
The Finkelstein halogen exchange reaction was performed with doubly distilled dry acetone 
and the reaction was performed in the same manner as previously. The Nl-(2-
bromoethyl)benzimidazole and NaI were refluxed in dry acetone, which gave Nl-(2-
iodoethyl)benzimidazole in 75% yield, as shown in Figure 2.10. The product was clearly 
identified using mass spectrometry, with the increased mass for the iodo compound and the 
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two mass peaks for the two isotopes at -272 and the second at -273, and by IH NMR 
spectroscopy with the shift of the signal for the CH2 protons adjacent to the halogen further 
upfield by about O.5ppm. The yield was however lower than expected even though the 
acetone was distilled twice and the NaI dried in the oven before use, but the yield was not 
so significantly decreased as to be synthetically unusable. 
2.3.2 Radical Conjugate Addition of Oxazolidinone and 
N-Haloalkyl heterocycles 
Radical addition of Uracil Derivative and Oxazolidinone Template 
An outline of the reaction scheme for the conjugate addition of the haloalkyluracil to the 
oxazolidinone template is shown in Figure 2.11. 
AlBN, Bu3SnH, 
Toluene 
or 
AlBN, Bu3SnCI, 
NaCNBH3, t-BuOH 
Figure 2.11 Radical Reaction: Uracil 
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Using Trihntyltin Hydride 
The oxazolidinone template, N3-henzoyl-NI-(2-iodoethyl)uracil and AIBN in toluene were 
heated at 80°C under nitrogen with tributyitin hydride added dropwise (Figure 2.11). The 
mixture was then refluxed overnight, however, no addition product was isolated. The 
reduced product, N3-benzoyl-Nl-ethyluracil, was present, as seen by IH NMR 
spectroscopy, but could not be isolated. The presence of the reduced product indicated that 
the desired radical had been formed, but had gone on to perform hydrogen abstraction 
rather than conjugate addition. 
Using Trihutyltin Chloride 
The oxazolidinone template and N3-benzoyl-NI-(2-iodoethyl)uracil, AIBN, sodium 
cyanoborohydride and tributyltin chloride were refluxed in tert-butanol under a positive 
atmosphere of nitrogen (Figure 2.11). The mixture was refluxed overnight then separated 
by column chromatography. It was necessary to separate without any confirmation of any 
addition product being present because the large number of peaks in the IH NMR spectrum 
made it impossible to analyse, a major source of these peaks being the tributyltin-
containing components of the reaction. The presence of the organotin compounds also 
caused problems with the column chromatography of the mixture due to the tendency of the 
tin compounds to streak, meaning a second column was always necessary. The fractions 
collected may have contained a trace of the desired product but even if it was present it was 
inseparable even on several attempts at the reaction and separations. 
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Radical addition of Benzimidazole Derivative and the Oxazolidinone Template 
Q~ 
? 
I 
AIBN, Bu,SnH, 
Toluene 
Or 
• 
AIBN, Bu,SnCI, 
NaCNBH" t-BuOH 
Q~ 
N 
Figure 2.12 Radical reaction: Benzimidazole 
Using TributyItin Chloride 
+ Q~ ) 
The tributyltin chloride method was tried first, as the chloride is a lot easier to use than the 
hydride. The NI-(2-iodoethyl)benzimidazole, oxazoIidinone template, AIBN, sodium 
cyanoborohydride and tributyltin chloride were refluxed under nitrogen in tert-butanol for 
up to 48 h (Figure 2.12). Two different protocols were tried, either that of adding AIBN 
only at the start or adding it in portions every hour for up to 6 h. 
Neither method produced any of the desired product but both the reactions produced greater 
than 40% of the reduced product N I-ethylbenzimidazole, both being assessed after 24 h 
and again after 48 h. 
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Using TributyItin Hydride 
NI-(2-Bromoethyl)benzimidazole, the oxazolidinone and AIBN were heated under a 
positive atmosphere of nitrogen in toluene after the dropwise addition of tributyltin hydride 
(Figure 2.12). After 24 hand 48 h the IH NMR spectra were again difficult to interpret so 
no conclusions were possible until the mixture had been separated by column 
chromatography twice. 
There was a large amount of reduced product (Figure 2.12), 45% after 24 hand 46% after 
48 h, and there was the possibility of a trace of the desired product but if so it proved 
impossible to separate, especially from the organotin residues, and hence this was not a 
viable reaction. The results are shown in Table 2.1. 
Uracil/ Tin Hydride AIBN Time of Yield Benzimidazole or Chloride Assessment (h) Reduced 
24 Trace 
Hydride 
48 Trace At Start Uracil Only 24 57% 
Chloride 
48 52% 
At Start 24 44% 
Only 48 48% 
Chloride Every 24 42% 
Benzimidazole hour for 
6h 48 43% 
At Start 24 45% Hydride Only 48 46% 
Table 2.1 Oxazohdmone With Benzimidazole 
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As mentioned previously the presence of the reduced product as the major product in the 
majority of the reactions shows that a radical is almost definitely being formed, but this is 
not leading to the desired conjugate addition product. 
Radical reaction using a greater excess of the oxazoIidinone template 
The radical reactions described above used 5 equivalents of the oxazolidinone template and 
these had resulted in none of the desired product, so it was suggested that if a greater excess 
of the oxazolidinone was present then the ethylheterocyc1e radical would stand a greater 
chance of reaction with the oxazolidinone than of picking up a hydrogen atom. 
NI-(2-Iodoethyl)benzimidazole and AIBN were stirred with up to 20 equivalents of the 
oxazolidinone template for up to 48 h (Figure 2.12). After the necessary two column 
chromatographic separations there was none of the desired conjugate addition product 
present for any of the experiments up to 20 equivalents, there was however still the 
presence of the reduced product in approximately the same quantities as for the previous 
reactions. The oxazolidinone starting material was also recovered, but the organotin 
compounds could not be fully separated from this so it could not be used again for any 
further reactions and the actual recovery could not be calculated precisely, but has been 
estimated to be quantitative. 
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Reaction using only the Sodium Cyanoborohydride 
It was thought that the sodium cyanoborohydride may be causing the problem in the 
tributyltin chloride reactions as these reactions produced the most amount of reduced 
product in the uracil reactions. 
To test this possibility the reaction was performed containing only the NI-(2-iodoethyl) 
benzimidazole and sodium cyanoborohydride, which were refluxed in tert-butanol under 
nitrogen for up to 48 h. After column chromatography it was seen that there had however 
been no reduction and only starting materials were obtained after the 48 h at reflux. 
Radical reaction using the Nl-(2-Bromoethyl)benzimidazole 
It was also possible that the iodoethyl heterocycles could have been the cause of the 
problem, in that they may have been too reactive. The radical reaction was attempted with 
Nl-(2-bromoethyl)benzimidazole, as in Figure 2.13, to see if this would react more slowly 
and hence be less likely to form the reduced product. 
HO Q) 
ZNyO Q) Q~ N + t-Bu N 
N 0 ) ( AIBN, Bu,SnCl, NaCNBH" t-BuOH 
ZNyO Br 
t-Bu 
Figure 2.13 Radical reaction with Nl-(2-Bromoethyl)benzimidazole 
51 
The same conditions were used as for the iodoethyl heterocycle reactions using the 
tributyltin chloride, as shown in Figure 2.13. This also proved fruitless as the 
bromoethylbenzimidazole was not reactive enough to even form the radical and only 
starting materials were recovered after 24 h of reaction time. 
2.3.3 Summary of Radical Reactions 
The radical reactions have produced none of the desired conjugate addition products. 
Although there have been signs that the radicals have been formed, they have picked up 
hydrogen atoms earlier in the reaction sequence than desired and only the reduced products 
have been seen. 
2.4 Other Metal-Mediated Reactions 
For both the hydroboration and cross-metathesis methods, to be discussed later, it was 
necessary to form an N-vinyl heterocycle.6J ,64 This was easily achieved via the Nl-(2-
chloroethyl)benzimidazole. 
Two attempts were made to form the chloroethyl precursor, the first was using a phase-
transfer catalyst, the second using the Mitsunobu method. All of the following reactions 
were performed under nitrogen. 
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N 1-(2-Chloroethyl)benzimidazole 
a) 1,2-dichloroethane, 
Bu.NI (PTC), 
KOH, K,C03, 4 h 
b) 2-Chloroethanol, 
DIAD, PPh3, 
Dioxane, 16 h 
• 
Figure 2.14 Formation ofNl-(2-chloroethyl)benzimidazole 
Phase-transfer catalyst method 
Benzimidazole was added to a mixture of 1,2-dichloroethane, which acted as both the 
solvent and the reagent, tetrabutylammonium iodide as the phase transfer catalyst (PTC), 
KOH and K2C03 (Figure 2.14). The reaction was stirred at room temperature for 4 h, so it 
does have the advantage of being a relatively fast reaction. After the inorganics had been 
filtered off and the organic portion worked up, the mixture was put through flash 
chromatography, where the desired product came off easily and cleanly but only gave a 
54% yield. 
Mitsunobu method 
Since the Mitsunobu method had worked so well for the bromoalkyl derivatives of 
benzimidazole, this method was tried for the chloroalkyl derivatives. To a stirred solution 
of benzimidazole, 2-chloroethanol and triphenylphosphine in dioxane at O°C was added 
DIAD slowly over 3 h (Figure 2.14). This was then allowed to warm to room temperature 
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and stirred for a further 16 h. After removing the solvent under reduced pressure the 
product was put through flash chromatography, from which it was separated quickly and 
relatively cleanly to give the desired product with a yield of 80%. 
For both the above reactions it was necessary to ensure that the reactions had gone to 
completion Gudged by lH NMR spectroscopy). Where the reaction had not gone to 
completion the products were difficult to separate from the starting materials. 
Vinyl Benzimidazole 
KOH,K,CO" 
Ethanol, 
Reflux, 40 min 
• 
Figure 2.15 Formation of vinyl benzimidazole 
Nl-(2-Chloroethyl)benzimidazole was then used in the formation of N-vinyl 
benzimidazole, shown in Figure 2.15. The Nl-(2-chloroethyl)benzimidazole, KOH and 
K2C03 were stirred in ethanol at reflux for 40 min. After work-up the product was purified 
using flash chromatography, from which the vinyl benzimidazole eluted cleanly, with a 
very good yield of97%. 
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2.4 Hydroboration 
As an alternative to radical C-C fonnation, use of a boron linker was proposed, partly 
because boron is reportedly found in a large number of saturated and unsaturated 
heterocycles.65 If a boron-containing reagent could be incorporated into the chain linking 
the heterocycle to the amino acid, this in itself would be a novel compound or, to fonn a C-
C bond, the boron can be easily removed using a number of reactions. The proposed 
linkage is shown in Figure 2.16. 
Figure 2.16 Planned Cross-Hydroboration of Oxazolidinone Template and Vinyl 
Benzimidazole to fonn a Linkage Containing Boron 
Boron in Organic Reactions 
Borane is a reducing agent and can add to C-C double bonds. In the past this has led to 
effective routes to functionalizing alkenes.66 It is in this capacity that it has been proposed 
that a borane compound is used to fonn the boron-containing heterocyclic amino acid. 
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Complexes of the borane are useful as they provide the borane in its monomer form and 
aIIow measurement for 1: 1 quantitative additions as weII as making the molecule soluble in 
other solvents. These complexes are usuaIIy with diethyl ether, THF or methyl sulfide.67 
There is facile addition of a B-H bond to the C=C bond. This is due to the eis-addition of 
BH via a four membered transition state,67 and it is this process that is known as 
hydroboration. This is shown in Figure 2.17 below: 
HB--H 
21 1 
I I 
R-/-r===--'\:---R 
R R 
. r2 I R ..... r----\ .... R 
R R 
Figure 2. I 7 Hydroboration mechanism - cyclic 
Hydroboration is best used for slightly hindered olefins where the boron is most likely to 
add regioselectively on one end of the double bond, the less hindered terminus;68 anti-
Markovnikov addition can usuaIIy be easily accomplished by the use of boron.67 
Obviously steric factors are a major influence but not the only one: delocaIisation can cause 
the borane to go to the more hindered end and electronic factors can play a role in the cyclic 
transition state. Most double bonds wiII react with boranes, from mono- to tetra-
substituted, although the more hindered the compound the fewer molecules can bond to 
boron. Steric factors also play an important part where the number and size of substituents 
on the boron are concemed.69 For less substituted boron atoms the reactions can be done at 
lower temperatures,67 this reduces the number of molecules bonding to a single boron atom. 
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There are a number of different ways to convert the organoborane into a different 
functional groUp.67 For the present case, once the boron has been added, the removal of 
boron is envisaged to form a C-C bond between two different moieties (the protected amino 
acid and the heterocycle). To do this the methods that could be used are: 
Coupling reaction - organoboranes + alkali + silver nitrate at O°C, even in the best case, 
this reaction will only give a maximum yield of50% due to side couplings.67.70.71.72 
Use of a haloform anion (Figure 2.1 8) - Facile reaction with haloforms in presence of 
strong stericaUy demanding bases, this reaction does however extend the chain by one 
carbon.67 
R'R2HCOH BOCHN EtOOC~ 
Figure 2.18 Proposed Removal of Boron to form Heterocyclic Amino Acid 
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Functional groups might cause a problem in hydroboration depending on the group in 
question but it has been noted by Brown67 that ester groups are not in competition with the 
reduction of the double bond. It has also been shown by Sucrow et al. that even conjugated 
esters (of which there is one present in the oxazolidinone template) do also undergo 
hydroboration and do not cause a complication.73 The proposed reaction scheme is shown 
in Figure 2.19. 
Figure 2.19 Proposed Reaction Scheme for Hydroboration of the Oxazolidinone 
Template and a Vinyl Heterocycle, in this case Vinylbenzimidazole 
Advantages and Disadvantages 
One major potential advantage of hydroboration is that the reactants for hydroboration are 
less toxic than the tin components often used in radical reactions. On the other hand 
N-vinyl benzimidazole looks like a classic reagent to undergo hydroboration, the 
oxazolidinone is however, more hindered and so could pose more problems. A syn-
oxazolidinone is expected as hydroboration should occur at the least hindered face (Figure 
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2.1812.19}. The initial hydroboration reaction was planned on the oxazolidinone template 
to provide a relatively hindered borane that might only add to one N-vinyl benzimidazole. 
Oxazolidinone Template Reactions with Borane Complexes 
BH3:OES, Diethyl Ether 
or BH3:THF, THF 
or BH3:SMe2, Dyglyme 
>( . 
Figure 2.20 Reaction ofborane complexes with oxazolidinone template 
The oxazoIidinone template was stirred vigorously in solvent (diethyl ether, THF or 
diglyme) in a flame-dried round-bottomed flask under nitrogen and cooled to O°C. Borane-
ether complex, borane-tetrahydrofuran complex or borane-methyl sulfide (respectively with 
solvent) was added to the mixture over 1 h (Figure 2.20). The mixture was warmed to 
30°C for 48 h and monitored using TLC. No reaction was indicated using TLC so the 
temperature was increased to reflux but again no reaction was shown by TLC up to 48 h. 
After this time, excess borane was destroyed using water. There was however no reaction 
of the oxazoIidinone with the borane in any of the complexes used, as shown by TLC and 
IH NMR spectroscopy. 
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Oxazolidinone Template Reactions with 9-BBN 
9-BBN, Solvent 
>< 
DOCIR T lHeatlReflux 
Figure 2.21 Reaction of9-BBN with Oxazolinone Template 
In parallel with the borane complex reactions, 9-BBN was also investigated as a 
hydroboration reagent. To a flame~dried round-bottomed flask was added the 
oxazolidinone template and 9-BBN in solvent (DCM, diethyl ether or THF) under nitrogen 
(Figure 2.21). This was stirred at DOC for 36 h and was monitored using TLC. When no 
reaction had occurred after this time, the temperature was raised to room temperature and 
the mixture stirred for a further 36 h, again monitored by TLC. Unlike the borane 
complexes, 9-BBN is supplied as a dimer, so keeping the reaction at DOC might not be 
beneficial as the compound is likely to stay as a dimer, but allowing the 9-BBN to warm up 
would allow it to form the monomer and hence it would be able to react. There was 
however still no reaction and the temperature was raised again to 3DoC, then to reflux. 
There was no reaction of the oxazolidinone with 9-BBN at reflux after 36 h in DCM, 
diethyl ether or THF as shown by TLC and 'H NMR spectroscopy. 
6D 
Coupling Reaction 
i) Borane, Alkali 
ii) AgNO" ooC 
Figure 2.22 Coupling reaction involving borane and oxazolidinone template 
This reaction, as shown in Figure 2.22, was performed in parallel to the other hydroboration 
attempts as described above on the oxazolidinone. To a flame-dried flask was added the 
oxazolidinone template and N-vinyl benzimidazole in THF under nitrogen. This was 
cooled to QOC again to prevent undesired side reactions, then the BH3:THF complex was 
added and the reaction mixture stirred for a further 12 h. KOH in methanol was then added 
followed by AgN03 solution at room temperature. After 2 h KOH was added and the 
mixture refluxed for 4 h. The reaction mixture was then poured onto water to destroy 
unreacted borane, acidified to pH 2 with HCI, filtered, impurities extracted from the 
precipitate and the precipitate was then recrystallised. 
The advantage of this reaction would be that it is a one-pot reaction so time is saved, the 
disadvantage is the unwanted side reactions. However none of the desired cross-coupling 
products were seen by NMR spectroscopic examination of the crude material. 
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2.5.1 Summary of Hydroboration 
If this method had worked the regiochemical effects would have added the borane in the 
desired anti-Markovnikov fashion, however, it has been seen that the oxazolidinone 
template has not reacted with the borane. This could be due to steric factors: the size of the 
oxazolidinone molecule could be preventing the attack by the borane, whether it be as a 
complex or as 9-BBN. At this stage it was decided not to try further hydroboration of the 
N-vinyl benzimidazole as the oxazolidinone hydroboration had failed to work. 
2.6 Cross Metathesis 
Cross metathesis is of interest as an alternative approach as, like the radical reaction, it is a 
straight bonding of carbon atoms. The metathesis reaction is where two alkenes are 
brought together at their double bonds and these bonds become interchanged.74 The term 
cross metathesis refers to the reaction of two different alkene groups, although this is only 
one utilization of this method. Other uses include: ring closing metathesis and ring opening 
metathesis.75 Metathesis was originally looked at from a mechanistic standpoint and 
polymer synthesis, only recently have investigations into its use in the synthesis of complex 
organic molecules become more common.75,76 The plan was to investigate cross metathesis 
- between the methylene oxazolidinone and an alkenyl heterocycle. This type of reaction has 
been investigated before with amino acids, but with different variations.77.78 
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The Metathesis Reaction 
The catalysts used for this type of reaction contain well defined single component metal 
carbene complexes of ruthenium or molybdenum and are usually sourced commercially as 
Grubbs (Figure 2.23) or Schrock catalysts respectively.75.76 These catalysts are however 
sensitive to air and moisture and have to be kept under nitrogen or argon in flame-dried 
vessels.75 
The example ofthe general process below is for two different alkenes (it could very well be 
a single olefin) and one problem is strikingly obvious, the number of different possible 
molecules created. 
Cl .. ~(CYhph 
'Ru='/ 
CI"-I 
P(CY)3 
Figure 2.23 Grubbs Catalyst 
In the example in Figure 2.24 only one of the facial reactions is shown but the total number 
of olefins that can come out of the reaction mixture is 14 if you include the starting olefins 
that may not have reacted.74 
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A>=<C E>=<G Metal Cat Number of + • Products B D F H 
A E A H 
B ; ~ F B f ~ G e.~ rG e.~ rF Reaction between different molecules possible products = 4 
D H D E 
A D A A B ; ~ e B f ~ B e.~ rB e.~ re Reaction between same molecules 
D A D D Possible products = 8 
!= E E H F ; ~ F F f ~ G G~ rG G~ rF Unreacted olefins = 2 
H H H E Total number ofpossiblities = 14 
Figure 2.24 The Number of Possible Products from a Cross Metathesis Reaction 
Steric hindrance can play an important role in reducing the number of unwanted side 
reactions and this is relevant in this investigation due to the size of the oxazoIidinone 
molecule which is quite large. Exceptionally large groups can stop a reactant metathesising 
with itself, allowing a greater possibility for the desired cross-metathesis between two 
separate compounds.79 Another way of controlling the reactions is by using an excess of 
one component. If the more reactive alkene is added in excess, there is more reactant able 
to combine with the less reactive component, which obviously means an increase in the 
yield of the desired compound but also an increase in undesired side reaction. This method 
is however only feasible if the more reactive component is relatively inexpensive.75•79 
Electronic factors can also play a part with the more electron deficient alkenes having a 
slower reaction. 
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Cross Metathesis Mechanism 
The generally accepted mechanism for metathesis, as shown in Figure 2.25, is one 
involving a chain of successive 2+2 cycloadditions and cycloreversions between alkenes 
and metal carbenoids.74•76 
)=(R 
H H 
Catalyst, 
C=M 
R R' R' R'fltR 
>=M + >=< -...... "" M -.-
H H H R' 
R 
>=M 
H 
R R' R' >=< +)=M 
H H H 
Figure 2.25 Mechanism for Cross Metathesis Reaction 
It has also been noted that different groups will react at different rates; as a general 
guideline: =CH2 > =CHCH2R > =CHCHR2 > =CR2 
Reactants containing allyl groups undergo cross-metathesis reaction in reasonable yields80 
for a range for different groups attached to the allyl group, including nitrogen containing 
groups. 
2.6.1 Cross Metathesis Reactions 
Two test reactions involving allyl bromide instead of the heterocycle, and the N-vinyl 
benzimidazole itself, were performed to check whether the oxazolidinone template would 
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undergo cross metathesis with another molecule. The Grubbs II Catalyst (Figure 2.23) was 
used for all the cross metathesis investigations. 
Cross Metathesis with Allyl Bromide 
+ ~Br Grubbs IT )( No Reaction 
Figure 2.26 Cross metathesis reaction with oxazolidinone template and allyl bromide 
Oxazolidinone and Grubbs II catalyst (lO%mol) were place in a flame-dried round-
bottomed flask in DCM under nitrogen. Allyl bromide was then added and the reaction 
mixture stirred at reflux for up to 48 h (Figure 2.26). The solvent was removed under 
reduced pressure. There was no point in performing any purification procedure as the IH 
NMR spectrum showed only oxazolidinone starting material and no cross metathesis 
product. 
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Cross Metathesis with N-Vinyl Benzimidazole 
Grubbs JI 
+ X • No Reaction 
Figure 2.27 Cross metathesis reaction of oxazoJidinone template and N-vinyl 
benzimidazole 
Oxazolidinone and Grubbs 11 catalyst were place in a flame-dried round-bottomed flask in 
DCM under nitrogen (Figure 2.27). N-Vinyl benzimidazole was then added and the 
reaction mixture stirred at reflux for up to 48 h. The solvent was removed under reduced 
pressure. Once again there was no point in performing any purification procedure as the I H 
NMR spectrum showed only oxazoIidinone and benzimidazole starting materials and no 
cross metathesis product. 
The N-vinyl benzimidazole was not tried again after the discovery of a paper on cross 
metathesis of nitrogen containing systems by VemaII and AbeII.81 This further background 
on the use of cross metathesis in the formation of novel amino acids made interesting 
reading. With amino acids and peptides, a substituent bearing a terminal double bond can 
be attached to the a-carbon, amino acid side chain or the amino or the carboxyl groups. 
Glycine has been used as a scaffold for cross metathesis and reactions have shown that 
vinylglycine does not readily undergo cross-metathesis. This is likely to be due to the 
steric inaccessibility of the double bond to the catalyst. Further experiments have shown 
67 
that a longer chain has generally meant improved cross metathesis.77 This is shown in 
Figure 2.28. 
H 
.... N~GOOR P ~ 
( )0 + V 
I 
n P R 
0 Boc Me 
I Boc tBU 
1 Boc Me 
2 Boc Me 
2 Fmoc Me 
2 Fmoc H 
Grubbs I, 
DCE, RT,30h 
• 
GOOR GOOR 
+ 
GOOR 
Yield % 
Cross-Metathesis Self-Metathesis 
7 0 
49 16 
45 17 
66 28 
58 25 
58 18 
Figure 2.28 Example of the use of Cross Metathesis in Amino Acid Substituent 
Formation and how Steric and Chemical Factors may play a part. 
This problem has also been demonstrated with amines78 and amides.82 In light of this 
information it is unsurprising that the oxazolidinone and N-vinyl benzimidazole proved 
unreactive substrates. 
2.6.2 Summary of Cross Metathesis 
There was no reaction of the oxazolidinone with the Grubbs II catalyst. As with 
hydroboration, this is likely to be due to steric factors. The Grubbs catalyst is a large 
molecule and so steric hindrance is even more likely to be the cause. 
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2.7 Organocuprates 
An alternative approach is to use a carbon nuc1eophile in a conjugate addition to the 
oxazolidinone template. As the carbon centre at which an attack will take place is soft, a 
soft carbon nuc1eophile reagent is needed, which is why organocuprates were considered. 
The planned reaction is shown in Figure 2.29. It was proposed to prepare the cuprate via 
Iithum-halogen exchange from the haloalkyl heterocyc1es that were already to hand, 
followed by transmetallation. 
To make the oxazolidinone template was time consummg, so test conjugate addition 
reactions were performed using methyl acrylate instead of using the oxazolidinone template 
as an acceptor and a haloalkylbenzimidazole as a cuprate precursor. If the desired addition 
product was formed in the test reactions the next step would be to try the reaction using the 
oxazolidinone template. 
MeO o 
Figure 2.29 Planned Reactions involving Organocuprates, Haloalkylbenzimidazole and 
either the Oxazolidinone Template or Methyl Acrylate 
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2.7.1 Methods for the Formation ofOrganocuprates 
Metal-Halogen Exchange 
Alkyl halides can react with some metals to form organometallic compounds.65,74,83 This 
method is famously used to form Grignard reagents, but these are not the only compounds 
that can be made this way. The halide can be iodo, bromo or chloro with decreasing 
reactivity in that order and can be primary, secondary, tertiary or aryl. Other functional 
groups may cause problems in the reaction. A1cohols, amines and carboxylic acids may be 
present but must be in the form of a salt, whereas ketones, aldehydes, cyanides, nitro and 
ester groups will interfere with the metal-halogen exchange reaction. Although the 
products of a lithium-halogen exchange reaction can be stored in a freezer at -20oe 
overnight, the best results are obtained from immediate use of the reagent. Problems in a 
reaction may arise if the reaction is very slow, then there is competition from the Wurtz 
reaction,74,84 although is quite rare with lithium. 
The Wurtz reaction is the generation of metal alkyls from electropositive metals and alkyl 
halides resulting in the coupling of the alkyl halides. 
2RX + 2M (Na or Li) ~ RR + 2MX 
The mechanism is either a 2 step polar reaction (as below), or a radical process. 
RX+2M~KM++MX 
KM++RX~RR+MX 
The mechanism for the metal-halogen exchange reaction for the organocuprates and 
Grignard reagents is not fully understood, but it is believed to involve radicals.74 
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Transmetallation 
Transmetallation involves replacement of one metal in an organic compound with another 
metal and can be used when the first metal is below the replacement metal in the 
electrochemical series. This method ensures that the organometaIIic compound is free from 
possible haIide. Sometimes however the reaction needed is one to replace the more 
electropositive metal, this can be done using metal haIides and is one of the most common 
methods for making organocuprate reagents. Two moles of an organolithium are reacted 
with one mole of copper(I) iodide at Iow temperatures in either ether or 
tetrahydrofuran 74,85,86 as shown in the following equation, to generate a lithum 
dialkyIcuprate. 
H C-Cu-CH Lt + LiI 3 3 
Organocuprate Reactivity 
Organocuprates add to n,f3-unsaturated aldehydes, ketones and to a lesser extent esters to 
give conjugate addition products. This is in contrast to Grignard reagents, which tend to 
afford 1,2-addition. The organic component of the cuprate can be alkyl, vinyl or aryl. One 
characteristic of this reaction is that only one of the organic groups is transferred, however, 
using a mixed reagent involving one slowly transferred group wiII overcome this if the 
reagent is expensive, for example: R(R'O=C)CuLi (where R'= tBu or nPr), R(O-tBu)CuLi 
or R(PhS)CuLi.74 The heterocyc\es to be used in this investigation are not expensive, so it 
was decided that two equivalents of the heterocyc\es would be used to form the standard 
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dialkyl cuprates. There is usually little or no competition from 1,2-addition to the C=O. 
Substitution at the carbonyl carbon aids in increasing yields.74 The mechanisms for these 
reactions have not been determined fully (Figure 2.30). 
There could be a cyclic mechanism or a SET process:65 
~ cut6 
/ 
• 
R 
o O-Li(Me2CuLi) O-Li(Me2CuLi) OLi 6 6' ~ A' ---., A +Me3CuLi 1+2Me2CuLi~ : ~CuMe2----~ ~ • CuMe2 Me 
Figure 2.30 Possible Reaction Mechanisms for Organocuprate Reactions 
Organocuprate couplings would simply not take place without the presence of a Lewis acid 
counter ion, either MgX+ or Li+. When lithium reacts with an alkyl halide, the compound 
formed does not exist as a free organolithium, but as a complex.87 
There can be many variations in organocuprate protocols as to the type of solvent, purity of 
copper(I) precursor, use of catalytic processes and one-pot reactions88,89 
One modification to the reaction scheme is to add either trimethylchlorosilane or 
trifluoroborane etherate.74 These help the reaction in two different ways: the TMSCl will 
help to trap enolate anion intermediates as they form and hence help to force the conjugate 
addition reaction to completion and the BF3,Et20 helps to establish an equilibrium by 
forming RLi.BF3 and the more reactive R3Cu2Ljz from (R2CuLi2)2. 
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There are certain practical points that should be remembered in organocuprate 
chemistry:65,87 
To obtain a lithium halogen exchange reaction it is essential to have the metal surface 
exposed as the surface of lithium quickly tarnishes in air;87 
All organocuprate reactions should be done under nitrogen or argon; 
All materials (chemicals and glassware) for the reaction must be completely dry as these 
reactions are very moisture sensitive; 
The temperature of the reaction is also important, organocuprate reactions are usually 
performed between -78°C and O°C, probably to hinder elimination and reduce other side 
reactions, The reactions are also usually performed in THF or ether, 
2.7.2 Lithium Halogen Exchange Reactions 
Use of Lithium Metal for Lithium!Halogen exchange 
CCN) Li (metal) CCN') ~ ~ THF CUI,~t~ ? 
r(YN I;lr THF (.i lAN') Oxazolidinone ~ //0 
~ 9 Template ~ y' )( CC') _---7)~(=OM=e'-. ZN_t THF ~ ~2 THF 
J\ CuLi MeO o 
Figure 2,31 Organocuprate Reaction Involving Lithium Metal 
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The reaction of lithium with N 1-(2-bromoethyl)benzimidazole was initially attempted in 
diethyl ether but there was no reaction at the initial stage where the lithium metal is used so 
this was abandoned and THF was used instead and the scheme is shown in Figure 2.31. 
Finely cut lithium was placed in a flame-dried round-bottomed flask and suspended in THF 
under nitrogen. NI-(2-Bromoethyl)benzimidazole dissolved in THF was added slowly to 
the round-bottomed flask and constantly stirred at room temperature. There was then a 
colour change in the reaction mixture, once this colour change had begun the reaction was 
either a) cooled to approximately _lOoC, b) kept at room temperature, or c) cooled down to 
_78°C. Any NI-(2-bromoethyl)benzimidazole not added before the colour change was now 
added. After 2 h below O°C, the solution was cooled further to -78°C then siphoned 
through glass wool into another flame-dried round-bottomed flask at -78°C and kept under 
nitrogen. A pre-cooled suspension of copper(I) iodide in THF was then added slowly to the 
stirred mixture and the temperature slowly raised to -10°C over I h and then to O°C over 
10 min, and then cooled again to -78°C. Over this time the mixture turn from an orange/red 
colour to a deep red, almost black colour and the copper iodide disappeared. Methyl 
acrylate was then added and the solution stirred for 2 h at -78°C before being allowed to 
warm slowly to room temperature and was stirred for a further 20 h at room temperature. 
The final colour for the reaction mixture was a dark green colour. The reaction mixture 
was filtered and the solvent removed under reduced pressure. An attempt at separation of 
the mixture was then made by flash column chromatography but no addition product was 
found in any of the fractions, and with further attempts at the reaction no separation was 
pursued as the crude I H NMR spectra showed no sign of the desired conjugate addition 
product. 
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Different temperatures were tried for the lithium-halogen exchange because the initial 
attempts of cooling to about -10°C gave dealkylated benzimidazole back from the reaction, 
presumably by,8-elimination of the alkyl lithium. Attempt b) at RT and c) at -78°C gave the 
N-ethyl and N-vinyl benzimidazoles by elimination of HBr from Nl-(2-
bromoalkyl)benzimidazole by initially formed lithioalkylbenzimidazole. 
This reaction was performed a number of times with slight variations. As well as changes 
in the temperature already described, chloroethyl and iodoethyl benzimidazole were used, 
but these either gave no reaction or no desired product. The reaction was also tried using 
TMSCI to aid the reaction but this also gave none of the desired products. 
The reactions were also repeated using the oxazolidinone template, but this also gave none 
of the desired product, and it was decided to move on to try with n-butyllithium. 
n-Butyl-Iithium 
CCN) ~O CCN n·BuLi CCN) CuI CCN) OMe I: ) )( . )(; X. N o N o N • o N ~ THF ~ THF ~2 THF ~r ~i CuLi 
o 
2.32 Organocuprate Reaction Involving n-Butyl-Iithium 
N-Butyl lithium was used as a possibly more reactive alternative to lithium metal in these 
circumstances, to promote rapid organolithium formation, the scheme being shown in 
Figure 2.32. To a flame-dried round-bottomed flask a solution of Nl-(2-
75 
bromoethyl)benzimidazole (or Nl-(2-chloroethyl)benzimidazole) in dry ether or THF was 
added under nitrogen at _78°C. To this solution fresh n-butyllithium (up to 3 mol equiv) 
was added and the reaction mixture stirred for 2 h at -78°C (or until there was a colour 
change). A pre-cooled suspension of copper(I) iodide in ether or THF was then added 
slowly to the solution and the temperature slowly raised to _lOoC over 1 h and then to O°C 
over 10 min, before cooling again to _78°C. Methyl acrylate was then added and the 
solution stirred for 2 h at -78°C before being allowed to warm slowly to RT and stirred for 
a further 20 h at RT. The reaction was then worked up using saturated ammonium chloride 
solution and extracted using ether. Separation was by flash column chromatography. 
Although there was a colour change for all the reactions tried, none of the variations gave 
any of the desired product and methyl acrylate was the only starting material recovered. 
Even after an attempt at separating the compounds the I H NMR spectra were inconclusive 
as the mixture proved to be inseparable. 
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2.7.3 Summary ofOrganocuprate Reactions 
Lithium benzimidazole Solvent ITemperature MSCI Occurrence 
form derivative (centigrade) 
Li metal Br Ether RTto -20 No No Reaction 
Br THF RTto-20 No Reduction and Elimination products 
Br THF RT Yes Gives Benzimidazole starting material 
Br THF -10 Yes Gives Benzimidazole starting material 
Br THF -78 Yes Reduction and Elimination products 
Cl Ether RT to -20 No No Reaction 
Cl THF RTto -20 No No Products 
I THF RTto 0 No No Reaction 
n-BuLi Br Ether -78 No Colour change, methyl acrylate back 
Br THF -78 No Colour change, methyl acrylate back 
Cl Ether -78 No Colour change, methyl acrylate back 
Cl THF -78 No Colour change, methyl acrylate back 
Table 2.2 Organocuprate reaction summary 
Table 2.2 shows the reactions performed and their outcome. Despite the change in colour 
indicating some kind of reaction, none of the desired product was formed. The reduction 
and elimination products from the benzimidazole are likely to be due to the lithium metal 
reacting too slowly with the bromo compounds and so allowing enough time for the 
reduction/elimination reaction of the alkyl lithium and residual alkyl bromide. There is a 
possibility that there were a number of undesired side reactions with using n-butyl lithium, 
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such as deprotonation at the carbon between the nitrogen atoms on the benzimidazole. 
These side reactions have not however led to any identifiable products and the I H NMR 
spectra are very inconclusive, containing a large number of peaks that makes them difficult 
to interpret. 
Given the lack of success with radicals, hydroboration, cross-metathesis and organocuprate 
approaches to forming c-e bonds as a link between amino acids and a heterocyclic side-
chain and not wishing to repeat the work of other people with different methods, it was 
decided to shift to CoX bonds as the linkage. 
78 
2.8 Carbon-Heteroatom Bond Formation 
The linkage between the heterocycle and the amino acid does not have to consist of just 
carbons, there can be other atoms present such as heteroatoms in tbe chain itself. This has 
been reported using different methods to form other PNAs90,91 or DNA type compounds.92 
The following reaction scheme shows tbe planned investigation into carbon-heteroatom 
linkage. Amino acids witb nucleophilic heteroatoms in their side-chains were required 
since the haloalkylheterocycles were already in hand as electrophiles. Initially a reaction 
without base present was considered, but it was decided tbat the lone pairs on the 
heteroatoms would not be sufficient for the nucleophilic substitution reaction to take place. 
It was planned that the base would remove a proton from the heteroatom to give a more 
reactive nucleophile, then for nucleophilic attack to take place. The general reaction 
scheme is shown in Figure 2.33. 
~ 
X, 
R 
+ R'HNACOOR" 
base 
• 
Figure 2.33 Formation of carbon-heteroatom linkage 
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The following amino acids were selected as potential candidates for this type of reaction, 
the naturally occurring L-cysteine, L-serine and the non-proteogenic 2,3-diaminopropionic 
acid, 2,4-diaminobutyric acid and homocysteine as in Figure 2.34. 
SH 
H2N
i COOH 
Cysteine Serine 
Figure 2.34 Suitable amino acids 
Diamino-
propionic acid 
Diamino-
butyric acid 
Homocysteine 
The first reactions to be investigated used L-cysteine because the thiol group should be the 
most nucleophilic and least basic of SH, OH and NH2. 
2.8.1 Cysteine 
Ester protection 
The L-cysteine carboxyl group was protected as the ethyl ester as this ester was available 
commercially. 
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Protection of Amino Group 
SH (Boc)zO, SH i DIEA, DCM, 2 h i 
CI-H
3
N COOEt-------· BocHN COOEt 
Figure 2.35 Boc protection ofL-cysteine 
To protect the amino group the t-butyloxycarbonyl function was selected, since it would be 
easily removed for couplings with other amino acids. To a dry round-bottomed flask was 
added cysteine ethyl ester, (Boc)20 and DIEA in dry DeM. The reaction was then stirred 
for 2 h at room temperature and aqueous work up and purification gave Boc-cysteine ethyl 
ester in 94% yield (Figure 2.35). 
2.8.1.1 Reactions of Cysteine with Iodoa\ky\ Heterocyc1es 
o 
N 
~ )n 
HS NaH, 1 THF 
+ BocHN COOEt----·~ 
I 
Figure 2.36 Substitution Reactions 
The above scheme, Figure 2.36, shows the general reaction plan for the substitution 
reactions. The protected cysteine in dry THF is added to a flame-dried round-bottomed 
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flask which was cooled via an ice bath to O°C. NaH is then added followed by the 
iodoethyl compound after a set time and the reaction allowed to warm to room temperature 
before refluxing overnight. The product is obtained by aqueous work up and column 
chromatography. 
Reaction of Cysteine with Nl-(2-Iodoethyl)benzimidazole 
~N~ SH ~N + f ~ BocHN COOEt 
I 
NaH, 
THF 
• 
Figure 2.37 Boc-cysteine ethyl ester with Nl-(2-iodoethyl)benzimidazole 
Protected cysteine in dry THF was added to a flame-dried round-bottomed flask which was 
cooled to O°C and under nitrogen. NaH was then added. In the first reaction the Nl-(2-
iodoethyl)benzimidazole was added immediately to the reaction mixture after the NaH, 
before the mixture was allowed to warm and then heated at reflux overnight. This first 
reaction gave some of the desired alkylation product, but more of the elimination product, 
N-vinyl benzimidazole and the cysteine starting material. The planned reaction scheme is 
shown in Figure 2.37. It was thought from these results that the N-vinyl benzimidazole had 
been formed from reaction of the iodoethyl compound directly with the NaH (Figure 2.38), 
implying that the reaction between NaH and Nl-(2-iodoethyl)benzimidazole is very rapid 
and hence the NaH did not have time to deprotonate the protected cysteine. 
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Figure 2.38 Elimination to N-Vinylbenzimidazole 
A number of reactions were therefore performed to test whether the time at which the 
NI-(2-iodoethyl)benzimidazole was added after the NaH addition had an effect on the 
reaction, these results are shown in Table 2.3 below. 
Time (min) Yield of S-benzimidazole 
Boc-cysteine ethyl ester 
0 46% 
5 56% 
10 62% 
15 64% 
20 66% 
30 65% 
45 67% 
60 56% 
Table 2.3 Cysteme With Nl-(2-Iodoethyl)benzimidazole Reactions 
It can be seen that for the first 20 minutes, the longer after the addition ofNaH that NI-(2-
iodoethyl)benzimidazole is added the better the yield of the desired alkylation product, 
showing that a delay in adding the iodo compound is beneficial in the formation of the 
desired alkylation product, although after 15 min the increase in yield becomes negligible. 
The product constitutes a novel S-linked heterocyclic amino acid as shown in Figure 2.37. 
83 
After the successful investigations with Nl-(2-iodoethyl)benzimidazole, a range of 
reactions were performed using the same general procedure with other heterocyc1es. 
Cysteine with Uracil Derivative 
NaH, 
THF 
I"" 
1 NAO 
~ 66% 
s 
BOCHNlCOOEt 
Figure 2.39 Boc-cysteine ethyl ester with N3-benzoylated-Nl-(2-iodoethyl)uracil 
This reaction was performed as detailed above and is shown in Figure 2.39, with the N3-
benzoylated-Nl-(2-iodoethyl)uracil being added to the reaction mixture 20 min after the 
NaH. The initial reaction with the Boc cysteine ethyl ester gave a lower than expected 
yield and so the time between NaH addition and addition of the uracil derivative was 
varied. The optimum time for the addition of the uracil derivative (to the nearest 5 min) 
was found to be 5 min, the yields for the various times are shown in Table 2.4. 
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Time (h) Yield of S-uracil Boc-cysteine ethyl ester 
0 67% 
5 70% 
10 66% 
15 64% 
20 62% 
30 57% 
45 55% 
60 55% 
Table 2.4 UracIl denvattve with Cysteme ReactIOns 
Thymine Reactions 
It was first necessary to protect the thymine and to fonn the N3-benzoyl-Nl-(2-
iodoethyl)thymine, by the same protection/alkylation sequence developed for uracil. 
N3-Benzoyl-Nl-(2-iodoethyl)thymine 
1 ~ 1 ~ 
o I) Benzoyl Chloride 0 ~ 0 ~ 
H Pyridine, Br 
1 I • 1 I • 1 I N~O 2) K,CO" N~O DIAD, Ph,P, N~O 
I Dioxane, 
H Water ~ Dioxane ~ 
Br 
Nal, 
Acetone 
Figure 2.40 Preparation of Thymine Derivative for Reaction with Amino Acid 
I~ 
'I A 
~ 0 
The same scheme was employed as for uracil previously and is shown in Figure 2.40. 
Firstly, thymine was protected at the N3 position using a suspension of thymine in a 
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solution of acetonitrile/pyridine with benzoyl chloride being added dropwise at O°C. After 
2 h the suspension had disappeared to give an orange solution. The solution was left to stir 
overnight to fonn NI,N3-benzoyithymine. This was confinned by 'H NMR spectroscopy 
which now showed no NH peaks in the 0 IO.5ppm region. The dibenzoylated compound 
again proved difficult to separate from the pyridine solvent so DCMlwater was added to the 
'slush' which produced a white suspension. The solvent was filtered off to give the 
dibenzoylated product. The NI benzoyl group was preferentially removed using potassium 
carbonate in water/dioxane (1: 1 v/v) to give the desired N3-benzoylthymine product in 71 % 
yield. 
The bromo ethyl group was then added. N3-benzoylthymine, 2-bromoethanol and 
triphenylphosphine (TPP) were stirred in dry dioxane with DIAD added dropwise over 1 h 
at 5°C. The mixture was allowed to wann to room temperature and was stirred overnight to 
give a yellow solution. The solvent was then removed under reduced pressure and the 
desired N I-alkylated product was purified using column chromatography. This gave a 
yield of 56% for the desired product, N3-benzoyl-NI-(2-bromoethyl)thymine, and further 
reactions after this also gave high yields. 
To fonn the iodoethyl derivative from the bromo ethyl derivative a simple halogen 
exchange, Finkelstein reaction, was again needed. N3-Benzoyl-NI-(2-bromoethyl)thymine 
was heated at relux in dry acetone with dry NaI to give the N3-benzoyl-NI-(2-
iodoethyl)thymine as the desired product in a yield of 54% (Figure 2.40). 
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Cysteine with Thymine Derivative 
2 iN -<0;:'" . 
NAO + BocHN COOEt-----
N.H, 
THF 
~ 
I 
I"" 
1 NAO 
~ 62% 
s 
BocHN1COOEt 
Figure 2.41 Boc-cysteine ethyl ester with N3-benzoylated-Nl-(2-iodoethyl)thymine 
This reaction was perfonned as previously detailed for the uracil derivative and is shown in 
Figure 2.41, with the N3-benzoylated-NI-(2-iodoethyl)thymine being added to the reaction 
mixture 20 min after the NaH. The initial reaction with the Boc-cysteine ethyl ester gave a 
lower than expected yield again and so the time the thymine derivative was added after the 
NaH was again varied. The optimum time for the addition of the thymine derivative was 
again found to be 5 minutes after the NaH, as shown in Table 2.5. 
Time (h) Yield of S-thymine Boc-cysteine ethyl ester 
0 60% 
5 80% 
10 62% 
15 57% 
20 56% 
30 54% 
45 54% 
60 55% 
Table 2.5 Thymine derivative with Cysteine Reactions 
87 
Indole Reactions 
Another heterocycle which was tried in this S-alkylation sequence, but not found in nature 
was indole. Like benzimidazole, indole does not need to be protected before it is used, and 
the bomoalkylation was tried directly on indole (Figure 2.42). 
The indole was firstly reacted under the Mitsunobu conditions, as described previously. 
Indole, 2-bromoethanol and TPP were stirred in dry dioxane with DIAD added dropwise 
over 1 h at 5°C. The mixture was allowed to warm to room temperature and was stirred 
overnight to give a yellow solution. The solvent was then removed under reduced pressure. 
The crude 'H NMR spectrum showed no sign of the bromoalkylated product and revealed 
only the starting materials. The unreacted TPP was removed, first by crystallization and 
then column chromatography and the starting material was retrieved quantitatively. It was 
concluded that the nitrogen on the indole was not acidic enough to react under Mitsunobu 
conditions. 
TPP, DIAD, dioxane, 
2-bromOeth~ 
~ VL-I 8 __________ 
1,2-<1ichloroethane, 
Bu4NI, KOH, K,CO, 
Figure 2.42 Formation ofN-(2-Iodoethyl)indole 
Na!, 
acetone 
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The phase transfer catalyst (PTC) method was then tried using 1,2-dichloroethane. Indole 
was added to a mixture of 1,2-dichloroethane, tetrabutylammonium iodide, solid KOH and 
K2C03. The reaction was stirred at room temperature for 24 h. After the inorganics had 
been filtered off and the organic portion worked up, the mixture was put through flash 
chromatography, where the desired product separated easily and cleanly to give an 81 % 
yield ofN-(2-chloroethyl)indole. 
It was then possible to do the halogen exchange (Finkelstein) reaction on the chloride, 
instead of the bromide. The reaction conditions used were the same, but the reaction times 
were longer. Chloroethylindole was heated at reflux in the dark in dry acetone with dry 
NaI. This gave the desired N-(2-iodoethyl)indole in a yield of64% (Figure 2.42). 
Cysteine with Iodoethylindole 
co iSH __ ~_~_~_' __ " A ~ 
+ BocHN COOEt Sl 
BocHN COOEt 
31% 
Figure 2.43 Boc-cysteine ethyl ester with N-(2-iodoethyl)indole 
This reaction was performed as previously detailed using the protected cysteine, with the 
iodoethylindole being added to the reaction mixture 10 min after the NaH. After 
purification by column chromatography the desired S-alkylation product was obtained in a 
89 
yield of 31 %. Subsequent reactions were perfonned, but with no improvement in yield, 
although it is unclear why the yield is only moderate (Figure 2.42). 
Purine Reactions 
Purine was also chosen as a heterocycle to be investigated because, although it does not 
occur naturally, it does possess the same ring structure as the nucleobases adenine (which 
has been investigated later) and guanine. Purine did not need to have any of its sites 
protected and so could be directly bromoalkylated (Figure 2.44). 
Purine was bromoalkylated under Mitsunobu conditions. Purine, 2-bromoethanol and TPP 
were stirred in dry dioxane with DIAD added dropwise over 1 h at 5°C. The mixture was 
allowed to wann to room temperature and was stirred overnight to give a yellow solution. 
The solvent was then removed under reduced pressure and the mixture worked up to give 
the desired product N9-(2-bromoethyl)purine in a yield of73%. 
The purine was also chloroalkylated under the PTC conditions for comparison. Purine was 
added to a mixture of 1,2-dichloroethane, tetrabutylamrnonium iodide, solid KOH and 
K2C03. The reaction was stirred at room temperature for 24 h. After the inorganics had 
been filtered off and the organic portion worked up, the mixture was put through flash 
chromatography, where the desired product, N9-(2-chloroethyl)purine, again separated 
easily and cleanly to give a 59% yield. 
The Finkelstein halogen exchange reaction was then perfonned on both haloalkyl purines 
using dry acetone and NaI to give the desired product. The yield for the bromide to the 
iodide halogen exchange was 79% and the yield from the chloride to the iodide halogen 
exchange was 64% (Figure 2.44). 
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TPP, DIAD, dioxane, 
2-bromoethanol 
--------
1,2-dichloroethane, 
Bu,NI, KOH, KzCO, 
Figure 2.44 Formation ofN9-(2-Iodoethyl)purine 
It was decided that subsequent reactions to form the iodoalkyl compounds would be via the 
Mitsunobu method as this gave the higher yields both to form the haloalkyl compound and 
for the halogen exchange. 
Cysteine with N9-(2-Iodoethyl)purine 
N~N~ 
tAl 
iSH __ ~_~~_' __ . N ~ 20% 
+ BocHN COOEt sl 
BocHN COOEt 
Figure 2.45 Boc-cysteine ethyl ester with N9-(2-iodoethyl)purine 
This reaction was performed as previously detailed, with the N9-(2-iodoethyl)purine being 
added to the reaction mixture 10 min after the NaH was added to the protected cysteine. 
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After purification by column chromatography the desired S-alkylation product was 
obtained in a yield of 20% (Figure 2.45). Subsequent reactions were performed, but with 
no improvement on this yield, although it is again unclear why such a low yield was 
obtained. 
Adenine Reactions 
Although the reactions with purine had not proved to be high yielding, some of the desired 
heteroeyciic amino acid derivative had been obtained so adenine was prepared for reaction 
with the protected cysteine. It was first necessary to protect the C-6 amino substituent of 
adenine, which can be done using the Boc protecting group. 
TPP DIAD NHBoc 
NHBoe (Boc),O, N~N DIEA, DCM N '::::: N II ~ 
ll .. ~ ~ --- II ~ N~ '---....... yNHBOC Br ./ N~ N 
N ~ N ~ ~ Nil ~ N~ /NaI, ~I 
t..:..... _... / acetone 
1,2·dichloroethane, N N~ 
t-Bu,NI, 
KOH, K,CO, 
Cl 
Figure 2.46 Formation of Boe Protected N9-(2-Iodoethyl)adenine 
To a dry round-bottomed flask was added adenine, (BochO and DIEA in dry DCM. The 
reaction was then stirred for 2 h at room temperature and the product was purified after 
aqueous work up to give Boe-adenine in quantitative yield, shown in Figure 2.46. 
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The next step involved the bromoalkylation of the protected adenine. This reaction had 
been performed before57 and it has been seen previously that the reaction does not have a 
very good yield. The same method was used as previously under Mitsunobu conditions. 
Boc-Adenine, 2-bromoethanol and TPP were stirred in dry dioxane with DIAD added 
drop wise over 1 h at 5°C. The mixture was alIowed to warm to room temperature and was 
stirred overnight to give a yelIow solution. The solvent was then removed under reduced 
pressure folIowed by some purification by column chromatography. The initial crude yield 
was less than 30%, so the crude products were reacted a second time under the same 
conditions and the total yield was calculated to be 37%. It was decided not to try for a third 
time as it was thought the yield would not increase by a sufficient amount to warrant such 
action. 
The chloroalkylation was also tried using the same method as previously, using a phase 
transfer catalyst. This however only gave an impure product which was inseparable from 
the mixture in about 59%. 
The Finkelstein halogen exchange reaction was then performed using dry acetone and NaI 
to give the desired product via halogen exchange of the bromide to the iodide with a yield 
of 51 % (Figure 2.46). 
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Cysteine with N9-(2-Iodoethyl)-Boc-adenine 
NHBoc 
N~N~ 
tJ-1 N~ 
I 
NHBoc 
N~N~ 
tJ-1 
iSH __ ~_~_~_' __ • N ~ 41% 
+ BocHN COOEt Sl 
BocHN COOEt 
Figure 2.47 Boc-cysteine ethyl ester with N9-(2-iodoethyl)-Boc-adenine 
This reaction was perfonned as previously detailed using the protected cysteine, with the 
N9-(2-iodoethyl)-Boc-adenine being added to the reaction mixture 10 min after the NaH. 
After purification by column chromatography the desired S-alkylation product, Figure 2.47, 
was obtained in a yield of 41%. Although still not a large yield this was higher than 
expected based on the purine results. 
Benzotriazole Reactions 
Benzotriazole was the next heterocycle to be investigated. This threw up a problem in that 
the reaction could occur at either nitrogen site, at NI or N2 (Figure 2.48). 
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Figure 2.48 Haloalkylation at NI and N2 sites 
Statistically one may naively predict that the reaction should occur in 2: I ratio NI to N2. 
In practise this has occurred for a number ofreactions,93 and NI-alkylation was the initial 
target, although the N2 product could also be used in the formation of a heterocylic amino 
acid. The ratio of the NI:N2 products may in practice differ depending on the method of 
forming the haloalkyl compound. 
Bromo/Chloro-ethylbenzotriazole 
Being the first method used in the formation of haloalkyl heterocyc1es for this investigation, 
the Mitsunobu method was the first method tried for benzotriazole (Figure 2.49). 
Benzotriazole, 2-bromoethanol and TPP were stirred in dry dioxane with DIAD added 
dropwise over 3 h at 5°C. The mixture was allowed to warm to room temperature and was 
stirred overnight to give a yellow solution. The solvent was then removed under reduced 
pressure and the mixture worked up to give the NI-(2-bromoethyl)benzotriazole in a yield 
of only 27% and the N2-(2-bromoethyl)benzotriazole in a yield of 56%. The ratio of 
NI :N2 alkylation was the opposite to what was expected at 1:2 and the isomers were 
identified using NMR spectroscopy. The IH NMR spectra showed symmetry in the 
aromatic region for the N2 compound, which was also backed up by NOE spectra. 
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The benzotriazole was also chloroalkylated by the PTC protocol to test the ratio of the 
chloroethyl products (Figure 2.49). Benzotriazole was added to a mixture of 1,2-
dichloroethane, tetrabutylammonium iodide, solid KOH and K2C03, and the reaction was 
stirred at room temperature for 24 h. After the inorganics had been filtered off and the 
organic portion worked up, the mixture was put through flash chromatography, where the 
products separated off easily and cleanly to give the NI-alkylated compound in 66% yield 
and the N2 compound was not isolated. The selectivity between the two products was not 
as for the Mitsunobu reaction, but was still not as expected statistically. 
TPP, DIAD, dioxane, 
2-bromoethanol 
--------
1,2-dichloroetbane, 
Bu.NI, KOH, Kzeo, 
Figure 2.49 Bromoalkylation and Chloroalkylation of Benzotriazole 
The Finkelstein halogen exchange reaction was then performed on all three haloalkyl 
compounds formed using dry acetone and NaI to give the desired products (Figure 2.50) via 
the halogen exchange of the bromide or chloride to the iodide in all cases: 
N I Bromo to NI Iodo ethyl benzotriazole = 95% 
NI Chloro to NI Iodo ethyl benzotriazole = 94% 
N2 Bromo to N2 Iodo ethyl benzotriazole = 97% 
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Figure 2.50 Formation ofIodoethylbenzotriazoles 
Cysteine with Iodoethylbenzotriazoles 
Both of the iodoethylbenzotriazoles in reaction with the protected cysteine gave good 
results. 
These reactions were performed as previously detailed, with the iodoethylbenzotriazoles 
being added to the reaction mixture 10 min after the NaH. After purification by column 
chromatography, the desired S-alkylation products were obtained in a yield of 75% from 
the NI-series and in a yield of 74% for the N2-series (Figure 2.51). 
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a) 
b) 
SH NaH, f THF 
+ BocHN COOEt------
NaH, 
THF 
Figure 2.51 a) NI-Iodoethylbenzotriazole with Boc-cysteine ethyl ester 
b) N2-Iodoethylbenzotriazole with Boc-cysteine ethyl ester 
Having prepared a number of heterocylic amino acids based on halo ethyl heterocycles, it 
was decided to extend the studies to use longer linkers available fromurhalopropyl or butyl 
heterocycIes, but first it was necessary to prepare suitable substrates. 
Iodopropyl and Iodobutyl Benzimidazole Reactions 
NI-(3-Iodopropyl)benzimidazole can, like NI-(2-iodoethyl)benzimidazole, be formed via 
both the Mitsunobu and PTC methods. Both methods were tried in order to identify which 
gave the highest yield of the NI-(3-iodopropyl)benzimidazole. 
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Nl-(3-Bromopropyl)benzimidazole 
3-bromopropan-I-QI'O=N 
~P, DIAD, I '-':: ~ 
dioxane / 
Figure 252 Fonnation ofN 1-(3-Bromopropyl)benzimidazole 
Benzimidazole was N-bromoalkylated under Mitsunobu conditions (Figure 2_52). The 
benzimidazole, 3-bromopropanol and TPP were stirred in dry dioxane with DIAD being 
added dropwise over 1 h. After being left to stir at room temperature overnight the solvent 
was removed under reduced pressure. The crude product was purified by column 
chromatography to give the NI-(3-bromopropyl)benzimidazole with a yield of78%. 
N 1-(3-Chloropropyl) benzimidazole 
1,3 -dichloropropane, 
Bu4NI (PT cat), 
KOH, ~C03' 8 h 
• 
Figure 253 Fonnation ofNI-(3-chloropropyl)benzimidazole 
Benzimidazole was added to a mixture of 1,3-dichloropropane, tetrabutylammonium 
iodide, KOH and K2C03• The reaction was however stirred for longer at room temperature 
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for 8 h (Figure 2.53). After the inorganics had been filtered off and the organic portion 
worked up, the mixture was put through flash chromatography, where the desired product 
came off easily and cleanly but still only gave a 62% yield. 
Nl-(3-Iodopropyl)benzimidazole 
+(1 21 
erN~ erN NX) 
NaI, I~ ,<~ ~I ~ N 
\,~ acetone l)+ X • erN~ ..Q N 
\ 
Figure 2.54 Attempted conversion of Bromo to NI-(3-Iodopropyl)benzimidazole 
The Finkelstein halogen exchange reaction was then performed using dry acetone and NaI 
(Figure 2.54). However the desired product via the halogen exchange of either the chloride 
or bromide to the iodide did not form. After careful examination by NMR spectroscopy 
and mass spectometry it was concluded that a macrocyclic double quaternary salt had been 
formed, in a quantitative yield. The IH NMR spectrum clearly showed the presence of 
triplets and a quintet, meaning that the iodo group had not been reduced or eliminated as 
has been see for otherreactions, and the mass spectrum gave ions ofmlz 317.30 and 158.93 
from Le/MS. The ion at 317.30 corresponds to loss ofa proton from the doubly charged 
quarternary salt, while 158.93 corresponds to the mass/charge ratio of the doubly charged 
cyclic salt. 
lOO 
Nl-(4-ChJorohutyJ)benzimidazoJe 
1,4-dichlorobutane, 
Bu,NI (PT cat), 
KOH, K,COJ, 4 h 
• 
Figure 2.55 Fonnation ofNl-(4-chlorobutyl)benzimidazole 
Benzimidazole was added to a mixture of 1,4-dichlorobutane, tetrabutylammonium iodide, 
KOH and K2C03 as shown in Figure 2.55. The reaction was stirred at room temperature for 
8 h. After the inorganics had been filtered off and the organic portion worked up, the 
mixture was put through flash chromatography, where the desired product came off easily 
and cleanly but only gave a 58% yield. 
Nl-(4-IodobutyJ)benzimidazoJe 
Figure 2.56 Bromo to Iodobutylbenzimidazole 
101 
The Finkelstein reaction was once again performed using Nal and acetone at reflux for 4 h 
(Figure 2.56). After careful examination by NMR spectroscopy and mass spectometry it 
was concluded that a quaternary salt had again been formed, in a quantitative yield. The 
NMR clearly showed the quintets and triplets as would be present in the quaternary salt, 
and the mass spectrum gave the ions at masses of 173.04 and 345.64, equivalent to the 
mass/charge ratio of the doubly charged salt and the double salt after the loss of a proton. 
The lack of success in preparing N-(3-iodopropyl) or N-( 4-iodobutyl)benzimidazole led to 
further investigation with the other heterocycles. 
Further Indole Reactions 
Next the formation of N-(3-iodopropyl) and N-(4-iodobutyl)indole was attempted. This 
was tried only via the PTC method as the Mitsunobu method had not been successful for 
the ethyl derivatives and the length of the alkyl group should make little or no difference 
under Mitsunobu conditions. 
N-(3-Iodopropyl)indole 
1,3-DCP, NI 
Bu.NI, ~I ~ ~ ac~tone 
KOH, KzCO,. V--l )( 
\, .00 
"""'"'\, 
Figure 2.57 Formation ofChloro (and lodo) propylindole 
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Indole was added to a mixture of 1,3-dichloropropane, tetrabutylammonium iodide, KOH 
and K2C03. The reaction was then stirred at 50°C for 24 h and it was noted that the 
reaction had formed a dark brown colour. After the inorganics had been filtered off and the 
organic portion worked up, the mixture was put through flash chromatography, where a 
major product was isolated, in a yield of 61%, which proved to be the N-(3-
chloropropyl)indole as shown in Figure 2.57. 
The Finkelstein halogen exchange reaction was then performed using dry acetone and NaI 
to give the desired product in an impure state via halogen exchange of the chloride to the 
iodide with an approximate yield of 66% as an dark brown oil (Figure 2.56). The product 
was inseparable from the mixture and no substitution reactions were attempted. 
N-(4-Chlorobutyl)Indole 
\,3-DCB, I ~ ~ ~ Bu.NI, 
V--{ -)*-( ---. 
H 
Cl 
Figure 2.58 Formation of Chlorobutylindole 
Indole was added to a mixture of 1,4-dichlorobutane, tetrabutylammonium iodide, KOH 
and K2C03 (Figure 2.58). The reaction was stirred at room temperature for 48 h. After the 
inorganics had been filtered off and the organic portion worked up, the 'H NMR spectrum 
was unclear and so flash chromatography was performed. After careful examination by 
NMR spectroscopy and mass spectometry of the different fractions, it was concluded that it 
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was not be possible for any chlorobutylindole to be separated from the mixture and so it 
would not be possible to fonn the corresponding iodo compound. 
Further Reactious Involving Benzotriazole 
As the investigations into the formation of iodoethylbenzotriazoles had given varying 
results depending on which reaction had been used, for the formation of the isometric 
iodopropylbenzotriazole compounds, both the Mitsunobu and the PTC methods were used. 
Bromopropylbenzotriazole 
0:"'" N'N ~ I N 
H 
3-Bromopropanol, 
TPP,DIAD, 
Dioxane 
Figure 2.59 Benzotriazole with 3-Bromopropanol 
Br 
Benzotriazole was bromoalkylated under Mitsunobu conditions. Benzotriazole, 3-
bromopropanol and TPP were stirred in dry dioxane with DIAD being added dropwise over 
1 h. After being left to stir at room temperature overnight the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography to 
unexpectedly give only the NI-(3-bromopropyl)benzotriazole isomer with a yield of 78% 
(Figure 2.59). 
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Chloropropylbenzotriazole 
1,3-Dichloropropane, 
Bu4NI, 
KOH, !<zeo, 
Figure 2.60 Benzotriazole with 1,3-dichloropropane 
Benzotriazole was added to a mixture of 1,3-dichloropropane, tetrabutylammonium iodide, 
KOH and K2C03 and the reaction was stirred at room temperature for 24 h. After the 
inorganics had been filtered off and the organic portion worked up, the mixture was 
subjected to column chromatography, where both products were separated easily and 
cleanly to give the NI alkylated compound in 52% yield and the N2 compound in a smaller 
yield of 24% (Figure 2.60). For the chloropropyl reaction the ratio of NI :N2 alkylation is 
2: 1, the statistical ratio that was not seen previously for the chloroethyl and bromoethyl 
reactions. Again this was confirmed by the use ofNMR techniques. 
Iodopropylbenzotriazole. 
As previously the Finkelstein halogen exchange reaction was then performed using dry 
acetone and NaI, at reflux for 48 h, to give the desired product via the halogen exchange of 
the chloride to the N-(3-iodopropyl)benzotriazoles (Figure 2.61). 
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Figure 2.61 Chloro to Iodopropylbenzotriazoles 
The yields vary for each case and in each case cream coloured crystals were formed: 
Nl-chloro to Nl-(3-iodopropyl)benzotriazole = 77% 
N2-chloro to N2-(3-iodopropyl)benzotriazole = 65%. 
Chlorobutylbenzotriazole 
As for the chloropropyl derivative above, only the chlorobutyl alkylation using the PTC 
method was performed (Figure 2.62). 
1,4-Dichlorobutane, 
Bu,NI, 
KOH.K,CO, 
Figure 2.62 Formation of Chlorobutylbenzotriazoles 
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Benzotriazole was added to a mixture of 1,4-dichlorobutane, tetrabutylammonium iodide, 
KOH and K2C03. The reaction was stirred at room temperature for 24 h. After the 
inorganics had been filtered off and the organic portion worked up, the mixture was 
subjected to column chromatography, where both products were separated easily and 
cleanly to give the NI-alkylated compound in 24% yield and the N2 compound in an 
almost equivalent yield of 21%. For the chlorobutyl reaction the ratio of NI:N2 was 
therefore 1: I. 
Iodobutylbenzotriazole 
NaI, 
acetone 
NaJ, 
acetone 
• 
Figure 2.63 Chloro to Iodobutylbenzotriazoles 
The Finkelstein halogen exchange reaction was again performed using dry acetone and NaI, 
at reflux for 48 h, to give the desired N-( 4-iodobutyl) products via halogen exchange of the 
chloride to the iodide (Figure 2.63). The NI-(4-iodobutyl)benzotriazole was formed in a 
yield of 70%, and the N2-(4-iodobutyl)benzotriazole also in a yield of 70%. This reaction 
was again simple to perform with good yields of the products being formed. 
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Cysteine with N-(3-IodopropyJ)benzotriazoJe 
The cysteine alkylations with N-(3-iodopropyl)benzotriazole reactions were both performed 
as for the previous nucleophilic substitution reactions. N-(3-Iodopropyl)benzotriazole was 
added to the reaction mixture 10 min after the N aH was added to the protected cysteine. 
Purification by column chromatography then gave the desired product. 
NaH. 
THF 
• 
Figure 2.64 Reaction of Boc-cysteine ethyl ester with Nl-(3-iodopropyl)benzotriazole 
N-Boc-S-[3-(Benzotriazol-l-yl)propyl] cysteine ethyl ester was obtained in a yield of 59% 
(Figure 2.64). This was a reasonable yield although a second column was necessary to 
completely purify the desired product. 
NaH. 
THF 
• 
!<=::o 
s 
BOCHNfCOOEt 
68% 
Figure 2.65 Reaction of Boc-cysteine ethyl ester with N2-(3-iodopropyl)benzotriazole 
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N-Boc-S-[3-(Benzotriazol-2-yl)propyl] cysteine ethyl ester was obtained in a yield of 68% 
(Figure 2.65). This was a reasonable yield although again a second column was necessary 
to completely purify the desired product. 
Cysteine with N-(4-IodobutyJ)benzotriazole 
The cysteine with N-( 4-iodobutyl)benzotriazole reactions were both performed as for the 
previous nucleophilic substitution reactions. N-(4-Iodobutyl)benzotriazole was added to 
the reaction mixture 10 min after the NaH was added to the protected cysteine. Purification 
by column chromatography then gave the desired product. 
NaH, 
THF 
• 
Figure 2.66 Reaction of Boc-cysteine ethyl ester with NI-(4-iodobutyl)benzotriazole 
N-Boc-S-[3-(Benzotriazol-I-yl)butyl] cysteine ethyl ester was obtained in a yield of 39% 
(Figure 2.66). Subsequent reactions were performed, but the yield did not improve above 
this, although it is unclear why such a low yield was obtained. 
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~N'N 
~I SH NaH, ~N ~ 62% ~N, ~ + r __ T_H_F __ • ~S COOEt 
~t/ BOCHNACOOEt "-< 
NHBoc 
Figure 2.67 Reaction of Boc-cysteine ethyl ester with N2-(4-iodobutyl)benzotriazole 
N-Boc-S-[3-(Benzotriazol-2-yl)butyl] cysteine ethyl ester was obtained in a yield of 61 % 
(Figure 2.67). This was a much better yield than for the NI compound, although it is 
unclear why. 
Further Adenine Reactions 
Due to time constraints it as decided that, being one of the five nucleobases, adenine, rather 
than purine would be investigated with the longer linker. 
NHBoc 
N~N~ 
tJ-1 N N I 
H 
3-Bromopropan-l-ol, 
Dioxane, 
TPP,DIAD 
>( . 
Figure 2.68 Formation ofN9-(3-Bromopropyl)-Boc-adenine 
It was shown from the previous reactions involving adenine and the Mitsunobu reaction 
that some problems may occur, and it was thought that as for the haloethyl reactions, there 
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would be a similar problem. Under Mitsunobu conditions, Boc-adenine, 3-bromopropanol 
and TPP were stirred in dry dioxane with DIAD added dropwise over 1 h at SOC, Figure 
2.68. The mixture was allowed to warm to room temperature and was stirred overnight to 
give a yellow solution. The solvent was then removed under reduced pressure followed by 
some purification by column chromatography. No N9-(3-bromopropyl)-(Boc)adenine was 
found, so the crude products were reacted a second time, and then a third time, under the 
same conditions, however none of the desired product was found and there was no further 
investigation with adenine. 
2.8.1.2 Summary of Cysteine Reactions 
The reactions of cysteine with various heterocycIes has been successful with a good variety 
of heterocyclic systems and linker chain lengths. These variations have been successfully 
employed to generate novel S-linked protected heterocyclic amino acids as shown in 
Figures 2.69 and 2.70. 
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Thymine Uracil 
2 2 N2-benzotriazole 1// Nl-benzotriazole Q ~" 40 ~N 0 (r\ I ~N ~ , N-N/ 1 N)"O 1 N)"O N 
~ ~ ~ ~ 
S S S S 
BOCHNlCOOEt BOCHNlCOOEt BOCHNlCOOEt BOCHNlCOOEt 
Adenine 
Indole Benzimidazole 
Figure 2.69 Ethyl-linked Cysteine Products 
2N-benzotriazole 1 N-benzotriazole 
2N-benzotriazole 
1 N-benzotriazole 
Figur 2.70 Propyl- and Butyl-linked Products 
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2.8.2 Serine 
Serine was an obvious choice for use in the substitution reactions as another heteroatom-
containing amino acid, providing an O-linker. The same route as with cysteine was used in 
the protection of serine by esterification on the acid moiety and by the use of a Boc group 
on the amino moiety. 
2.8.2.1 Ester Protected Serine 
Protection of Acid group by Esterification 
The methyl ester of L-serine was available comercially, so no ester protection reaction at 
the acid moiety was necessary. 
Protection of Amino Group 
The Boc protection of serine was performed as for the Boc protection of the amino group 
. 94 
oncysteme. 
OH (Boc),O, OH 
-
+ 
( -------- ( ~ DIEA,DCM,2h - A 
Cl H3N COOMe BocHN COOMe 
Figure 2.71 Boc protection of serine 
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To a dry round-bottomed flask was added serine methyl ester, (Boc)zO and DIEA in dry 
DeM. The reaction was then stirred for 2 h at room temperature and the product was 
purified after aqueous work up to give Boc serine methyl ester in 94% yield (Figure 2.71). 
Reaction ofBoc Serine Methyl Ester with Nl-(2-Iodoethyl)benzimidazole 
The first substitution reaction that was attempted with Boc serine methyl ester was again 
with NI-(2-iodoethyl)benzimidazole. To a flame-dried round-bottomed flask was added 
the protected serine in THF which was then cooled before the addition of NaH. The N-(2-
iodoethyl)benzimidazole was then added after 5 to 10 min. After refluxing overnight the 
reaction was worked up as before (Figure 2.72). No substitution products from reaction of 
the protected serine derivative and Nl-(2-iodoethyl)benzimidazole were seen. 
+ f OH 
BocHN cOOMe 
NaH, THF, 
reflux, 24 h 
)" • 
~N~ ~,p\ 
fO 
BocHN COO Me 
Figure 2.72 Planned Reaction for Addition of Serine to NI-(2-iodoethyl)benzimidazole 
Initially it was thought that the benzimidazole derivative was being added to the reaction 
too soon after the addition of the NaH so this was investigated further by varying the time 
at which the Nl-(2-iodoethyl)benzimidazole was added after the NaH. 
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The NI-(2-iodoethyl)benzimidazole was added directly after the NaH (at 0 min) or at IS, 
30, 45 and 60 min after the addition of the NaH. In all cases none of the desired product 
was seen and the results are shown in Table 2.5 below: 
Time (min) Results 
0 Vinyl benzimidazole + other inseparable material 
IS Vinyl benzimidazole + other inseparable material 
30 Iodoethyl benzimidazole + Vinyl benzimidazole 
+ other inseparable material 
45 Iodoethyl benzimidazole + Vinyl benzimidazole 
+ other inseparable material 
60 Iodoethyl benzimidazole + other inseparable material 
Table 2.5 .. .. Times after addition ofNaH for the NI-(2-lOdoethyl)benzlmldazole additIOn 
It was suggested that the nucleophilic oxygen on the side-chain was attacking the ester 
group on another protected serine, shown in Figure 2.73, and hence not forming the desired 
addition product. 
(~ (o-~~ 
A (OMe 
BocHN COOMe 
Figure 2.73 Nucleophilic nature of Oxygen 
This could happen to form a number of different molecular mass ogliomers based on the 
same 'monomer' serine unit, which could explain the messy NMR spectra. The alkoxide 
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side-chain is less nucleophilic in SN2 reactions than the thiolate of deprotonated cysteine, 
and is 'harder'. 
t-Butyl Ester Protected Serine 
It was thought that a bulkier ester group may prevent the deprotonated oxygen attacking the 
ester moiety, so the use of a t-butyl group was investigated (Figure 2.74).95 
P 
i O BocHN COOH 
BF3 ·OEt" 
HA,DCM, 
Cyclohexane 
p 
. i O 
BocHN COOtBu 
I H2' Pd(OH),IC. Q:N EtOH, I ~ ~ CH,COOH .& I 
+ i OH 
BocHN COOtBu 
NaH, THF, N~ 
reflux, 24 h 
--»7<':'<:::-----
i O BocHN COOtBu 
Figure 2.74 Preparation oft-butyl protected serine and reaction with 
Nl-(2-iodoethyl)benzimidazole 
Commercially available O-benzyl-Boc-L-serine in DCM was stirred in a round-bottomed 
flask under nitrogen. To this was added t-butyltrichloroacetimidate (ITA) in dry 
cyclohexane followed by BF3:0Et2 and the mixture was stirred for 14 h at room 
temperature. NaHC03 was then added to neutralise the acid. The solvent was removed 
under reduced pressure and the desired t-butyl ester purified by column chromatography in 
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a yield of 99%. The benzyl group was then removed in hydrogen saturated 
EtOHlCH3COOH under a hydrogen atmosphere in the presence of Pd(OH)2/C (10%) 
catalyst to give a quantitative yield of Boc-L-serine t-butyl ester (Figure 2.74). 
The same reactions were then performed on the Boc serine t-butyl ester as for the Boc 
serine methyl ester. As shown in Figure 2.75, a flame-dried round-bottomed flask 
containing the serine derivative in THF was cooled before the addition ofNaH and then the 
NI-(2-iodoethyl)benzimidazole after varying time periods as summarised in Table 2.6. The 
use of the t-butyl ester did not seem to aid in the formation of the desired substitution 
product and it did not seem to matter at what time after the NaH the NI-(2-
iodoethyl)benzimidazole was added, the 'H NMR spectra of the reactions were still 
complex and the products could not be separated. A summary is shown in Table 2.6. 
Time (min) Results 
0 Vinyl benzimidazole + other inseparable material 
15 Vinyl benzimidazole + other inseparable material 
30 Vinyl benzimidazole + other inseparable material 
45 Iodoethyl benzimidazole + Vinyl benzimidazole 
+ other inseparable material 
60 Iodoethyl benzimidazole + Vinyl benzimidazole 
+ other inseparable material 
Table 2.6 .. Times after additIOn ofNaH for the Nl-(2-lOdoethyl)benzlmldazole addition 
Although complex, the 'H NMR spectra did however show a lack of any peak atOl.5 and 
2.0, meaning that both the t-butyl ester and Boc groups have disappeared. An explanation 
for the former has already been shown for the methyl ester. Despite the bulkiness of the 
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t-butyl group the nucleophilic nature of the deprotonated oxygen means it is attacking at the 
ester to give an ester exchange. 
~HN~ ;yo (OtBu BocHN ----_. 0 ----.. Further Reactions 
fO BocHNfCOOtBU 
BocHN COOtBu 
Figure 2.75 The Nucleophilic Nature of Oxygen 
2.8.2.2 Amide Protected Serine 
It was at this time that a paper was found which appeared to support this explanation for the 
problems that had been experienced with serine. Katoh et al.96 (Figure 2.76) have tried to 
use the method of alkylating a nucleophilic oxygen using a halo ester in just such a way as 
in this investigation, but also encountered the same problems as surmised above in Figure 
2.76. It was also shown in this paper that an iodo group, if present, is eliminated under 
these conditions and does not take part in any substitution reaction. Katoh solved the 
problem to some degree by the use of different groups, which was not feasible for this case. 
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The groups picked out 
are those as used in 
this study: 
lodo, I-butyl and alcohol 
lodo group either 
still present or 
eliminated 
o 
Exchange of 
t·butyl ester 
for new ester 
+ 
Figure 2.76 The ester exchange reaction as shown by Katoh et al.96 
Amide Protection of Serine 
o/'-....,. 
It was then decided that an amide should be tried as a replacement to the ester protection, to 
reduce the carbonyl electrophilicity. The procedure for amidation of serine is not overly 
complicated. Methanol was saturated with ammonia at 78°C and Boc serine methyl ester 
was then added. This mixture was then shaken at room temperature overnight and the 
product obtained in 98% yield simply by removal of the ammonia and solvent under 
reduced pressure (Figure 2.77). The reaction could be easily followed by the use of IR 
spectroscopy as the carbonyl peak moves from 1740 to 1685 cm-I. 
(OH
oMe 
BOCHN1( 
o 
NH" 
MeOH 
16 h 
Figure 2.77 Amide protection of serine 
(OH
NH 
BOCHN1( 2 
o 
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The Boc serine amide was then reacted with Nl-(2-iodoethyl)benzimidazole by the same 
method as for the previous experiments, using THF and NaH, but again none of the desired 
substitution product was seen (Figure 2.78), nor any N-vinyl benzimidazole. The IH NMR 
spectra were unclear as were the TLCs and it was decided not to pursue this approach any 
further. 
~OH + NH BocHN 2 
o 
NaH, THF, 
reflux, 24 h 
x 
cc""= N-;> 
o ~ 
(0 NH 
BOCHNTI 2 
o 
Figure 2.78 Reaction ofiodoethyl benzimidazole with Boc serine amide 
It was possible that the NH of the secondary amide group could have been causing a 
problem and so an attempt was made at protecting the serine carboxylic acid moiety using a 
tertiary amide. 
Boc serine piperidine amide 
MeOH, 
~OH ___ ~T_pe~*.d_ine_, ____ • (OH 0 BocHN OMe BOCHN1( DCC,PFP, o piperidine, 0 
DCM,OoC 
Figure 2.79 Piperidine protection of serine 
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The first method of piperidine amide formation from Boc-serine methyl ester, by reaction 
of piperidine in MeOH at room temperature, was tried without success (Figure 2.79). 
Before any further investigation could take place a method was found for the substitution 
using a serine derivative which did not involve the protection of the acid moiety. 
2.8.2.3 Boc Only Protected Serine 
Sugano and Miyoshi97 have reported the side-chain benzylation of Boc-serine using DMF 
and NaH, i.e. having the carboxylic acid group present as the carboxylic salt. It was 
decided to try this method for serine with Nl-(2-iodoethyl)benzimidazole. 
(Boc),O, 
OH DIEA, OH i 2h,RT i 
H2N eOOH-----~~ .. OCHN eOOH 
+ 
DMF,NaH, 
30oC, 16 h 
)( 
Figure 2.80 Boc-serine with Nl-(2-Iodoethyl)benzimidazole 
L-Serine was first protected using the Boc procedure as outlined previously, using (Boc )20 
and DIEA in dry DCM at room temperature for 2 h. This gave a quantitative yield of Boc 
protected serine at 100% (Figure 2.80). 
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The next stage involving the substitution reaction was perfonned similar to the reactions 
involving THF/NaH but using DMF due to solubility problems of the Boc-amino acid in 
THF. To a flame-dried round-bottomed flask was added Boc-serine in DMF under 
nitrogen. This was cooled to O°C and NaH (2 equiv) was added. The reaction was then 
allowed to wann slowly to room temperature and all the NaH was given time to react 
b_ef()re_the_addition of Nl-(2-iodoethyl)benzimidazole. The reaction was then stirred 
-----
overnight at 30°C. The solvent was removed under reduced pressure and the residue 
dissolved in H20/ether. The ether was separated off and, upon acidification, the aqueous 
layer was extracted with EtOAc. The solvents were removed from both the ether and 
EtOAc solutions under reduced pressure. 
With a reaction time of 30 min between Boc-serine and NaH the only product obtained was 
N-vinyl benzimidazole in both the ether and EtOAc solutions and the recovery of the Boc 
protected serine from the water layer, despite the acidification. It was decided that the NaH 
needed more time to react with serine so the time that the NaH was given to react was 
raised to 90 min. 
With the 90 min reaction the IH NMR spectrum of the EtOAc extract showed no sign of the 
desired product, but some N 1-(2-iodoethyl)benzimidazole starting material was seen. The 
ether layer for both reactions showed only the elimination product, vinyl benzimidazole. 
The water layer was also examined for product by IH NMR spectroscopy but again there 
was no product seen. 
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From these results it is possible to say that the 30 min time was too short and when the N 1-
(2-iodoethy1)benzimidazole was added the residual NaH simply caused elimination. The 
90 min delay time showed that not all of the N1-(2-iodoethyl)benzimidazole was eliminated 
(presumably as less NaH remained) and was probably a reasonable time for addition of the 
reactant. It was decided to perform the reaction in the same manner as the earlier 
alkylations, using THF at reflux despite the solubility problems. 
cc~ N~ (OH ho / A + N 
BocHN COOH ~ 
1 
THF,NaH, 
reflux, 16 h 
Figure 2.81 Reaction of Boc serine with iodoethyl benzimidazole 
To a flame-dried round-bottomed flask was added Boc-serine in THF under nitrogen. This 
was cooled to O°C and NaH (2 equiv) added. The reaction was allowed to warm to room 
temperature and after 90 min N1-(2-iodoethyl)benzimidazole was added and the reaction 
was then refluxed for 16 h (Figure 2.81). The solvent was removed under reduced pressure 
and the residue dissolved in H20/ether, the ether layer separated off and the water acidified 
and extracted with EtOAc. The solvents in both cases were removed under reduced 
pressure. The ether layer contained only N-vinyl benzimidazole, but the EtOAc layer was 
more promising and the IH NMR spectrum showed signs of a different product that could 
be the desired product, but it needed to be purified. After column chromatography of the 
residue from the EtOAc layer the I H NMR spectrum showed a promising spectrum of the 
123 
desired O-alkylation product although not yet completely clear. Support was given by the 
mass spectra where LCMS which uses ESMS and FAB showed peaks at masses 349 (±lH) 
and 247 (±IH), respectively. The former is the mass of the desired addition product and the 
latter corresponds to the mass if the Boc group has been removed in the mass spectrometer. 
The yield for this reaction was however low at only 35%. 
2.8.2.4 Summary of Serine Reactions 
After attempts to perform the O-alkylation of serine with Nl-(2-iodoethyl)benzimidazole 
by first protecting the acid moiety, it was eventually found that a promising result was 
obtained from the reaction with no protection on the acid moiety. Although it was never 
possible to obtain the completely pure product, these were promising results for any future 
work with serine that may be performed in this area of research. 
2.9 2,3-Diaminopropionic Acid 
Another analogous compound to the cysteine that contains a heteroatom IS 2,3-
diaminopropionic acid, which would provide N-liIiked heterocyclic amino acids. 
Like the other amino acids used, the amino and acid moieties can be protected using Boc 
and ester respectively. The 2,3-diaminopropionic acid reactions were run in parallel to 
those of serine described above. 
124 
Esterification 
The racemic 2,3-diaminopropionic acid was converted into the methyl ester by heating at 
reflux in methanol in the presence of acid. The first attempt used acetyl chloride as the 
source of HCl.98 To a flame-dried multi-necked round-bottomed flask under nitrogen was 
added the amino acid in dry methanol. This was then cooled in an ice bath to DOC before 
the addition of acetyl chloride due the exothennic nature of the reaction. Acetyl chloride 
was then added slowly to the reaction, which was then allowed to wann to room 
temperature. The reaction was then heated at reflux for 48 h before purification of methyl 
ester hydrochloride salt by crystallisation. Although this reaction gave a very pure product, 
it unfortunately gave a very poor yield of only 20%. Many methods for fonning the ester in 
the literature have used thionyl chloride (Figure 2.82), so this was the next reaction 
attempted. 
Figure 2.82 Methyl Ester Protection of 2,3-Diaminopropionic Acid 
The same procedure was used for the addition of thionyl chloride as for acetyl chloride. 
The amino acid and dry methanol were added to a flame-dried multi-neck round-bottomed 
flask, which was then cooled in an ice bath to DOC. The thionyl chloride was added slowly 
and the reaction mixture was then allowed to wann to room temperature before being 
heated at reflux for 4 h. Upon examination of the products after this time, the reaction had 
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gone a good way to completion, but starting material was left so another quantity ofthionyl 
chloride was added at O°C and then the reaction was refluxed for a further 24 h. This time 
the reaction had gone to completion and no starting material was left. The methyl ester bis-
hydrochloride was purified by crystallisation in a 92% yield.99.100.101 
Boc-protection I Lactam formation 
The amino protection of diaminopropionic acid was more troublesome than for the oxygen 
or sulphur-containing amino acids as it is necessary to protect only one amino group of two 
which have comparable nucleophilic reactivity. Figure 2.83 below, highlights the problem 
of the two amino groups. 
BOCHN1 + 
c'H3Nl A A BocHN COOMe 
C1H3N coo-M-e----' BocHN + 
CIH3N
l cooMe + 
Figure 2.83 Possible Products of Boc Protection 
Boc-protection was initially attempted on the simple ester with one equivalent of (Boc)20 
to confirm that both amino groups would become protected. To a dry round-bottomed flask 
was added the methyl 2,3-diaminopropanoate hydrochloride salt, DIEA and (Boc)20 in dry 
DCM under nitrogen and the mixture was stirred for 2 h. The crude product was isolated 
and examined using IH NMR spectroscopy and mass spectrometry. The IH NMR spectrum 
showed what looked like two equal singlets at ..01.5 of 18 protons, and LCMS contained a 
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peak at 318.3, which confinn that some of the sample had become diprotected. A singly 
protected compound would have a single peak at ...Q1.5 and a mass of 253.7. It was 
therefore necessary to find a method where only one of the amino groups is protected and 
the formation ofaJ>.lactam (Figure 2.84) was therefore considered.98.102.103 
CIH N CHCI3, NH3, 31 2h,RT 
C1H3N COOMe 
(Boc),O, 
DlEA,DCM, 
24h,RT 
Figure 2.84 Formation of Lactam ring and Boc protection 
H 
• A 
BocHN 0 
There have been a number of other routes reported,102.103.104 but due to time constraints the 
simplest method was tried as perfonned by lones and Crockett to form the corresponding 5-
membered ring system.98 Chlorofonn was saturated with ammonia gas and the diamino 
ester bis-hydrochloride salt was added to the saturated solution, which was then shaken for 
3 h at room temperature. The chlorofonn and ammonia gas were removed to leave the 
product, hopefully the J>.lactam. It was difficult to characterise the product as the white 
solid produced was only soluble in water and although IH NMR spectra seemed to show 
the correct peaks, no NH peaks were visible in D20 due to exchange. An IR spectrum of 
the compound was run as a KBr disc and this showed a movement of the carbonyl peak. It 
was decided to attempt to add a Boc group to any 'free' amino group in the hope that the 
compound would become more soluble. This was attempted using the same method as 
before in dry DCM with DIEA and (BochO. The product was slightly more soluble than 
before and the IH NMR analysis could be run in methanol. An LCMS of the product was 
also recorded. The IH NMR spectrum was not clean but the major peaks were those of the 
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desired product and the mass spectrum showed a clear peak at 186.4 (±1R). The product 
showed only one spot by TLC but although a short column was run it was difficult to clean 
up the product and the LCMS still showed masses at the desired 186.4 (±IR) and some 
diprotected product at 318.6 (±IH). It was decided to move on from the 2,3-
diaminopropionic acid and look at the 2,4-diaminobutyric acid. 
2.10 2,4-Diaminobutyric Acid 
2,4-Diaminobutyric acid can be looked at in the same way as 2,3-diaminopropionic acid. It 
was decided to use the method to make the 5-membered lactam ring to selectively protect 
one amino group as this procedure has been previously successfully performed, probably 
due to less strain on the ring structure. The same route was used as for the four-membered 
lactam ring attempt, but with the use of commercial racemic 2,4-diaminobutyric acid. 
Esterification 
Firstly the methyl ester was formed using thionyl chloride and dry methanol at reflux for 
48 h via the same method as described previously for 2,3-diaminopropionic acid, which 
gave the desired bis-hydrochloride product in a quantitative yield as white crystals (Figure 
2.85). 
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NH Cl thionyl chloride, 
( methanol, 
.~ reflux, 48 h 
Figure 2.85 Ester protection of 2,4-diaminobutyric acid 
Lactam Formation 
2,4-Diaminobutyric acid ester can then be cyc1ised by shaking in ammonia-saturated 
chloroform for 3 h at room temperature. The product was gained in a yield of 86% after the 
removal of the solvents under reduced pressure. This product was difficult to analysis 
since, as had been found with the four-membered ring, it only dissolved in water. The IR 
analysis was performed using a KEr disc and this again showed a movement of the 
carbonyl peak from around 1710 to I 690cm·1 , indicating that the ester peak had changed to 
a lactam (Figure 2.86). I H NMR spectroscopy was also performed, signals at 53.25 and 
03.38 for the methylene groups were present, but as the analysis was performed in D20 no 
amino peaks were present. 
CHCI3,NH3, 
3h,RT 
• 
Figure 2.86 Lactam formation of2,4-Diaminobutyric acid 
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Boc protection of Lactam 
The 'free' amino group substituent of the presumed lactam was then protected using Boc in 
the hope that this would aid solubility. The Boc protection was performed in the same 
manner as before, by the use of (Boc)zO and DIEA in dry DeM, for up to 24 h at room 
temperature (Figure 2.87). 
(BOC)20, 
DCM,DIEA, 
24h,RT qH 
BocHN 0 
Figure 2.87 Boc protection of 5-membered Lactam 
The IH NMR spectrum showed the Boc group to be present in the correct ratio with the 
lactam peaks by comparison ofNMR integrals, with the Boc resonance occurring ato1.63, 
but the Boc group did not seem to help solubility, and the NMR spectra had to be 
performed in D20 so it was still not possible to see the NH peaks. 
Reaction of 5-membered Lactam with Nl-(2-Iodoethyl)benzimidazole 
It was decided to try the N-alkylation of the lactam, despite the solubility problems making 
it difficult to analyse, with Nl-(2-iodoethyl)benzimidazole (Figure 2.88) to see ifthe lactam 
could be reacted in the presence of the carbamate. 
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NaH, THF, 
24 h, reflux 
)~ • 
Figure 2.88 Reaction of 5-membered Lactam ring with NI-(2-Iodoethyl)benzimidazole 
The lactam was suspended in dry THF in a flame-dried round-bottomed flask and cooled in 
an ice bath, NaH was then added and allowed to react for about 30 min, before the slow 
addition of the NI-(2-iodoethyl)benzimidazole. The mixture was then heated at reflux for 
24 h. After work-up none of the substitution product was seen. N-Vinyl benzimidazole 
was the major product seen, which was disappointing as it was hoped that adding the NI-
(2-iodoethyl)benzimidazole slowly would allow time for the desired substitution reaction to 
take place. In this case it is possible that the deprotonation of the nitrogen in the lactam 
ring is not occurring and the NI-(2-iodoethyl)benzimidazole simply reacts with the NaH. 
Opening of the Lactam 
Due to the failure of the laclam to react with NI-(2-iodoethyl)benzimidazole it was decided 
to open the ring and attempt the alkylation reaction again but using the singly Boc-
protected 2,4-diaminobutyric acid. 
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• 1"' 
BocHN coo 
QH 
BocHN 0 
NaOH (aq), 4 h 
+ 
Na 
Figure 2.89 Opening of the Lactam ring 
The 5-membered lactam ring was opened using a basic system, shown in Figure 2.89, as the 
use of an acid would remove the Boc protecting group. The lactam ring was stirred in 
aqueous NaOH for 4 h. The product, presumably as the salt, was obtained in a quantitative 
yield by the removal of water under reduced pressure. This was supported by IH NMR 
spectroscopy, where the CH2 peaks had moved from 03.25 and03.38 to02.91 and03.09, and 
IR spectometry where the lactam peak at 1690cm-1 was no longer present, and there was a 
peak at 1616cm-l . 
Reaction of Boc-2,4-Diaminobutyric Acid Sodium Salt with Nl-(2-
Iodoethy1)benzimidazole 
NH2 i -+ 
BocHN COO 
+ 
Na 
NaH,THF, 
24 h, reflux 
>< 
Figure 2.90 Reaction of Boc protected diaminobutyric acid and 
N 1-(2-iodoethyl)benzimidazole 
132 
It was next attempted to use the crude salt in a substitution reaction with N 1-(2-
iodoethyl)benzimidazole. In a flame-dried round-bottomed flask under nitrogen was added 
the salt in THF which was then cooled to O°C before the addition of the NaH (lequiv). The 
N 1-(2-iodoethyl)benzimidazole was then added after IS min and reaction warmed to room 
temperature and refluxed for 24 h (Figure 2.90). After work up the product was analysed 
using IH NMR spectroscopy, but this again showed no sign of the desired product, only 
vinyl benzimidazole from the elimination reaction with NaH. The failure may be due to 
deprotonation at the carbonyl moiety, or that the lactam formation/opening had not 
occurred as had been hoped. 
2.11 Summary for Diamino Reactions 
The major disadvantage of the diamino acid compounds is that of protection, the acid 
moiety can be easily protected in the same fashion as for the serine and cysteine 
compounds, but due to the presence of two amino groups the Boc protection ofthea-amino 
group is more difficult. Even if the desired groups had been protected (which was difficult 
to confirm due to the insolubility of the compounds in organic solvents), the final 
substitution reaction was unsuccessful. 
2.12 Homocysteine 
Due to the success with cysteine itself, it was decided to investigate the use of 
homocysteine in these reactions, the added advantage being that if the reactions did work 
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this would open up the possibility of various chain lengths on the amino acid side of the 
heteroatom. 
Homocysteine protection 
Due to the lack of time available, racemic homocysteine was obtained commercially, ready 
protected as Boc-homocysteine methyl ester. 
Boc-Homocysteine methyl ester with Nl-(2-Iodoethyl)benzimidazole 
SH CtN) 
57% 
BocHN COOEt 
Figure 2.91 Boc-Homocysteine methyl ester with NI-(2-Iodoethyl)benzimidazole 
As for the other alkylation reactions, to a dry round-bottomed flask was added the NaH, dry 
THF and protected homocysteine at o·e and under nitrogen. These were stirred together 
for 15 min and allowed to warm before the addition of Nl-(2-iodoethyl)benzimidazole. 
The reaction was then heated at reflux for 24 h. After this time the THF was removed 
under reduced pressure and the reaction worked up to leave the crude product that was 
purified by column chromatography to give the desired S-linked alkylation product in 57% 
yield (Figure 2.91). 
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The IH NMR spectrum showed all the necessary peaks, however the mass spectrum 
showed no sign of the required molecular mass at 393. However peaks at 261 from ES 
mass spectrometry and 362 from ElMS correspond to the reacted but deprotected amino 
acid with the loss of the Boc group and methoxy group and the methoxy group only, 
respectively. 
2 .. 13 Deprotection 
Finally the protected cysteine ethyl-linked benzimidazole amino acid was deprotected as an 
example to test the protocols to give the deprotected heterocyc1ic amino acids. 
Ester Removal 
LiOH <aq) 
THF !Methanol 
• 
Figure 2.92 Ester deprotection 
The deprotection of the carboxylic acid group was performed using LiOH(aq) in 
THF/methanol stirring for 8 h.105 The organic solvents were removed under reduced 
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pressure, the water layer acidified, and the product extracted by EtOAc to afford the 
deprotected acid, obtained as a white solid in 97% yield (Figure 2.92). 
BocRemoval 
TFAlDCM, 
DIEAlDCM 
• 
Figure 2.93 Boc deprotection 
The Boc group was removed under acidic conditions using 50% TF AlDCM for 2 h 
followed by 5% DIEA to neutralise the acid. 106 The solvents were removed under reduced 
pressure to give the Boc-deprotected product in 86% yield (Figure 2.93). The removal of 
the TFA and OlEA under reduced pressure was difficult and was aided by the addition of 
ethanol to the mixture as a high boiling solvent to take the higher boiling compounds out of 
the mixture as it evaporated. For the complete removal of the TFA and DIEA, a short 
column was run, followed by removal of solvents under reduced pressure for about 8 h. 
These protocols could be applied to all of the heterocyclic amino acids formed in this 
investigation to enable selective incorporation into peptide sequences. 
136 
2.14 Conclusion 
After initial problems with the formation of the oxazolidinone template, as a method of 
amino acid protection, it was successfully synthesised in a reasonable overall yield. The 
other, simpler methods of amino acid protection also gave excellent yields of the protected 
amino acids. Almost all the heterocyclic derivatives that were attempted were successfully 
synthesised, although some had quite low yields, the majority were formed cleanly with 
very good, even excellent yields, which were then used in the attempted linker formation of 
heterocyclic amino acids. 
The radical and organocuprate conjugate addition reactions involving the oxazolidinone 
template with Nl-(2-haloethyl)benzimidazole (as well as the uracil derivative) produced 
none of the desired products. There was evidence of reduced product indicating that 
radicals had been formed in the radical reactions, and evidence also of lithiumlhalogen 
exchange, leading to a number of undesired side reactions, in the organocuprate reactions. 
The hydroboration and metathesis coupling reactions, involving the oxazolidinone template 
with N-vinyl heterocycle derivatives, also proved fruitless, steric factors may have been a 
problem for these methods. 
The carbon-heterocycle bond-forming substitution reaction involving serine indicated the 
desired product had been formed, with yields of the carbon-heterocycle bond-forming 
substitution reactions involving cysteine being over 60% in many of the cases and several 
new heterocyclic amino acids were prepared by this method. 
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3 Future Work 
The work in this thesis is based on two protected amino acid systems only, the 
oxazolidinone template for the carbon-carbon bonds and Boc protected amino acids for the 
heteroatom-carbon bonds in the heterocyc1e carrying side chain. The heterocyc1e 
derivatives used throughout this work have all been obtainable through the use of halo alkyl 
substituents as in Figure 3.1. 
Figure 3.1 Haloalkyl Heterocyc1e Derivatives 
Future work in this area could be by the use of different heterocycle derivatives with 
different amino acid derivatives. 
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3.1 Expansion oCCurrent Work 
As the work with cysteine has produced a number of promising results it would be possible 
to carry on to produce further heterocyclic amino acids containing sulphur in the linkage 
chain. It would also be possible to take the compounds created so far and create a new 
range of compounds by the addition of oxygen to make the corresponding sulfoxides or 
sulfones. An example of this is given in Figure 3.2. 
Oxone R 
• 
Figure 3.2 Oxidation of Sulphur 
As well as work with cysteine, the work with serine could be continued. Some promising 
results were observed and with further investigation some respectable yields could be 
obtained as previously indicated in section 2.8.2. 
Substitution Reactions 
Another method based on the successfully utilised alkylation method in the formation of 
C-S bonds is the reversal offunctionalities as exemplified in Figure 3.3. 
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Figure 3.3 Reversed Substitution Reactions 
Lactam Formation 
The formation of a CoN linkage could still be performed by initiallactam formation for the 
selective aamino acid protection. A further method for the formation of the lactam, as 
previously attempted from 2,3-diaminopropanoic acid, has been described by Miller 
et al. 103.104,107,108 and utilises serine as the starting material as shown in Figure 3.4. 
EtN=C=NCH2CH2CH=NMe, 
H,o,pH3.5 
OH BOCHN~O 
OH 
H2NOCH2Ph • (OH 0 
BOCHN~ 
I) KOH, 
NHOCH2Ph 
Mitsunobu (DEAD, Ph,P, THF) 
or 
Ph,P, CCl., NEt, 
2)H2-PdlC ~ ~NH2 ... >--_A_c_et_OD_i_tn_·le_ I'N~,OCH2Ph BocHN 0 • BocHN 0 
OH 
Figure 3.4 Formation of J3-Lactam 
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One advantage of this method is that the use of ammonia gas is not necessary. Another 
major advantage over any others is that the optically pure starting material is readily 
available. This would provide a mono-protected diamine suitable for alkylation reactions. 
3.2 Other Methods Utilising the same Starting Material 
Addition of Sulphur to Double Bond 
A well studied method for the addition of sulphur (thiol) to double bonds is by the use of 
radicals,97,98,J09 however little work has been done involving amino acids. Radicals have 
been looked at previously in this thesis for the formation of C-C bonds, and the general idea 
behind radical couplings has been introduced previously. 
It should be possible to form a C-S bond using the N-Boc-cysteine alkyl ester with a vinyl 
or allyl heterocycle as shown in Figure 3.5. 
+ • 
Free radical initiator 
JSH 
BocHN C02Me 
Figure 3.5 Cysteine and Vinylbenzimidazole 
This method is the almost guaranteed anti-Markovnikov addition to the less hindered or 
terminal end of the double bond as illustrated above, since this would proceed via the most 
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stable carbon radical. On a further positive note the planned reactions involve tenninal 
double bonds, and it has been seen that tenninal double bonds are the most reactive towards 
radical reactions. 
Methods Involving a Different Template 
During the course of this research programme, infonnation was also found on 
adisubstituted amino acids, and although the aim of the investigation was not the fonnation 
of a-disubstituted derivatives, at least one of the methods used could have the potential to 
be used for monoa-substituted amino acids. 
Previous disubstituted work has been carried out by Obrecht et al. 1l0,1l1,ll2 into the 
fonnation Of (R)-4-(bromoethyl)-4-methyl-2-phenyloxazol-5( 4l:1)-one and (S)-4-
(bromoethyl)-4-methyl-2-phenyloxazol-5(4l:1)-one (Figure 3.6). In this work, a racemic 
iodomethyl oxazolidinone was resolved by separation of diastereoisomers. 
Br 
N~O )-0 
Ph 
(R) 
Figure 3.6 
Br 
( Me 
N!ZrO )-0 
Ph 
(5) 
(R)-4-(Bromoethyl)-4-methyl-2-phenyloxazol-5(4l:1)-one 
and (S)-4-(Bromoethyl)-4-methyl-2-phenyloxazol-5( 4l:1)-one 
Figure 3.7 shows an outline for future work involving the preparation of an optically active 
iodomethyl glycine template, following a similar scheme as Orbrecht.l10,1 Il,l12 
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o ?Zrl H 11 /'... ___ • N~O ____ N 0 
Ph/'-.-N eOOH ,\ r 
H }-o ~O 
Figure 3.7 
Ph Ph I 
Plan for Forming (R)-4-(iodomethyl)-2-phenyloxazol-5( 4H)-one 
and (S)-4-(iodomethyl)-2-phenyloxazol-5( 4H)-one 
The next stage could be substitution or radical reactions as shown in Figure 3.8. 
Figure 3.8 
where X is 0, S or N 
CCN) 
NaH, 0 N,-
THForDMF. \ 
/ 
N~O )Lo ~NPh 
~.~ 
r(YN AIBN. Bu,SnCI, N 
~t NaCNBH"I-BuOH ? 
Ph 
Substitution and Radical Reactions 
N~O )Lo 
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Suzuki Coupling 
This again involves the use of a boron derivative, in the fonn of a boronic acid, and 
palladium as a catalyst but it would not be necessary to attach the boron directly to the 
oxazolidinone template, which had proved to be problematic. A suggested Suzuki coupling 
is shown in Figure 3.9. It may then be possible to reduce the double bonds in the product 
by hydrogenation. 
crN~ 
~N~ B{OH)2 0 N\ V-N + i -------.~ --~ BOCHN C02Me 0-Br BOCHN C02Me 
Figure 3.9 Suzuki Coupling 
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Experimental 
General Experimental Details 
Starting materials were supplied by either Aldrich, Lancaster or Avacado and were used 
without purification unless otherwise stated. 
Solvents were dried where necessary in the following manners: 
THF - pre-dried in presence of potassium carbonate then distilled from sodium metal and 
benzophenone under a positive atmosphere of nitrogen; 
EtOAc - distilled over calcium chloride; 
DCM - distilled over calcium hydide (anhydrous); 
1,4-Dioxane - Shaken over potassium hydroxide; 
Column chromatography was performed using silica gel 60 (40-63 /l, 230-400 mesh, 60 A); 
Thin layer chromatography (TLC) performed on Merck 0.2 mm silica 60 F254 coated UV 
active aluminium sheets; 
Melting Points were measured on a Stuart Scientific Bibby SMP3 Melting Point Apparatus; 
The Optical Rotations were performed on a polar 2001 using a 1 cm sample vessel using 
DCM as the solvent; 
The Elemental Analysis was performed on a Perkin-Elmer CHN-2400; 
The Molecular Mass was measured on a JEOL SXI02 at Loughborough University and by 
the ESPRC national spectrometry unit at Swansea University, by either El (Electron 
Impact) or FAB (Fast Atom Bombardment); 
Liquid Chromatography - Mass Spectrometry (LC-MS) was performed using a Waters 600 
controllers instrument, a Waters Symmetry C8 3.5 /lm 4.6x50 nm column and a Waters 996 
photodiode array detector attached to a Micromass Platform mass spectrometer which uses 
ES (Electrospray) ionization; 
Infrared Spectra was obtained using either a Perkin-Elmer Paragon 1000 FTIR 
spectrometer for neat samples on NaCl discs (DCM used as a 'transport' solvent where 
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necessary) or a Shimadzu FfIR-8300 for KBr discs and recorded in the range 5000-
500 cm-I; 
In most cases the IH and 13C NMR analysis was performed at 400 MHz on a Broker DPX-
400 and the remaining IH NMR at 250 MHz on a Broker AC-250_ The solvents used were 
CDCI), DMSO-d6, MeOH-d4 or acetone-d6 and the actual solvent used is specified in each 
experiment_ Chemical shifts are quoted in ppm (parts per million) and the coupling 
constants (Jvalues) in Hz (hertz)_ The following abbreviations have been used: s (singlet), 
d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad)_ 
(2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) 
oxazolidin-5-one and (2R,2R)-isomer58 
tBu 
S-Methyl-(R)-cysteine (4.00 g, 29.60 mmol) was treated with aqueous sodium hydroxide 
(1.18 g, 29.60 mmol in 20 cm3 of water). After 5 min the solution was evaporated to 
dryness under reduced pressure to leave a creamy white solid. 2,2-Dimethylpropanal 
(3.21 cm3, 29.60 mmol) in hexane (44 cm3) was added and the suspension was stirred and 
heated under reflux with Dean-Stark water removal for 24 h. The reaction mixture was 
then evaporated to dryness under reduced pressure and the residual creamy white solid 
suspended in dry dichloromethane (40 cm3). Benzyl chloroformate (6.58 cm3, 50.00 mmol) 
was added dropwise to the stirred suspension at O°C over 3 h. The mixture was stirred for a 
further 36 h at room temperature before adding aqueous sodium bicarbonate (lO%w/v, 
15 cm3) and stirring for a further 4 h. The layers were then separated and the 
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dichloromethane solution dried (MgS04), filtered and evaporated. The residue was stirred 
in acetonitrile (30 cm\ then oxone® (14.60 g, 23.00 mmol) in water (75 cm3) was added 
and the solution stirred for 24 h. Water (30 cm3) was then added and the mixture extracted 
with dichloromethane (3 x 30 cm3), the combined extracts were dried (MgS04), filtered and 
evaporated. Purification of the products was by column chromatography (ethyl acetate--
hexane, 9:1 v/v to pure ethyl acetate on silica gel). This gave the title compounds: anti-
diastereoisomer as a clear oil and the desired syn-diastereoisomer as a yellow oil, white 
crystals from ethyl acetate (5.14 g, 52%), m.p. 150-151°C (lit.,58 m.p. 151-152°C). Found: 
MW 370.1308; C'7H23N06S requires: MW 370.1324. Vmax (NaCllcm·') 2970 (CH2), 1791 
(NC=O), 1722 (conjugated C=O), 1482 (Ar), 1398 (CMe3), 1308 (C-O), 1129 (S02Me), 
1040 (C-O), 968 (CH), 737 and 698 (ArH). SH (400 MHz, CDCh) 0.95 (9 H, s, QCH3)3), 
3.11 (3 H, s, S02Me), 3.39 (1 H, dd, J3.6, 15.3 Hz, CHHS02Me), 3.51 (1 H, dd,J7.9, 15.3 
Hz, CHHS02Me), 4.99 (1 H, dd, J 3.6,7.9 Hz, CHCH2) 5.22 (2 H, 2 x d, J 12.0, 13.4 Hz, 
CH2Ph), 5.62 (1 H, s, CHCMe3), 7.38 (5 H, m, ArH). Se (100 MHz, CDCI3) 24.6 (CMe3), 
37.8 (CMe3), 43.0 (S02Me), 53.5 (CHCH2), 58.4 (CH2S02Me) 68.8 (CH2Ph), 96.0 
(CHCMe3), 128.6, 128.7, 128.8 (ArCH), 130.3 (ArC), 156.4, 168.5 (C=O). 
(2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(ene)oxazolidin_5_one58 
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(2S,4R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) oxazolidin-5-one 
(2.00 g, 5.93 mmol) in dry DCM (50 cm3) was treated dropwise with DBU (1.77 cm3, 
11.85 mmol) and stirred at O°C over 1 h. Water was then added and the organic layer was 
separated, washed with water, dried (MgS04)' filtered and evaporated under reduced 
pressure. The crude product was filtered though a short column of silica gel using DCM to 
yield the product as a colourless gel which solidified when left overnight under high 
vacuum as white crystals (1.14 g, 66%), m.p. 66-67°C (lit.,58 m.p. 69-71°C), [ajZ5D 68.0 (c 
1 in DCM) (lit.,57 65.4, c 0.4 in EtOH). Found: C,65.9, H,6.3, N,4.6%; Cl6Hl9N04 
requires: C,66.4, H,6.6, N,4.8%. Found: M' 289.1310; Cl6Hl9N04 requires: M+ 289.1314. 
mlz: 232, 188, 176, 92. Vrnax (NaCl/cm-1) 2969 (CHz), 1794 (conjugated C=O), 1727 
(NC=O), 1656 (C=C), 1397, 1326 (CMe3), 1269, 1011 (C-O) and 759m, 697m (ArH). OH 
(400 MHz, CDCI3) 0.93 (9 H, s, CMe3), 5.26 (2 H, s, CHHPh and CHCMe3), 5.68 (2 H, s, 
C=CHz), 5.72 (1 H, s, CHHPh), 7.38 (5 H, m, ArH). Oc (100 MHz, CDCh) 24.3 (CMe3), 
38.7 (CMe3), 68.8 (ClhPh), 94.0 (CHCMe3), 104.3 (C=CHz), 128.6, 128.7, 128.8 (ArCH), 
130.2 (ArC), 134.7 (C=CHz), 152.4 (O(C=O)-N), 164.5 (C=C-C=O). 
N3-Benzoyluracill13 
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Benzoyl chloride (11.30 cm3, 88.40 mmol) was added dropwise to a stirred suspension of 
uracil (5.00 g, 44.20 mmol) in a mixture of dry acetonitrile/pyridine (100 cm3 5:1 v/v). 
After leaving to stir for 24 h at RT the solvents were removed under reduced pressure. The 
residue was then treated with K2C03 in dioxane/water (0.25 M, 100 cm3, 1:1 v/v) for 2 h. 
The solution was filtered, washed with acetonitrile (50 cm\ and dried under vacuum to 
give the title compound as a white powder (7.03 g, 72%), m.p. 170-171°C (lit.,113 m.p. 148-
149°C). Found: M+ 216.0531; CllHsN203 requires: W 216.0535. rnIz: 188, 146, 105. 
vrnax (NaCI/cm· l ) 3321 (N-H), 2922 (C=C-H), 1747 (C-(C=O)-N), 1705 (Ph-(C=O)-N), 
1652 (N-(C=O)-N), 1417, 1068 and 801 (ArH). OH (400 MHz, DMSO-d6) 5.73 (1 H, d, 
J 8.0 Hz, CHCO), 7.60 (2 H, t, J 8.0 Hz, ArH), 7.65 (1 H, d, J 8.0 Hz, ArH), 7.78 (1 H, t, J 
8.0 Hz, CHN), 7.95 (2 H, d, J 8.0 Hz, ArH), 11.59 (1 H, hr, NH). OC (100 MHz, DMSO-
d6) 100.4 (C-6), 129.8, 130.5 (ArCH), 131.7 (ArC), 135.7 (ArCH), 143.7 (C-5), 150.4, 
163.3,170.4 (C=O). 
N-(2-Bromoethyl) heterocycle (Method A) 
Heterocycle (1 mol equiv), triphenylphosphine (1.2 mol equiv) and 2-hromoethanol (1.2 
mol equiv) were suspended in dry dioxane (50 cm3 per mmol of heterocycle) at 5°C, to 
which was added DIAD (1.2 mol equiv) dropwise over 3 h. The mixture was stirred under 
nitrogen at room temperature to give a clear solution. The solvent was removed under 
reduced pressure and the residue purified by flash chromatography to give the title 
compound as a yellow oil, which was in some cases recrystallised to give the product. 
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N-(2-Iodoethyl) heterocycIe (Method B) 
N-(2-Haloethyl) heterocycle (I mol equiv) and dry sodium iodide (5 mol equiv) were 
heated in dry acetone (50 cm3 per mmol ofheterocycle) at reflux overnight under nitrogen 
in the dark. After cooling, the acetone was removed under reduced pressure and the residue 
taken up in ethyl acetate/water (1: 1 v/v), the organic layer was separated and the aqueous 
layer was extracted with ethyl acetate twice more. The organic layers were combined and 
washed twice with sodium thiosulfate solution (2% w/v), then dried (MgS04)' filtered and 
the solvent removed under reduced pressure to yield the title compound. 
N-(2-Chloroethyl)heterocycIe (Method C) 
Heterocycle (I mol equiv.) was added to a mixture of 1,2-dichloroethane, which acted as 
both the solvent and the reagent, tetrabutylammonium iodide (5%) as the phase transfer 
catalyst (PTC), KOH (6 mol equiv.) and K2C03 (2.5 mol equiv.). The reaction was stirred 
at room temperature for 4 h. The inorganics filtered off and the organic portion washed 
(H20, 5 cm3 per mmol), dried (MgS04)' filtered and the solvent removed under reduced 
pressure. The mixture was then put through flash column chromatography to isolated the 
title compound. 
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3-Benzoyl-l-(2-bromoethyl)uracil58 
1'-':: 
lA 
~ 0 
Br 
Prepared according to method A, using 3-benzoyluracil (5.00 g, 2.30 mmol), 
triphenylphosphine (7.24 g, 2.76 mmol) and 2-bromoethanol (1.96 cmJ, 2.76 mmol) in dry 
dioxane (100 cm3) at 5°C, with DIAD (5.43 cm3, 2.76 mmol) to give the title compound as 
a white solid (7.07 g, 95%), m.p. 177-179°C (Iit.,S8 m.p. 183-184°C). Found: M+ 321.9959; 
CIJHII79BrN20J requires: M+ 321.9953. m/z: 296, 294, 277, 254, 252, 215, 188, 105. 
Vrnax (NaCl/cm·l) 2920 (C=C-H), 2850 (CH2), 1747 (C-(C=O)-N), 1704 (Ph-(C=O)-N), 
1662 (N-(C=O)-N), 1437 (CH2), 1346, 1241, 760, 697 (ArH) and 685 (C-Br). OH (400 
MHz, CDCb) 3.69 (2 H, t, J 5.6 Hz, CH2Br), 4.16 (2 H, t, J 5.6 Hz, CH2N), 5.83, (1 H, d, J 
8.0 Hz, CHC=O), 7.33 (2 H, d, J8.0 Hz, ArH), 7.51 (2 H, t, J8.0 Hz, ArH), 7.67 (1 H, d, J 
8.0 Hz, ArH), 7.93 (1 H, d, J 8.0 Hz, CHN). OC (lOO MHz, CDCb) 29.4 (CH2Br), 51.3 
(CH2N), 101.9 (C-6), 129.3, 130.5 (ArCH), 132.1 (ArC), 135.2 (ArCH), 144.8 (C-5), 149.7, 
159.9, 168.1 (C=O). 
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3-Benzoyl-l-(2-iodoethyl)uracil58 
Prepared according to method B, using 3-benzoyl-I-(2-bromoethyl)uracil (5.00 g, 
1.56 mmol) and dry sodium iodide (11.71 g, 7.81 mmol) in dry acetone (lOO cm3) to yield 
the title compound as a pale yellow solid (2.11 g, 36%), m.p. 185-187°C (lit.,58 m.p. 190-
191°C). Found: C,42.3, H,3.4, N,7.9%; C13Hll1N203 requires: C,42.2, H,3.0, N,7.6%. 
Found: M" 369.9807; C13H lIIN20 3 requires: M+ 369.9814. mlz: 342, 277, 215, 188, 155, 
105. Vmax (NaCI/cm'!) 2920 (C=C-H), 2850 (CH2) 1747 (C-(C=O)-N), 1705 (Ph-(C=O)-N), 
1664 (N-(C=O)-N), 1436 (CH2), 1254, 722 and 695 (ArH). DH (400 MHz, CD Ch) 3.48 
(2 H, t, J 6.4 Hz, CH2I), 4.11 (2 H, t, J 6.4 Hz, CH2N), 5.84 (1 H, d, J 8.0 Hz, CHC=O), 
7.28 (2 H, d, J 8.0 Hz, ArH), 7.51 (2 H, t, J 8.0 Hz, ArH), 7.66 (1 H, d, J 8.0 Hz, CHN), 
7.93 (I H, d, J 8.0 Hz, ArH). Dc (100 MHz, CD Ch) 22.9 (CH2I), 51.8 (CH2N), 102.0 
(C-6), 129.2, 130.5 (ArCH), 133.3 (ArC), 135.9 (ArCH), 144.2 (C-5), 149.1, 162.5 and 
171.1 (C=O). 
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N3-Benzoylthyminel13 
Benzoyl chloride (10.11 cm3, 79.40 mmol) was added dropwise to a stirred suspension of 
thymine (5.00 g, 39.70 mmol) in a mixture of dry acetonitrile/pyridine (100 cm\ 5: 1 v/v). 
After leaving to stir for 24 h at RT the solvents were removed under reduced pressure. The 
residue was then treated with K2C03 in dioxane/water (0.25 M, 100 cm3, 1:1 v/v) for 2 h. 
The solution was filtered, washed with acetonitrile (50 cm3), and dried under vaccum to 
give the title compound as a white powder (6.46 g, 71 %), m.p. 148-149°C (lit.,1I3 m.p. 150-
152°C). Found: M+ 230.0687; C12HlON203 requires: M+ 230.0691. mlz: 203, 146, 105. 
Vmax (NaCI/cm-1) 3398 (N-H), 2933 (C=C), 1745 (C-(C=O)-N), 1700 (Ph-(C=O)-N), 1596 
(N-(C=O)-N), 1511, 1441, 1381 (CH3), 1233,907 and 730 (ArH). OH (400 MHz, DMSO-
d6) 1.82 (3 H, s, CH3), 7.54 (1 H, s, C=CHN), 7.60 (2 H, t, J7.6 Hz, ArH), 7.78 (1 H, t,J 
7.6 Hz, ArH), 7.94 (2 H, d, J 7.6 Hz, ArH). Oc (100 MHz, DMSO-d6) 11.7 (CH3), 107.9 
(CCH3), 129.4, 130.2 (ArCH), 131.3 (ArC), 135.3, (ArCH), 138.7 (C-6), 149.9, 163.5, 
170.1 (C=O)_ 
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3-Benzoyl-l-(2-bromoethyl)thymine58 
I~ 
lA 
~ 0 
Br 
Prepared according to method A, using N3-benzoylthymine (5.00 g, 21.70 mmol), 
triphenylphosphine (6.84 g, 2.60 mmol) and 2-bromoethanol (1.85 cm3, 2.60 mmol) in dry 
dioxane (100 cm3) at 5°C, with DIAD (5.13 cm3, 26.01 mmol) to give the title compound 
as a white solid (7.32 g, 56%), m.p. 166-167°C (1it.,58 m.p. 183-184°C). Found: M' 
336.0112; C14H1379BrN203 requires: M+ 336.0109. mlz: 310, 308, 277, 254, 252, 230, 188, 
105. Vmax (NaCl/cm-l) 3390, 2898 (CH2)' 2342, 1746 (C-(C=O)-N), 1699 (Ph-(C=O)-N), 
1662 (N-(C=O)-N), 1462, 1414 (CH2), 1429, 1376 (CH3), 720 (ArH) and 672 (C-Br). OH 
(400 MHZ, CDCh) 1.98 (3 H, s, CHl), 3.44 (2 H, t, J 6.6 Hz, CH2Br), 4.07 (2 H, t, J 6.6 
Hz, CH2N), 7.13 (1 H, d, J 1.2 Hz, CHN), 7.50 (2 H, t,J7.4 Hz, ArH), 7.65 (1 H, t, J7.4 
Hz, ArH), 7.93 (2 H, d,J7.4 Hz, ArH). Dc (100 MHz, CDCh) 11.6 (CH3), 36.7 (CHzBr), 
50.4 (CH2N), 109.7 (CCHl), 128.3, 129.6 (ArCH), 130.6 (ArC), 134.2 (ArCH), 139.3 (C-
6),148.7,162.1,167.8 (C=O). 
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3-Benzoyl-l-(2-iodoethyl)thymine58 
I"" 
lA 
~ 0 
Prepared according to method B, using 3-benzoyl-1-(2-bromoethyl)thymine (5.00 g, 
14.83 mmol) and dry sodium iodide (11.11 g, 74.15 mmol) in dry acetone (100 cml) to 
yield the title compound as a pale yellow solid (3.11 g, 54%), m.p. 145-147°C (Iit.,58 m.p. 
138-139°C). Found: M' 383.9968; CI4HllINZOl requires: M" 383.9972. m1z: 356, 277, 
215, 230, 155, 105. Vrnax (NaCIIcm·l) 2954 (C=C), 1743 (C-(C=O)-N), 1702 (Ph-(C=O)-
N), 1640 (N-(C=O)-N), 1451 (CHl), 1411 (CHz), 1363,730 (ArH) and 598 (C-I). OH (400 
MHz, CDCh) 2.04 (3 H, s, CHl), 3.57 (2 H, t, J 6.8 Hz, CHzI), 4.33 (2 H, t, J 6.8 Hz, 
CHzN), 7.47 (2 H, t, J 7.4 Hz, ArH), 7.62 (1 H, t, J 7.4 Hz, ArH), 7.66 (1 H, d, J 2.6 Hz, 
CHN), 7.75 (2 H, d, J7.4 Hz, ArH). Oc (100 MHz, CDCh) 13.2 (CHl), 29.4 (CHzI), 42.0 
(CHzN), 112.3 (CCHl), 128.6, 129.3, (ArCH), 132.8 (ArC), 134.0 (ArCH), 140.7 (C-6), 
149.9,162.9,169.7 (C=O). 
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Nl-(2-Bromoethyl) benzimidazole58 
Prepared according to method A, using benzimidazole (2.00 g, 16.93 mmol), 
triphenylphosphine (5.33 g, 20.31 mmol) and 2-bromoethanol (1.44 cm3, 20.31 mmol) in 
dry dioxane (lOO cm3) at 5°C with DIAD (4.00 cm3, 20.31 mmol) to yield the title product 
as colourless crystals (3.75 g, 98%), m.p. 77-79°C. Found: M+ 223.9950, C9H/9BrN2 
requires: W 223.9949. mlz: 145, 131, 118, 104,90. vmax(NaCl/cm· l ) 3345,2980 (CH2), 
2360, 1719 (conjugated C=N), 1497, 1438 (CH2), 1246, 1119, 745, 722 (ArH) and 696 
(C-Br). OH (400 MHz, CDCb) 3.71 (2 H, t, J 6.0 Hz, CH2Br), 4.61 (2 H, t, J 6.0 Hz, 
CH2N), 7.23-7.62 (4 H, m, ArH), 7.90 (1 H, s, CH). OC (100 MHz, CDCh) 39.2 (CH2Br), 
45.1 (CH2N), 109.2 (CH), 119.3, 123.1, 129.0, 130.4 (ArCH), 133.7, 144.9 (ArC). 
Nl-(2-Chloroethyl)benzimidazolel14,115 
Prepared according to method C, using benzimidazole (1.00 g, 8.47 mmol) in 
1,2-dichloroethane (70 cm3) with tetrabutylammonium iodide (0.05 g, 5%), KOH (2.85 g, 
50.79 mmol) and K2C03 (2.93 g, 21.16 mmol). After stirring for 4 h, work up gave title 
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product (0.85 g, 54%), m.p. 76-78°C (lit.,1l4,1l5 m.p. 84-86°C). Found: C,60.3, H,5.2, 
requires: W 180.0454. mlz: 144, 131, 117, 104,90. Vrnax (NaCl/cm·1) 3404,3056 (ArH), 
2960 (CH2), 2359, 1615 (C=N), 1494, 1437 (CH2), 1257, 1118, 744, 721 (ArH) and 663 
(C-I). OH (400 MHz, CDCh) 3.76 (2 H, t,J 6.0 Hz, CH2CI), 4.42 (2 H, t,J 6.0 Hz, CH2N), 
7.22-7.45 (3 H, m, ArH,), 7.59 (I H, m, ArH), 7.89 (I H, s, CH). OC (lOO MHz, CDCh) 
42.5 (CH2CI), 47.0 (NCH2), 109.6 (CH), 121.0, 122.9, 129.0, 132.4 (ArCH), 133.3, 143.7 
(ArC). 
Prepared by a modification to method A, using benzimidazole (1.00 g, 8.47 mmol), 
2-chloroethanol (0.82 g, 10.16 mmol) and triphenylphosphine (2.66 g, 10.16 mmol) in dry 
dioxane (20 cm3) at 5°C, with DIAD (2.00 cm\ 2.05 g, 10.16 mmol). After stirring for 
16 h, work up gave title product (1.23 g, 80%) 72-74°C (Iit.,1l4 m.p. 84-86°C). Found: 
C,60.4, H,5.0, N,16.1%; c9Hl5CIN2 requires: C,59.8, H,5.0, N,15.5%. Data as for NI-(2-
chloroethyl)benzotriazole using method C. 
Nl-(2-Iodoethyl)benzimidazole 
Prepared according to method B, using N 1-(2-bromoethyl)benzimidazole (2.00 g, 
8.88 mmol) and dry sodium iodide (6.66 g, 44.42 mmol) in dry acetone (100 cm\ Work 
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up gave the title compound as a pale yellow solid (1.82 g, 75%). Data as for N1-(2-
iodoethyl)benzotriazole using chloro derivative. 
Prepared according to method B, using N1-(2-chloroethyl)benzimidazole (2.00g, 
10.83 mmol) and dry sodium iodide (8.12 g, 54.25 mmol) in dry acetone (100 cm\ Work 
up gave the title compound as a pale yellow solid (2.12 g, 72%). Found: M' 271.9808; 
C9H9IN2 requires: M' 271.9808. mlz: 144, 131, 118, 104, 90. Vmax (NaCl/cm·1)3315, 2980 
(CH2), 1653, 1506 (C=N), 1374 (CH2), 1240, 1108,698 (ArH), 511 (C-I). OH (400 MHz, 
CDCh) 3.51 (2 H, t, J 7.2 Hz, CH2I), 4.58 (2 H, t, J 7.2 Hz, CH2N), 7.34-7.53 (3 H, m, 
ArH,), 7.83 (1 H, m, ArH), 7.99 (1 H, s, CH). OC (lOO MHz, CDCh) 44.2 (CH2I), 53.1 
(NCH2), 109.9 (CH), 121.3, 121.9, 124.9, 130.2 (ArCH), 140.8, 146.4 (ArC). 
Nl-Vinylbenzimidazole 
Nl-(2-Chloroethyl)benzimidazole (0.50 g, 2.71 mmol), KOH (3.66 g, 64.99 mmol) and 
hydroquinone (0.02 g, 0.14 mmol) were stirred in ethanol (50 cml ) at reflux for 40 min. 
After this time the alcohol was removed under reduced pressure and the organic material 
extracted from the residue using DCM. The extract was dried (MgS04), filtered and the 
solvent removed under reduced pressure. Purification using flash chromatography gave the 
title product as a clear colourless liquid (0.39 g, 97%). Found: M' 144.0688, C9HSN2 
requires: M' 144.0686. mlz: 118,91. Vmax (NaClIcm·1) 3389, 3089 (C=C-H), 1731, 1697, 
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1610 (C=N, C=C), 1479, 1285,886 and 742 (ArH). OH (250 MHz, CDCh) 5.08 (1 H, dd, J 
9.0, 9.0 Hz, CHH), 5.53 (1 H, dd, J 15.7, 16.0 Hz, CHH), 7.11 (1 H, dd, J 9.0, 15.7 Hz, 
NCH), 7.33 (2 H, m, ArH), 7.53 (1 H, m, ArH), 7.80 (1 H, m, ArH), 8.12 (1 H, s, NCHN). 
oe (100 MHz, CDCh) 109.0 (NCHN), 117.2 (CH2), 120.8 (NCH), 121.1, 122.4, 123.1, 
124.8 (ArCH), 143.1, 145.2 (ArC). 
Nl-(3-BromopropyJ)benzimidazoJe 
~N) 
V-\B' 
Prepared by modification to method A, using benzimidazole (1.00 g, 8.47 mmol), 
triphenylphosphine (2.66 g, 10.15 mmol) and 3-bromopropanol (0.72 cm3, 10.15 mmol) in 
dry dioxane (100 cm3) at 5°C with DIAD (4.00 cm3, 20.31 mmol) to yield the title product 
as an oil (1.58 g, 78%). Found: MH+ 238.9920; ClOH1179BrN2 requires: MH+ 239.0106. 
mlz: 160, 118, 104,90. OH (400 MHz, CDCh) 2.10 (2 H, m, CH2), 3.54 (2 H, t,J 6.3 Hz, 
CH2Br), 4.20 (2 H, t,1 6.6 Hz, CH2N), 7.23 (2 H, m, ArH,), 7.74 (2 H, rn, ArH,), 7.83 (1 H, 
s, CH). Oe (100 MHz, CDCh) 27.0 (CH2)' 29.6 (CH2Br), 34.0 (NCH2), 109.6 (CH), 120.5, 
122.1,123.0, (ArCH), 133.7 (ArC), 142.9 (ArCH), 143.9 (ArC). 
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Nl-(3-Chloropropyl)benzimidazole 
Prepared by modification to method C, using benzimidazole (1.00 g, 8.47 mmol) in 1,3-
dichloropropane (70 cm3) with tetrabutylammonium iodide (0.05 g, 5%), KOH (2.85 g, 
50.79 mmol) and K2C03 (2.93 g, 21.16 mmol). After stirring for 8 h, work up gave title 
product as an oil (1.04 g, 62%). Found: M' 194.0609; CIOH1I35CIN2 requires: M' 
194.0608. mlz: 159,118,104,90. OH (400 MHz, CDCh) 2.23 (2 H, m, CH2CI), 3.38 (2 H, 
t,J 6.5 Hz, CH2N), 4.32 (2 H, t,J6.5 Hz, CH2), 7.23 (2 H, m, ArH,), 7.74 (2 H, m, ArH,), 
7.83 (I H, s, CH). OC (lOO MHz, CDCh) 22.7 (CH2), 32.2 (CH2CI), 46.4 (NCH2), 102.8 
(CH), 121.1, 128.9, 129.2, 133.6 (ArCH), 138.2, 147.3 (ArC). 
Nl-(3-Iodopropyl)benzimidazole - Quarternary Salt 
Prepared by modification to method B, using Nl-(2-bromopropyl)benzimidazole and 
(1.00 g, 4.20 mmol) and dry sodium iodide (3.15 g, 21.01 mmol) in dry acetone (100 cm3). 
Also by using Nl-(2-chloropropyl)benzimidazole and (1.00 g, 5.16 mmol) and dry sodium 
160 
iodide (3.86 g, 25.78 mmol) in dry acetone (100 cm3). Work up in both cases did not give 
the title compound, but gave what is believed to be the dimeric quaternary salt. Found: M+ 
158.93, 317.30; ClOHllIN2 requires: M+ 286.00, but a double quaternary cation C2oH22N4 
requires: 159.09 (M2+), 317.18 ([MHll. OH (250 MHz, CDCh) 1.90 (2 H, br, CH2), 4.90 
(4H, t,J6.9 Hz, CH2), 7.22 -7.78 (4H, m, ArH), 7.95 (lH, s, NCH). 
Nl-(4-Chlorobutyl)benzimidazole - Quaternary Salt 
Prepared by modification to method C, using benzimidazole (1.00 g, 8.47 mmol) in 1,4-
dichlorobutane (70 cm3) with tetrabutylammonium iodide (0.05 g, 5%), KOH (2.85 g, 
50.79 rnrnol) and K2C03 (2.30 g, 21.16 rnrnol). After stirring for 8 h, work up did not give 
the title compound, but gave what is believed to be the dirneric quaternary salt. Found: M+ 
173.04, 345.64; CllH1l sClN2 requires: M+ 208.08, but dirneric quarternary cations, 
C22H26N4 requires: 173.09 (M2+), 345.19 ([M-Hll. OH (400 MHz, DMSO-d6) 2.08 (4 H, 
br, CH2), 4.57 (4 H, t, J 5.6 Hz, CH2), 7.67 (2 H, m, ArH), 8.34 (2 H, rn, ArH), 9.77 (1 H, s, 
NCH). Oc (100 MHz, DMSO-d6) 24.9 (CH2), 26.0 (CH2), 29.7 (CH2), 46.2 (NCH2), 113.8 
(CH), 126.4, 126.8 (ArCH), 130.1 (ArC), 141.5, 142.1 (ArCH), 144.6 (ArC). 
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N-(2-Bromoethyl)indole 
Prepared according to method A, using indole (1.00 g, 34.14 mmol), triphenylphosphine 
(2.69 g, 40.97 mmol) and 2-bromoethanol (0.73 cm3, 40.97 mmol) in dry dioxane (100 
cml) and DIAD (2.017 cml, 40.97 mmol). After workup this yielded none of the desired 
product, and quantitative amounts of the indole starting material was retrieved. 
N-(2-Chloroethyl)indole 
Prepared according to method C, using indole (2.00 g, 17.07 mmol), 1,2-dichloroethane 
(150 cm3), tetrabutylammonium bromide (0.10 g, 5%), KOH (5.75 g, 0.10 mol) and K2C03 
(5.90 g, 0.04 mol). After stirring for 24 h, work up this gave title product as a brown oil 
(2.46 g, 81%). Found: C, 66.8, H, 5.9, N, 7.6%; CIOHIOCIN requires: C, 66.8, H, 5.6, N, 
7.8%. Found: MH+ 180.0510; ClOHI035CIN requires: MW 180.0579. mlz: 144, 116,90. 
vrnax (NaCl/cm·1) 3407, 3286, 3050 (C=C), 2959 (CH2), 1614 (C=C), 1454 (CH2), 1334, 
1093 and 742 (C-Cl). OH (400 MHz, CDCh) 3.84 (2 H, t,J6.6 Hz, CH2), 4.48 (2 H, t,J6.6 
Hz, CH2), 6.61 (1 H, m, CH), 7.18 - 7.28 (3 H, m, ArH, CH), 7.43 (1 H, d,J7.9 Hz, ArH), 
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(1 H, d, J7.9 Hz, ArH). Dc (100 MHz, CDCh) 42.5 (CHzCI), 48.0 (NCHz), 102.0 (CH), 
111.0 (NCH), 120.0, 121.9, 124.2 (ArCH), 127.9 (ArC), 128.8 (ArCH), 135.8 (ArC). 
N-(2-Iodoethyl)indole 
Prepared according to method B, using N-(2-chloroethyl)indole (1.40 g, 7.79 mmol) and 
dry sodium iodide (5.84 g, 38.97 mmol) in dry acetone (100 cm3). After work up this gave 
the title compound as a dark brown oil (1.36 g, 64%). Found: C,44.3, H,3.9, N,5.0%; 
CIOHlOlN requires: C,44.3, H,3.9, N,5.2%. Found (LCMS): MH+ 272.03; CIOHlOlN 
requires: MH+ 272.00. m1z: 130, 117,90. V max (NaCl/cm·1) 3031 (C=C-H), 2924 (CHz), 
1563 (C=C), 1439 (CHz), 1329, 1234, 1126,743,729 (ArH) and 504 (C-I). DH (400 MHz, 
CDCh) 3.44 (2 H, t, J 7.7 Hz, CHz), 4.55 (2 H, t, J 7.7 Hz, CHz), 6.60 (1 H, m, CH), 7.41-
7.92 (3 H, m, ArH, CH), (1 H, d, J 7.5 Hz, ArH), (1 H, d, J 7.5 Hz, ArH). Dc (100 MHz, 
CDCh) 44.3 (CHzI), 59.2 (NCHz), 101.9 (CH), 106.7 (NCH), 109.7 (ArC), 119.2, 127.3, 
127.8, 134.1 (ArCH), 145.5 (ArC). 
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N-(3-Chloropropyl)indole 
Prepared by modification to method C, using indole (2.00 g, 17.07 mmol), 1,3-
dichloropropane (ISO cml), tetrabutylammonium bromide (0.10 g, 5%), KOH (5.75 g, 0.10 
mol) and K2COl (5.90 g, 0.04 mol). Purification by flash column chromatography gave 
title product as a brown oil (2.01 g, 61%). Found: MH+ 194.0823, CIlH12lSCIN requires: 
MH+ 194.0738. mlz: 158, 118, 91. Vmax (NaCl/cm·l) 3421, 3054 (C=C-H), 2970, 2862 
(CH2), 2218, 1718, 1589 (C=C), 1437 (CH2), 1191, 1119, 1070,746,720 (ArH) and 695 
(C-Cl). OH (400 MHz, CDCh) 2.35 (2 H, q, J 6.4 Hz, CH2), 3.55 (2 H, t, J 6.4 Hz, CH2CI), 
4.42 (2 H, t,J6.4 Hz, NCH2), 6.75 (I H, d,J3.14 Hz, CH), 7.28 (1 H, d,J3.14 Hz, CH), 
7.38 (I H, t (dd),J7.1, 8.1Hz, ArH), 7.46 (I H, t (dd),J7.1, 8.1 Hz, ArH), 7.56 (I H, d,J 
8.1 Hz, ArH) 7.80 (I H, d,J8.! Hz, ArH). Oe (lOO MHz, CDCh) 30.4 (CH2CH2CH2), 42.2 
(CH2Cl), 43.1 (NCH2), 101.7 (CH), 109.5 (NCH), 117.4, 119.7, 121.6, 122.1 (ArCH), 
133.7, 136.1 (ArC). 
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N-(3-Iodopropyl)indole 
Prepared by modification to method B, using N-(3-chloropropyl)indole (2.00 g, 10.32 
mmol) and dry sodium iodide (7.74 g, 51.62 mmol) in dry acetone (100 cm3). The work up 
gave a dark brown oil of an impure mixture containing the desired product. Limited values 
due to impurities. Found: MH+ 286.01; CllHdN requires: MH+ 286.01. No IR run due to 
impurity of mixture. OH (400 MHz, CDCh) 2.!0 (2 H, m, CH2), 3.29 (2 H, t, J 6.6 Hz, 
CH2CI), 4.42 (2 H, t,J6.2 Hz, NCH2), 6.76 (1 H, d,J3.! Hz, CH), 7.21 (1 H, d,J3.! Hz, 
CH), 7.35 (1 H, m, ArH), 7.50 (I H, m, ArH), 7.58 (1 H, d,J7.8 Hz, ArH) 7.69 (1 H, t,J 
7.8 Hz, ArH). 
N -( 4-Chlorobutyl)indole 
Prepared by modification to method C, using indole (2.00 g, 17.07 mmol), 1,4-
dichlorobutane (150 cm\ tetrabutylammonium bromide (0.10 g, 5%), KOH (5.75 g, 0.10 
mol) and K2C03 (5.90 g, 0.04 mol). The work up gave a dark brown oil of an impure 
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mixture containing the desired product. Limited values due to impurities. Found (LCMS): 
2.06 (2 H, m, CH2), 3.57 (2 H, t,J 6.5 Hz, CH2C1), 4.21 (2 H, t,J 6.9 Hz, CH2N), 6.61 (1 H, 
d,J3.1 Hz, CH), 7.16 (1 H, d,J3.1 Hz, CH), 7.22 (1 H, t (dd),J7.5 Hz, ArH), 7.32 (1 H, t 
(dd),J7.5 Hz, ArH), 7.43 (1 H, d, J7.5 Hz, ArH), 7.75 (1 H, d, J7.5 Hz, ArH). Oc (100 
(NCH2), 101.3(CH), 109.4 (NCH), 119.5, 121.1, 121.6, 127.9 (ArCH), 128.7, 136.0 (ArC). 
Nl-(2-BromoethyJ)benzotriazoJe and N2-(2-BromoethyJ)benzotriazoJe 
Prepared according to method A, using benzotriazole (2.00 g, 16.79 mmol), 
triphenylphosphine (5.28 g, 20.15 mmol) and 2-bromoethanol (1.43 cm\ 20.15 mmol) in 
dry dioxane (100 cm3) with DIAD (3.97 cm3, 4.07 g, 20.15 mmol). After workup and 
chromatography this yielded the title products. Nl-(2-bromoethyl)benzotriazole: yellow 
crystals (1.03 g, 27%), m.p. 107°C (\it.,116 m.p. 119-120°C). Found: C,42.2, H,3.8, 
N,18.2%; CsHsBrN3 requires: C,42.5, H,3.6, N,18.6%. Found: M+ 224.9902 CSHS79BrN3 
requires: ~ 224.9902. mlz: 146, 132, 119. Vrnax (NaCllcm·1) 3446, 2929 (CH2), 1650 
(C=N), 1444 (CH2), 1329, 1249,740 (ArH) and 624 (C-Br). OH (400 MHz, CDCI3) 3.88 (2 
H, t, J 6.6 Hz, CH2Br), 5.03 (2 H, t, J 6.6 Hz, CH2N), 7.41 (1 H, t (dd), J7.4, 8.4 Hz, ArH), 
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7.54 (1 H, t (dd), J 6.8, 7.4 Hz, ArH), 7.60 (1 H, d, J 8.4 Hz, ArH), 8.00 (1 H, d, J 6.8 Hz, 
ArH) Oc (lOO MHz, CDCh) 28.9 (CH2Br), 49.3 (CH2N), 109.2 (ArCH), 120.2 (ArCH), 
124.2 (ArCH), 127.8 (ArCH), 133.3 (ArC), 145.8 (ArC). N2-(2-bromoethyl)benzotriazole: 
yellow crystals (2.13 g, 56%), m.p. 62-64 (lit.,117 m.p. 59-60°C). Found: C,43.0, H,3.2, 
N,18.6%; CsHsBrN3 requires: C,42.5%, H,3.6%, N,18.6%. Found: M+ 224.9902 
CsHs79BrN3 requires: M+ 224.9902. mlz: 146, 132, 119. Vmax(NaCI/cm· l ) 3414, 2960 
(CH2)' 1648 (C=N), 1583, 1454 (CH2)' 1284, 886, 743 (ArH) and 630 (C-Br). OH (400 
MHz, CDCh) 3.98 (2 H, t, J 6.7 Hz, CH2Br), 5.12 (2 H, t,J 6.7 Hz, CH2N), 7.42 (2 H, m, 
ArH), 7.88 (2 H, m, ArH). Oc (100 MHz, CD Ch) 28.1 (CH2Br), 57.3 (CH2N), 118.2 
(ArCH), 126.7 (ArCH), 144.5 (ArC). 
Nl-(2-Chloroethyl)benzotriazole 
Prepared according to method C, using benzotriazole (2.00 g, 16.79 mmol), 1,2-
dichlorothane (70 cm\ tetrabutylammonium bromide (0.10 g, 5%), KOH (5.65 g, 
0.10 mol) and K2C03 (5.80 g, 0.04 mol). Work up gave the title product, N1-(2-
chloroethyl)benzotriazole, as white crystals (2.01 g, 66%), m.p. 118°C (lit.,llS m.p. 108-
109°C). Found: MW 182.0478; CsHs35C1N3 requires: MH+ 182.0480. mlz: 146, 131,119. 
Vmax (NaC1/cm· l ) 3424, 2938 (CH2), 1638 (C=N), 1457 (CH2), J3J6, 1274, 1228, 1164, 
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767, 747 (ArH) and (C-CI). OH (400 MHz, CDCh) 4.06 (2 H, t, J 6.2 Hz, CH2CI), 4.96 
(2 H, t,J6.2 Hz, CH2N), 7.41 (1 H, t,J8.4 Hz, ArH), 7.55 (1 H, t,J6.8 Hz, ArH), 7.61 
(1 H, d, J6.8 Hz, ArH), 8.10 (I H, d,J8.4 Hz, ArH). Oe (100 MHz, CDCh) 42.3 (CH2CI), 
49.5 (CH2N), 109.3, 120.2, 124.1, 127.8 (ArCH), 133.5, 145.9 (ArC). None of the isomeric 
N2-(2-chloroethyl)benzotriazole was isolated. 
Nl-(2-Iodoethyl)benzotriazole from Bromide 
Prepared according to method B, using Nl-(2-bromoethyl)benzotriazole (1.00 g, 
4.42 mmol) and dry sodium iodide (3.32 g, 22.12 mmol) in dry acetone (100 cm3). Work 
up gave the title compound as a pale yellow solid (1.15 g, 95%), m.p. 106°C. Found: MH+ 
273.9836; CsHsIN3 requires: MH+ 273.9836. rn/z: 146, 132, 118. Vrnax (NaCl/cm·l) 3352, 
3018 (C=C-H), 2350, 1722 (C=N), 1613, 1435 (CH2), 1311, 1072,944 (C=C), 747 (ArH) 
and 665 (C-I). OH (400 MHz, CDCI3) 3.67 (2 H, t,J7.4 Hz, CH2I), 5.02 (2 H, t,17.4 Hz, 
CH2N), 7.36 (1 H, d, J 6.6 Hz, ArH), 7.48 (2 H, m, ArH), 8.04 (I H, d, J 8.4 Hz, ArH). Oe 
(100 MHz, CDCh) 30.2 (CH21), 50.8 (CH2N), 109.5, 120.8, 124.9, 128.3 (ArCH), 133.8, 
146.4 (ArC). 
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Nl-(2-Iodoethyl)benzotriazole from Chloride 
Prepared according to method B, using NI-(2-chloroethyl)benzotriazole (2.00 g, 
11.01 mmol) and dry sodium iodide (8.22 g, 55.05 mmol) in dry acetone (lOO cm\ Work 
up gave the title compound as a pale yellow solid (2.82 g, 94%), m.p. 102°C. Found: MH+ 
273.9836; CgHSIN3 requires: MH+ 273.9836. mlz: 146, 132, 118. Vrnax (NaCllcm·1) 3446, 
3018 (C=C-H), 2359,1785 (C=N), 1613, 1455 (CH2), 1310, 1240, 1160, 944 (C=C), 747 
(ArH) and 665 (C-I). OH (400 MHz, CD Ch) 3.65 (2 H, t,J7.3 Hz, CH2I), 5.00 (2 H, t,J 
7.3 Hz, CH2N), 7.39 (I H, t (dd), J 6.1, 6.5 Hz, ArH), 7.52 (2 H, m, ArH), 8.08 (I H, d, J 
8.4 Hz, ArH). Oc (lOO MHz, CDCI3) 30.3 (CH2I), 50.7 (CH2N), 109.6, 120.9, 124.7, 128.3 
(ArCH), 133.4, 146.5 (ArC). 
N2-(2-Iodoethyl)benzotriazole from Bromide 
Prepared according to method B, using N2-(2-bromoethyl)benzotriazole (2.10 g, 
9.29 mmol) and dry sodium iodide (6.96 g, 46.45 mmol) in dry acetone (lOO cm3). Work 
up gave the title compound as a pale yellow solid (2.46 g, 97%), m.p. 66-69°C. Found: ~ 
272.9757; CgHSIN3 requires: M+ 272.9755. mlz: 146, 131, 120. Vmax (NaCl/cm·l) 3424, 
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3030 (C=C-H), 1636 (C=N), 1439 (CH2), 1234, 1130, 849 (C=C), 747 (ArH) and 598 
(C-I). OH (400 MHz, CDCh) 3.75 (2 H, t, J 7.3 Hz, CH2I), 5.09 (2 H, t, J 7.3 Hz, CH2I), 
7.42 (2 H, m, ArH), 7.88 (2 H, m, ArH). Oc (lOO MHz, CDCI3) 31.3 (CH2I), 59.3 (CH2N), 
119.2 (ArCH), 127.8 (ArCH), 145.5 (ArC). 
Nl-(3-Bromopropyl)benzotriazole 
Prepared by modification to method A, using benzotriazole (2.00 g, 33.58 mmol), 
triphenylphosphine (10.57 g, 40.30 mmol) and 3-bromopropanol (3.64 cm3, 44.30 mmol) in 
dry dioxane (lOO cm3) with DIAD (7.93 cm3, 40.30 mmol). After workup this yielded the 
title product, NI-(3-bromopropyl)benzotriazole as a yellow oil (3.15 g, 78%). Found: MW 
240.0153; C9HlO79BrN3 requires: MH+ 240.0136. mlz: 160, 132, 119. Vrnax (NaCl/cm·1) 
3345,2900 (CH2), 1660 (C=N), 1542, 1447 (CH2), 1287, 1140,821 (ArH) and 707 (C-Br). 
OH (400 MHz, CDCh) 2.33 (2 H, tt,J6.8, 7.3 Hz, CH2) 3.28 (2 H, t, J6.8 Hz, CH2CI), 4.75 
(2 H, t, 17.3 Hz, CH2N), 7.37 (I H, m, ArH), 7.46 to 7.58 (2 H, m, ArH), 8.01 (I H, d,17.9 
Hz, ArH). Oc (lOO MHz, CDCh) 27.8 (CH2), 32.4 (CH2CI), 51.9 (CH2N), 109.7, 121.2, 
123.7, 126.5 (ArCH), 136.3, 144.4 (ArC). None of the isomeric N2-(3-
bromopropyl)benzotriazole was isolated. 
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Nl-(3-Chloropropyl)benzotriazole and N2-(3-Chloropropyl)benzotriazole 
Prepared by modification to method C, using benzotriazole (2.00 g, 16.79 mmol), 1,3-
dichloropropane (100 cm\ tetrabutylammonium bromide (0.10 g, 5%), KOH (5.65 g, 
0.10 mol) and K2C03 (5.80g, 0.04 mol). Work up and chromatography gave title products. 
N1-(3-chloropropyl)benzotriazole: cream oil (1.59 g, 52%). Found: C,55.9, H,4.7, 
N,21.8%; C9HIOClN3 requires: C,55.2, H,5.1, N,21.5%. Found: MH+ 196.0642; 
C9H I035ClN3 requires: MH+ 196.0642. mlz: 160, 133, 120. Vrnax (NaCl/cm-l) 3408, 2879 
(CH2), 1687 (C=N), 1523, 1438 (CH2), 1202, 765 (ArH) and 720 (C-Cl). OH (400 MHz, 
CDCh) 2.45 (2 H, dt, J 6.0,6.5 Hz, CH2) 3.49 (2 H, t, J 6.0 Hz, CH2Cl), 4.79 (2 H, t, J 6.5 
Hz, CH2N), 7.34 (1 H, t, J 8.3 Hz, ArH), 7.48 (1 H, t, J 8.3 Hz, ArH), 7.58 (1 H, d, J 8.3 
Hz, ArH), 8.03 (1 H, d,J8.3 Hz, ArH). Oc (100 MHz, CDCh) 32.4 (CH2), 41.5 (CH2Cl), 
44.7 (CH2N), 109.2, 120.0, 124.0, 127.5 (ArCH), 133.2, 145.9 (ArC). N2-(3-
chloropropyl)benzotriazole: yellow oil (0.72 g, 24%). Found: C,54.9, H,5.2, N,20.9%; 
C9HIOClN3 requires: C,55.2%, H,5.1%, N,21.5%. Found: ~ 195.0560; C9HI035ClN3 
requires: ~ 195.0563. mlz: 146, 133, 119. Vrnax (NaCl/cm·l) 3298, 2901 (CH2), 1732, 
1647 (C=N), 1519, 1468 (CH2), 1232, 1111, 1047, 770 (ArH) and 723 (C-Cl). OH (400 
MHz, CDCh) 2.53 (2 H, dt,J6.2, 6.5 Hz, CH2), 3.56 (2 H, t,J6.2 Hz, CH2CI), 4.89 (2 H, t, 
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J 6.5 Hz, CH2N), 7.35 (2 H, m, ArH), 7.84 (2 H, m, ArH). Oc (lOO MHz, CDC1l) 32.6 
(CH2), 41.4 (CH2Cl), 53.4 (CH2N), 117.9, 126.4 (ArCH), 144.4 (ArC). 
Nl-(3-Iodopropyl)benzotriazole from Chloride 
Prepared by modification to method S, using NI-(2-chloropropyl)benzotriazole (1.50 g, 
8.26 mmol) and dry sodium iodide (6.19 g, 41.30 mmol) in dry acetone (lOO cml). Work 
up gave the title compound as a pale yellow solid (1.73 g, 77%), m.p. 98-99°C. Found: 
MH+ 285.9887; C9HlOINl requires: MH+ 285.9843. m/z: 160, 132, 119. Vrnax (NaCl/cm·l) 
3423, 2958 (CH2), 1610 (C=C), 1464 (CH2), 1357, 1205, 739 (ArH) and 544 (C-I). OH 
(400 MHz, CDCh) 2.44 (2 H, dt, J 6.4,6.5 Hz, CH2), 3.12 (2 H, t, J 6.5 Hz, CH2I), 4.73 
(2 H, t,J6.4 Hz, CH2N), 7.01 (I H, t,J7.0 Hz, ArH), 7.39 (I H, t,J7.0 Hz, ArH), 7.44 (I 
H, d,J8.1 Hz, ArH), 7.68 (I H, d,J8.1 Hz, ArH). OC (lOO MHz, CDCh) 3.5 (CH2I), 33.3 
(CH2), 45.9 (CH2N), 109.3, 118.3, 121.5, 124.5 (ArCH), 127.0, 136.8 (ArC). 
N2-(3-Iodopropyl)benzotriazole from Chloride 
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Prepared by modification to method B, using N2-(3-chloropropyl)benzimidazole (3.20 g, 
17.62 mmol) and dry sodium iodide (13.20 g, 88.10 mmol) in dry acetone (lOO cm\ Work 
up gave the title compound as a pale yellow oil (2.94 g, 65%). Found: M+ 285.9856, 
C9HlOINl requires: M+ 285.9843. mlz: 160, 133, 119. Vrnax (NaCl/cm-1) 3463, 2962 (CH2), 
1615 (C=N), 1448 (CH2), 1278, 1145,969 (C=C), 751 (ArH) and 568 (C-I). OH (400 MHz, 
CD Ch) 2.58 (2 H, dt,J6.4, 6.7 Hz, CH2), 3.15 (2 H, t,J6.7 Hz, CH2I), 4.81 (2 H, t, J6.4 
Hz, CH2N), 7.37 (2 H, m, ArH), 7.82 (2 H, m, ArH). Oc (lOO MHz, CDCh) 4.2 (CH2I), 
30.6 (CH2), 50.9 (CH2N), 115.7 (ArCH), 128.2 (ArCH), 138.1 (ArC). 
Nl-(4-ChJorobutyJ)benzotriazoJe and N2-(4-ChJorobutyJ)benzotriazoJe 
Prepared by modification to method C, using benzotriazole (6.00 g, 50.37 mmol) 
1,3-dichlorobutane (150 cm\ tetrabutylammonium bromide (0.30 g, 5%), KOH (16.96 g, 
0.30 mol) and K2COl (17.40 g, 0.13 mol). Work up gave title product. Nl-(4-
chlorobutyl)benzotriazole: brown crystals (2.56 g, 24%), m.p. 104-106°C. Found: MH+ 
210.0794; CIOH12lSC1Nl requires: MH+ 210.0793. mlz: 175, 137, 121. Vrnax(NaCl/cm·1) 
3051 (C=C), 2958 (CH2), 1566, 1445 (CH2), 1327, 1264, 770 (ArH) and 736 (C-Cl). OH 
(400 MHz, CDCh) 1.85 (2 H, rn, CH2), 2.17 (2 H, m, CH2) 3.56 (2 H, t, J 6.4 Hz, CH2Cl), 
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4.68 (2 H, t,J6.9 Hz, CH2N), 7.38 (1 H, t,J7.1 Hz, ArH), 7.51 (2 H, m, ArH), 8.05 (1 H, 
d, J8.4 Hz, ArH). Oc (100 MHz, CDCh) 26.8, 29.4 (CH2CH2), 44.1 (CH2I), 47.3 (CH2N), 
109.2, 120.1, 123.9, 127.4 (ArCH), 132.8, 146.0 (ArC). N2-(4-chlorobutyl) benzotriazole: 
brown crystals (2.23 g, 21%), m.p. 87-88°C. Found: MH+ 210.0791; CIOH1235ClN3 
requires: MH+ 210.0793. mlz: 175, 137, 121. Vrnax(NaCl/cm- l ) 3305, 2980 (CH2), 1699 
(C=N), 1504 (CH2), 1385, 1240, 1107,761 (ArH) and 723 (C-Cl). OH (400 MHz, CD Ch) 
1.81 (2 H, m, CH2), 2.28 (2 H, m, CH2), 3.55 (2 H, t,J6.4 Hz, CH2I), 4.76 (2 H, t, J6.8 Hz, 
CH2N), 7.36 (2 H, m, ArH), 7.87 (2 H, m, ArH). Oc (100 MHz, CDCh) 27.1, 29.3, (CH2), 
44.1 (CH2I), 55.6 (CH2N), 118.0 (ArCH), 126.3 (ArCH), 144.3 (ArC). 
Nl-( 4-Iodobutyl)benzotriazole 
Prepared by modification to method B, using Nl-(4-chlorobutyl)benzotriazole (2.00 g, 
9.54 mmol) and dry sodium iodide (7.15 g, 47.69 mmol) in dry acetone (100 cm\ Work 
up gave the title compound as a pale yellow oil (2.01 g, 70%). Found: C,39.5, H,4.0, 
N,13.6%; ClOHI21N3 requires: C,39.9, H,4.0, N,14.0%. Found: M+ 301.0073; CIOH121N3 
requires: ~ 301.0076. mlz: 174, 146, 120. Vrnax(NaCl/cm-l ) 3030 (C=C), 2934 (CH2), 
1601, 1462 (CH2), 1137,756 (ArH) and 526 (C-I). OH (400 MHz, CDCh) 1.83 (2 H, m, 
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CH2), 2.13 (2 H, m, CH2), 3.18 (2 H, t,J6.7 Hz, CH2I), 4.68 (2 H, t,J6.9 Hz, CH2N), 7.33 
(1 H, t, J 6.2 Hz, ArH), 7.48 (2 H, m, ArH), 8.06 (I H, d, J7.2 Hz, ArH). Cc (lOO MHz, 
CDCh) 6.9(CH2I), 32.5, 35.4 (CH2), 55.5 (CH2N), 119.2, 123.8, 124.1, 128.9 (ArCH), 
137.0, 142.7 (ArC). 
N2-(4-IodobutyJ)benzotriazoJe 
Prepared by modification to method B, using N2-( 4-chlorobutyl)benzimidazole (2.00 g, 
9.54 mmol) and dry sodium iodide (7.15 g, 47.69 mmol) in dry acetone (100 cm3). Work 
up gave the title compound as a pale yellow solid (2.00 g, 70%). Found: C,39.3%, H,4.1, 
NI4.3%; CIOHdN3 requires: C39.9, H4.0, NI4.0%. Found: M+ 301.0069; CIOHI2IN3 
requires: M+ 301.0070. rnIz: 174, 147, 120. Vmax(NaCl/cm·l ) 3101 (C=C), 2944 (CH2)' 
1599, 1445 (CH2), 1221,732 (ArH) and 511 (C-I). OH (400 MHz, CDCh) 1.84 (2 H, q, J 
6.9,7.3 Hz CH2), 2.16 (2 H, dt, J 6.8,7.3 Hz, CH2), 3.22 (2 H, t,J 6.9 Hz, CH2I), 4.77 (2 H, 
t, J 6.8 Hz, CH2N), 7.36 (2 H, m, ArH), 7.48 (2 H, m, ArH). Qc (100 MHz, CDCh) 
5.8(CH2I), 30.1, 30.8 (CH2), 55.3 (CH2N), 118.0, 126.4 (ArCH), 144.3 (ArC). 
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N9-(2-Bromoethyl)purinel19 
N~N~ 
ll.~/ 
N ~ 
Br 
Prepared according to Method A, using purine (0.50 g, 4.20 rnmol), triphenylphosphine 
(1.32 g, 5.04 rnrnol) and 2-bromoethanol (0.36 crn3, 5.04 rnmol) in dry dioxane (lOO crn3) 
and DIAD (0.99 cm3, 5.04 mmol). After workup this yielded the title product as a brown 
solid (0.62 g, 73%), rn.p. 188-190°C (Iit.,119 rn.p. 195°C). Found: M+ 227.9751; 
C7H/9BrN4 requires: M+ 227.9834. rnIz: 144, 117, 91. vrnax(NaCVcrn") 3289 (C=C-H), 
2979 (CH2), 1700, 1496, 1456 (CH2)' 1267, 1219, 1108 (C=C) and 746 (C-Br). OH (400 
MHz, CDCI3) 3.68 (2 H, t, J 5.5 Hz, CH2Br), 4.58 (2 H, t, J 5.5 Hz, CH2N), 8.14 (1 H, s, 
ArH), 8.74 (I H, s, ArH) 8.92 (I H, s, ArH). Oc (100 MHz, CDCh) 55.0 (CH2Br), 60.3 
(CH2N), 138.8, 141.6 (ArCH), 143.7 (ArC), 155.6 (ArCH), 160.8 (ArC). 
N9-(2-Chloroethyl)purine 
Prepared according to Method C, using Purine (0.50 g, 4.20 rnmol) in 1,2-dichlorothane 
(50 crn3) with tetrabutylamrnonium iodide (0.03 g, 5%), KOH (1.41 g, 25.19 rnmol) and 
K2C03 (1.45 g, 10.50 mrnol). Purification gave the title product as a yellow oil (0.39 g, 
59%). Found: MH+ 183.0548; C7H735CIN4 requires: MH+ 183.0437. rnIz: 144, 117, 91. 
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V max (NaCl/cm·I) 3411, 3082 (C=C-H), 2962 (CH2), 1594, 1502, 1408 (CH2), 1305, 1200, 
1096 (C=C) and 643 (C-Cl). OH (400 MHz, CDCh) 3.91 (2 H, t, J 5.6 Hz, CH2CI), 4.59 (2 
H, t,1 5.6 Hz, CH2N), 8.16 (1 H, s, ArH,), 8.91 (1 H, s, CH), 9.09 (1 H, s, ArH). Oc (100 
MHz, CDCh) 42.2 (CH2CI), 45.6 (NCH2), 134.1 (ArC), 145.8, 148.7, (ArCH), 151.1 
(ArC), 153.2 (ArCH). 
N9-(2-IodoethyJ)purine 
N~N~ 
tAl N N ~ 
I 
Prepared according to method B, using N9-(2-bromoethyl)purine (0.25 g, 1.23 mmol) and 
dry sodium iodide (0.92 g, 6.16 mmol) in dry acetone (100 cm3). Work up gave the title 
compound as a pale yellow oil in a yield (0.24 g, 79%). Found MH+ 274.9748; C7H7IN4 
requires: MW 274.9795. mlz: 145, 117, 90. Vmax (NaCl/cm·I) 3425, 2983 (CH2), 1642, 
1496, 1436 (CH2), 1312, 1118 (C=C), 720 (ArH) and 520 (C-I). OH (400 MHz, CDCh) 
3.61 (2 H, t,1 65 Hz, CH2Cl), 4.66 (2 H, t, J 65 Hz, CH2N), 8.16 (1 H, s, ArH,), 8.95 (1 H, 
s, CH), 9.14 (1 H, s, ArH),. OC (lOO MHz, CDCh) 23.2 (CH2I), 45.9 (NCH2), 135.0 (ArC), 
144.9, 148.8, (ArCH), 152.0 (ArC), 152.6 (ArCH). 
Prepared according to method B, using N9-(2-chloroethyl)purine (0.25 g, 1.58 mmol) and 
dry sodium iodide (1.18 g, 7.88 mmol) in dry acetone (100 cm3). Work up gave the title 
compound as a pale yellow oil (0.25 g, 64%). Found MH+ 274.9750; C7H7N4I requires: 
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MH+ 274.9795. mlz: 144, 117,91. Vmax (NaCl/cm·1) 3385, 2976 (CH2) 1644, 1489, 1455 
(CH2), 1340, 1311, 1121 (C=C), 693 (ArH) and 514 (C-I). OH (400 MHz, CDCh) 3.61 
(2 H, t,J6.5 Hz, CH2CI), 4.67 (2 H, t,J6.5 Hz, CH2N), 8.15 (1 H, s ArH,), 8.95 (1 H, s, 
CH), 9.13 (1 H, s, ArH). Oc (100 MHz, CDCh) 23.9 (CH2!), 44.7 (NCH2), 135.3 (ArC), 
143.2, 148.5, (ArCH), 150.9 (ArC), 153.9 (ArCH). 
6-Boc-aminopurine120 
NHBoc 
N~N~ lL.~1 N N I 
H 
To a dry round-bottomed flask was added adenine (2.00 g, 14.80 mmol), (BOC)20 (3.23 g, 
14.80 mmol) and OlEA (3.84 cm3, 22.20 mmol) in dry DCM (100 cm\ The reaction was 
then stirred for 2 h at room temperature. The solution was washed with H20 (20 cm3 x 3), 
dried (MgS04), filtered and the solvent removed under reduced pressure to give 
6-Boc-aminopurine in quantitative yield (3.46 g), m.p. 280-282°C (lit.,120 m.p. 280-300°C). 
Found: M+ 235.1069; CIOH13Ns02 requires: M' 235.1069. mlz: 134, 119, 90. 
Vrnax(NaCl/cm·1) 3174, 2922,1697 (C=N), 1437 (CH3), 1386, 1118,721 and 540. OH (400 
MHz, CDCh) 1.71 (9 H, s, QCH3h), 1.85 (1 H, br, CNH), 5.78 (1 H, br, NHBOC), 8.51 (1 
H, s, ArH), 8.52 (1 H, s, N=CH). OC (100 MHz, CDCh) 27.9 (CMe3), 37.6 (CMe3), 144.6 
(N=CH), 147.9, 151.8 (ArC), 155.4 (ArCH), 161.5 (ArC-N),204.6(C=O). 
178 
N9-(2-Bromoethyl)-6-Boc-aminopurine 
Prepared according to method A, using 6-Boc-aminopurine (3.45 g, 14.67 mmol), 
triphenylphosphine (4.616 g, 17.60 mmol) and 2-bromoethanol (1.24 cm3, 17.60 mmol) in 
dry dioxane (lOO cm3) with DIAD (3.47 cm3, 17.60 mmol). After workup this yielded the 
title product as colourless crystals (1.88 g, 37%), m.p. 197°C (lit.,64 m.p. 195-197°C). 
Found: M+ 341.04; ClzH1779BrNsOz requires: ~ 341.05. mlz: 241, 133,118,90. OH (400 
MHz, CDCh) 1.63 (9 H, s, QCH3h), 3.82 (2 H, t,J7.8 Hz, CHzBr), 4.41 (2 H, t,J7.8 Hz, 
CHzN), 6.30 (1 H, br, NHBOC), 8.19 (1 H, s, ArH), 8.47 (1 H, s, ArH). Oc (100 MHz, 
CDCh) 31.9 (CMe3), 38.2 (CMe3), 38.6 (CHzBr), 51.9 (CHzN), 137.5 (N=CH), 147.2, 
149.3 (ArC), 157.8 (ArCH), 161.2 (ArC-N) 216.4 (C=O). 
N9-(2-Chloroethyl)-6-Boc-aminopurine 
NHBoc 
N~N~ tJ--/ 
N ~ 
Cl 
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Prepared according to method C, usmg 6-benzyloxycarbonylaminopurine (0.50 g, 
2.13 mmol) in 1,2-dichloroethane (50 cm\ tetrabutylammonium iodide (0.03 g, 5%), KOH 
(0.72 g, 12.75 mmol) and K1C03 (0.73 g, 5.31 mmol). The material could not be further 
purified and work up gave title product as an impure yellow oil (0.39 g, 59%). OH (400 
MHz, CDCh) 1.58 (9 H, s, QCH3)3), 3.93 (2 H, t,J 5.5 Hz, CH1CI), 4.54 (2 H, t, J 5.5 Hz, 
CH1N), 5.61 (1 H, br, NHBoc), 7.89 (I H, s, ArH), 8.36 (1 H, s, ArH). 
N9-(2-IodoethyJ)-N4-Boc-adenine 
Prepared according to method B, using N9-(2-bromoethyl)6-Boc-aminopurine (1.60 g, 4.68 
mmol) and dry sodium iodide (3.50 g, 23.38 mmol) in dry acetone (100 cm\ Work up 
gave the title compound as a pale yellow oil (0.92 g, 51 %). Found (LCMS): ~ 389.05; 
C11H17IN501 requires: M+ 389.05. m/z: 288, 134, 118, 90. Vmax(NaCIIcm·l) 3419, 1642 
(C=N), 1516 (C=C), 1436 (CH1), 1373 (CH3), 1277, 1l08, 741. OH (400 MHz, CDCh) 
1.39 (9 H, s, QCH3h), 3.57 (2 H, t, J 6.6 Hz CH1I), 4.51 (2 H, t, J 6.6 Hz, CH1N), 5.99 
(l H, br, NH), 7.80 (1 H, s, ArH,), 8.34 (1 H, s, CH), 8.87 (1 H, s, ArH). OC (lOO MHz, 
CDCh) 28.2 (CMe3), 29.9 (CH2I), 38.2 (CMe3), 51.7 (CH1N), 139.1 (N=CH), 148.7, 150.7 
(ArC), 155.8 (ArCH), 163.9 (ArCN) 213.4 (C=O). 
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Carbon - Carbon bond forming reactions 
Conjugate radical addition of Uracil Derivative to Oxazolidinone: 
Method A 
3-Benzoyl-I-(2-iodoethyl)uracil (1.00 g, 2.69 mmol), (2S,2R)-3-benzyloxycarbonyl-2-tert-
butyl-4-(ene)oxazolidin-5-one (1.56 g, 5.39 mmol), tributyltin chloride (0.18 cm3, 0.22 g, 
0.67 mmol), sodium cyanoborohydride (0.33 g, 5.39 mmol) and AmN (0.04 g, 0.27 mmol) 
were stirred under reflux under nitrogen for 6 h: 1) with AmN only added at the start; 
2) with further additions of AmN (0.04 g, 0.27 mmol) every hour, then refluxed for 24 h or 
44 h. The solvent was removed under reduced pressure and the residue purified by flash 
chromatography (EtOAc:Hexane 1:4 to 4:1 v/v). 
Only the oxazolidinone starting material and the reduced product, 3-benzoyl-1-ethyluracil, 
was found for the reactions at 24 h [1) 56% and 2) 54%]. OH (250 MHz, CDCh) 1.32 (3 H, 
t, J 7.3 Hz, CH3), 3.84 (2 H, q, J 7.3 Hz, CH2), 7.34-7.54 (5 H, m, ArH), 7.97 (I H, br, 
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N=CH) 8.04 (1 H, br, CHC=O). The reactions at 48 h both produced the reduction product 
again at I)S7%, 2)S2%. 
MethodB 
3-Benzoyl-l-(2-iodoethyl)uracil (1.00 g, 2.69 mmol), (2S,2R)-3-benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-S-one (1.S6 g, S.39 mmol) and AIBN (0.04 g, 
0.27 mmol) were stirred at reflux under nitrogen with tributyltin hydride (0.09 cm3, 0.09 g, 
0.32 mmol) added dropwise over 1 h and heating continued for 6 h or 24 h. The solvent 
was removed under reduced pressure. Reduction and addition products were not isolated, 
although possibly a trace was observed in the mixture, by NMR spectroscopy. 
Conjugate radical addition of Nl-(2-Iodoethyl)benzimidazole to Oxazolidinone: 
Method A 
Nl-(2-Iodoethyl)benzimidazole (0.10 g, 0.37 mmol), (2S,2R)-3-Benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-S-one (0.21 g, 0.74 mmol), tributyltin chloride 
(0.03 cm3, 0.67 mmol), sodium cyanoborohydride (O.OS g, 0.09 mmol) and AIBN (0.006 g, 
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0.04 mol) were stirred at reflux under nitrogen for 6 h or 24 h. The solvent was removed 
under reduced pressure and the residue purified by flash chromatography (EtOAc:Hexane 
1:4 to 4:1 v/v) to yield only the oxazolidinone starting material and the reduced Nl-
ethylbenzimidazole product (42% after 6 hand 45% after 12 h). Found: M" 146.0842; 
C9HION2 requires M" 146.0844. Vmax (NaClIcm-1) 3062, 2980, 2360, 1714, 1498, 1460, 
1228, 745. OH (250 MHz, CDCh) 1.34 (3 H, t, J 7.3 Hz, CH3), 4.18 (2 H, q, J 7.3 Hz, 
CH2), 7.46-7.58 (4 H, m, ArH), 7.98 (1 H, s, N=CH). 
MethodB 
Nl-(2-Iodoethyl)benzimidazole (0.10 g, 0_37 mmol), (2S,2R)-3-Benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-5-one (0.13 g, 0.44 mmol) and AmN (0.006 g, 
0.04 mmol) were stirred under reflux under nitrogen with tributyltin hydride (0.12 cm\ 
0.44 mmol) added dropwise over 1 h and heating continued for 6 h or 24 h. The solvent 
was removed under reduced pressure and the products purified under column 
chromatography (EtOAc:Hexane 9:1-1:9 v/v). The oxazolidinone starting material and the 
reduced Nl-ethylbenzimidazole product was obtained as a white gum (45% and 46%). 
OH (250MHz, CDCh) as above. 
Conjugate radical addition to Oxazolidinone using Nl-(2-BromoethyJ)benzimidazoJe 
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NI-(2-Bromoethyl)benzimidazole (0.10 g, 0.44 mmol), (2S,2R)-3-Benzyloxycarbonyl-2-
tert-butyl-4-( methylsulfonylmethyl)oxazolidin-5-one (0.51 g, 1.78 mmol), tributyltin 
chloride (0.06 cm3, 1.63 mmol), sodium cyanoborohydride (0.11 g, 0.22 mmol) and AIBN 
(0.01 g, 0.09 mol) were stirred at reflux under nitrogen for 48 h. The solvent was removed 
under reduced pressure and the residue purified by flash chromatography (EtOAc:Hexane 
1:4 to 4:1 v/v) to yield only the oxazolidinone and NI-(2-bromoethy1)benzimidazole 
starting materials. 
Reaction between Nl-(2-Iodoethyl)benzimidazole and Cyanoborohydride 
NI-(2-Iodoethyl)benzimidazole (0.10 g, 0.37 mmol), sodium cyanoborohydride (0.05 g, 
0.09 mmol) and AIBN (0.006 g, 0.04 mmol) were stirred at reflux under nitrogen for 48 h. 
The solvent was removed by reduced pressure and the residue purified by flash 
chromatography (EtOAc:Hexane 1:4 to 4:1 v/v) to yield only the unchanged NI-(2-
iodoethyl)benzimidazole starting material. 
Conjugate radical addition with 20 equivalent of Oxazolidinone 
NI-(2-Iodoethyl)benzimidazole (0.10 g, 0.37 mmol), (2S,2R)-3-Benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-5-one (4.26 g, 7.35 mmol), tributyltin chloride 
(0.03 cm3, 0.67 mmol), sodium cyanoborohydride (0.05 g, 0.09 mmol) and AIBN (0.006 g, 
0.04 mol) were stirred at reflux under nitrogen for 48 h. The solvent was removed under 
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reduced pressure and the residue purified by flash chromatography (EtOAc:Hexane 1:4 to 
4:1 v/v) to yield only the oxazolidinone starting material and the reduced NI-
ethylbenzimidazole product in 43% yield. 
Hydroboration with Borane complexes 
Hydroboration with diethylether, THF or dimethyl sulphide complex 
(2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) oxazolidin-5-one 
(0.40 g, 1.38 mmol) was stirred vigorously in diethyl ether (lOO cm3) in a flame-dried 
round-bottomed flask under nitrogen and cooled to O°C. Borane diethylether complex 
(0.28 cm3, 5.53 mmol), borane tetrahydrofuran complex (0.28 cm3, 5.53 mmol) or borane 
methylsulfide (0.52 cm3, 5.53 mmol) was added to the mixture over I h. The mixture was 
warmed to 30°C for 48 h then to reflux for 48 h. Water (1 cm3) was then added and the 
organic layer separated off, dried (MgS04) and the solvent removed under reduced 
pressure. No hydroboration products were seen from any of the reactions. 
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Hydroboration with 9-BBN 
To a flame-dried round-bottomed flask was added (2S,2R)-3-Benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-5-one (0.05 g, 0.17 mmol) and 9-BBN (0.04 g, 
0.17 mmol) in solvent [DCM, diethyl ether or THF (50 cm3)] under nitrogen. This mixture 
was stirred at O°C for 36 h and was monitored using TLC. When no reaction had occurred 
after this time, the temperature was raised to RT and the mixture stirred for a further 36 h, 
again monitored by TLC. As no reaction was observed, the temperature was raised again to 
30°C, then reflux. Water was added and organic layer separated off, dried (MgS04) and 
the solvent removed under reduced pressure. There was no reaction of the oxazolidinone 
with 9-BBN at reflux after 36 h in DCM, diethyl ether or THF. 
Coupling Reaction 
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To a flame dried flask was added N-vinylbenzimidazole (0.30 g, 2.07 mmol) and 
(2S,2R)-3-benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) oxazolidin-5-one 
(0.6 g, 2.07 mmol) in THF (20 cm3) under nitrogen. This was cooled to O°C and BH3:THF 
complex (IM, 1.0369cml) added and the reaction mixture stirred for a further 12 h. KOH 
in methanol was then added (2 M, 10 cml) followed by AgNOl(aq) (5 M, 2 cml) at RT. 
After 2 h, KOH (3.00 g) was added and the mixture refluxed for 4 h. The reaction mixture 
was then poured onto water (50 cml), acidified to pH 2 with HCl, filtered and the 
precipitate extracted with boiling acetone. The acetone was filtered and evaporated off, but 
no product of the reaction of the heterocycle with the oxazolidinone template was isolated. 
Cross Metathesis 
Cross Metathesis of Oxazolidinone Template with Allyl Bromide 
Br 
(2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) oxazolidin-5-one 
(0.05 g, 0.17 mmol) and Grubbs catalyst (II) (0.001 g, 10 mol%) were place in a flame-
dried round-bottomed flask in DCM (20 cm3) under nitrogen. Allyl bromide (0.21 g, 
1.73 mmol) was then added and the reaction mixture stirred at reflux for up to 48 h. The 
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solvent was removed under reduced pressure. None of the desired products were seen, only 
oxazolidinone starting material was recovered. 
Cross Metathesis of Oxazolidinone Template with NI-Vinylbenzimidazole 
(2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl)oxazolidin-5-one 
(0.05 g, 0.17 mmol) and Grubbs catalyst (I1) (0.001 g, 10 mol%) were place in a flame-
dried round-bottomed flask in DCM (20 cm3) under nitrogen. NI-Vinylbenzimidazole 
(0.05 g, 0.35 mmol) was then added and the reaction mixture stirred at reflux for up to 48 h. 
The solvent was removed under reduced pressure. No purification was performed as the 
IH NMR spectrum showed only oxazolidinone and Nl-vinylbenzimidazole starting 
materials and no cross metathesis product. 
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Organocuprates 
LithiumlHalogen Exchange (Methyl Acrylate Acceptor) 
Finely cut lithium (0.003 g, 0.44 mmol) was placed in a flame-dried round-bottomed flask 
and suspended in THF (40 cm3) under nitrogen. NI-(2-Bromoethyl)benzimidazole (0.10 g, 
0.44 mmol), in THF (10 cm\ was added slowly to the round-bottomed flask and the 
solution stirred at room temperature. Once a colour change had occurred the reaction was 
either a) cooled to approximately -10°C, b) kept at RT, or c) cooled to -78°C. Any NI-(2-
bromoethyl)benzimidazole not added before the colour change was then added. After 2 h 
the solution was cooled further (as necessary) to -78°C then siphoned through glass wool 
into another flame-dried round-bottomed flask at -78°C and kept under nitrogen. A pre-
cooled suspension of copper(I) iodide (0.04 g, 0.22 mmol) in THF (10 cm3) was then added 
slowly to the stirred mixture and the temperature slowly raised to -10°C over I h and then 
to O°C over 10 min, before cooling again to -78°C. Methyl acrylate (0.02 cm3, 0.33 mmol) 
was then added and the solution stirred for 2 h at -78°C before being allowed to warm 
slowly to RT and stirred for a further 20 h at RT. The reaction mixture was filtered and the 
solvent removed under reduced pressure. The mixture was then subject to flash column 
chromatography but no addition product was found in any of the fractions, and with further 
attempts at the reaction no separation was pursued as the crude I H NMR spectra showed no 
sign of the desired conjugate addition product. 
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Initial attempts of cooling to a) -10°C gave the ,a-elimination product, dealkylated 
benzimidazole. Attempts at b) RT and c) -78°C gave the alternative elimination products of 
ethyl and vinyl benzimidazoles. 
The data for the ethyl product is as detailed for Nl-ethylbenzimidazole, an undesired 
product from the attempted radical reaction of the oxazolidinone template and N 1-(2-
iodoethyl)benzimidazole. The data for the vinyl product is as detailed previously for 
N I-vinylbenzimidazole. 
This reaction was repeated using Nl-(2-chloroethyl)benzimidazole (0.08 g, 0.44 mmol) and 
Nl-(2-iodoethyl)benzimidazole (0.12 g, 0.44 mmol) as well as the addition of TMSCl 
(0.44 mmol), but these gave none of the desired product giving complex TLC results and 
inconclusive IH NMR spectra. 
LithiumlHalogen Exchange (Oxazolidinone Acceptor) 
Finely cut lithium (0.003 g, 0.44 mmol) was placed in a flame-dried round-bottomed flask 
and suspended in THF (40 cm3) under nitrogen. Nl-(2-Bromoethyl)benzimidazole (0.10 g, 
0.44 mmol), in THF (10 cm\ was added slowly to the round-bottomed flask and the 
solution stirred at room temperature. Once a colour change had occurred the reaction was 
either a) cooled to approximately -lOoC, b) kept at RT, or c) cooled to -78°C. Any Nl-(2-
bromoethyl)benzimidazole not added before the colour change was then added. After 2 h 
the solution was cooled further (as necessary) to -78°C then siphoned through glass wool 
into another flame-dried round-bottomed flask at -78°C and kept under nitrogen. A pre-
cooled suspension of copper(I) iodide (0.04 g, 0.22 mmol) in THF (10 cm3) was then added 
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slowly to the stirred mixture and the temperature slowly raised to -10°C over 1 h and then 
to O°C over 10 min, before cooling again to -7SoC. (2S,2R)-3-Benzyloxycarbonyl-2-tert-
butyl-4-(methylsulfonylmethyl)oxazolidin-5-one (0.06 g, 0.22 mmol) was then added and 
the solution stirred for 2 hat -7SoC before being allowed to warm slowly to RT and stirred 
for a further 20 h at RT. The reaction mixture was filtered and the solvent removed under 
reduced pressure. The mixture was then subject to flash column chromatography but no 
addition product was found in any of the fractions, and with further attempts at the reaction 
no separation was pursued as the crude IH NMR spectra again showed no sign of the 
desired conjugate addition product. 
The reactions at a) -10°C gave the ,8-elimination product, dealkylated benzimidazole and at 
b) RT and c) -7SoC gave the alternative elimination products of ethyl and vinyl 
benzimidazoles, both obtained as white gums. 
Again, the data for the ethyl product is as detailed for N l-ethylbenzimidazole, an undesired 
product from the attempted radical reaction of the oxazolidinone template and Nl-(2-
iodoethyl)benzimidazole. The data for the vinyl product is as detailed previously for 
N I-vinylbenzimidazole. 
The addition of TMSCl (0.44 mmol), also gave none of the desired product, giving 
complex TLC results and inconclusive IH NMR spectra. 
n-ButylIithium (Methyl Acrylate Acceptor) 
To a flame-dried round-bottomed flask a solution of a) Nl-(2-bromoethyl)benzimidazole 
(0.10 g, 0.44 mmol) or b) Nl-(2-chloroethyl)benzimidazole (O.OS g, 0.44 mmol) in 1) dry 
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ether or 2) THF (40 cm3) was added under nitrogen at -7SoC. To this solution fresh 
n-butyllithium (0.09 g, 1.47 mmol) was added and the reaction mixture stirred for 2 h at 
_78°C (or until there was a colour change). A pre-cooled suspension of copper(I) iodide 
(0.04 g, 0.22 mmol) in ether or THF (10 cm3) was then added slowly to the solution and the 
temperature slowly raised to -10°C over 1 h and then to O°C over 10 min, before cooling 
again to -7SoC. Methyl acrylate (0.02 g, 0.22 mmol) was then added and the solution 
stirred for 2 h at _78°C before being allowed to warm slowly to RT and stirred for a further 
20 h at RT. The reaction was then worked up using saturated ammonium chloride solution 
(20 cm3) and extracted using ether (20 cm3). This was then dried (MgS04) and the solvent 
evaporated off under reduced pressure. Separation was attempted by flash column 
chromatography. The starting material methyl acrylate was the only compound recovered 
from any of the reaction combinations. Even upon an attempt at separating the compounds 
the IH NMR spectra were inconclusive as the mixture proved to be inseparable. 
n-Butyllithium (Oxazolidinone Acceptor) 
To a flame-dried round-bottomed flask a solution of a) NI-(2-bromoethyl)benzimidazole 
(0.10 g, 0.44 mmol) or b) NI-(2-chloroethyl)benzimidazole (O.OS g, 0.44 mmol) in 1) dry 
ether or 2) THF (40 cm3) was added under nitrogen at -7SoC. To this solution fresh 
n-butyllithium (0.09 g, 1.47 mmol) was added and the reaction mixture stirred for 2 h at 
-7SoC (or until there was a colour change). A pre-cooled suspension of copper(I) iodide 
(0.04 g, 0.22 mmol) in ether or THF (10 cm3) was then added slowly to the solution and the 
temperature slowly raised to - JOoC over 1 h and then to O°C over 10 min, before cooling 
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again to _78°C. (2S,2R)-3-Benzyloxycarbonyl-2-tert-butyl-4-(methylsulfonylmethyl) 
oxazolidin-5-one (0.06 g, 0.22 mmol) was then added and the solution stirred for 2 h at 
-78°C before being allowed to warm slowly to RT and stirred for a further 20 h at RT. The 
reaction was then worked up using saturated ammonium chloride (20 cm3) solution and 
extracted using ether (20 cm3). This was then dried (MgS04) and the solvent evaporated 
off under reduced pressure. Separation was attempted by flash column chromatography. 
The starting material of the oxazolidinone template was again the only compound 
recovered from any of the reaction combinations. Even upon an attempt at separating the 
compounds the 1 H NMR spectra were again inconclusive as the mixture proved to be 
inseparable. 
DL-MethyI2,3-diaminopropanoate98 
DL-2,3-Diaminopropionic acid (1.20 g, 8.54 mmol) and dry methanol (100 cm3) were 
added to a flame-dried multi-neck round-bottomed flask, which was then cooled in an ice 
bath to O°C. Thionyl chloride (0.62 cm\ 85.38 mmol) was added slowly and the reaction 
mixture was then allowed to warm to RT before heating at reflux for 24 h. The methyl 
ester bis-hydrochloride was purified by crystallisation (1.20 g, 92%), m.p. 91'C. Found: 
MW 119.0813; C4HlON202 requires: MH+ 119.0815. mlz: 102, 81. Y rn .. (NaCI/cm-1) 
3304,2928 (CH2), 1698 (C=O), 1456, 1198, lOSS, 598. OH (400 MHz, DMSO-d6) 3.32 
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(2 H, dd, J 5.8, 6.1 Hz, CH2), 3.78 (3 H, s, CH3), 4.44 (1 H, t, J 6.1 Hz CH), 8.90 (4 H, br, 
2 X NH2). OC (100 MHz, DMSO- d6) 37.1 (CH2), 50.0 (CH), 53.4 (OMe), 167.0 (C=O). 
DL-Methyl 2,4-diaminobutyrateI21 
DL-2,4-Diaminobutyric acid (0.50 g, 4.23 mmol) and dry methanol (100 cm3) were added 
to a flame-dried multi-neck round-bottomed flask, which was then cooled in an ice bath to 
O°C. Thionyl chloride (0.31 cm3, 4.23 mmol) was added slowly and the reaction mixture 
was then allowed to warm to RT before heating at reflux for 48 h. The methyl ester bis-
hydrochloride salt was purified by crystallisation (0.54 g, 96%), m.p. 182°C (lit.,121 m.p. 
239°C). Found: MW 133.0974; CSHl2N202 requires: MH+ 133.0971. mlz: 91, 86. Vmax 
(NaCl/cm·1) 3201 (NH2), 2931 (CH2), 1744 (C=O), 1636 (NH2), 1493 1151 (CH2), 941 and 
598 (CH). OH (400 MHz, CD30D) 2.27 (2 H, br, CH2), 3.27 (2 H, br, NCH2), 3.90 (3 H, s, 
CH3), 4.29 (2 H, br, CH). Qc (100 MHz, CD30D) 29.2 (CH2), 34.7 (CH2), 51.7 (CH), 54.5 
(OMe), 170.0 (C=O). 
Attempted Preparation of 3-Aminopyrrolidin-2-one 
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Chlorofonn (50 cm3) was saturated with ammonia gas and methyl 2,4-diaminobutyrate 
(0.50 g, 3.78 mmol) was added to the saturated solution, which was then shaken for 3 h at 
RT. The chloroform and ammonia gas were removed under reduced pressure to give the 
presumed lactam product (0.33 g, 86%). Vmax (NaCI/cm· l ) 3425 (NH2), 1652, 1635 (C=O), 
1404 (CH2), 1140, 974 and 689 (Ar). OH (400 MHz, D20) 2.05 (1 H, br, CHCHH), 2.98 
(I H, br, NHCH2), 4.31 (I H, br, CH,). oc(IOO MHz, D20) 28.6 (CH2), 36.7 (NCH2), 52.7 
(CH), 173.0 (C=O). 
Attempted Preparation of 3-Boc-Aminopyrrolidin-2-one 
qH 
BocHN 0 
To a dry round-bottomed flask was added lactam (0.40 g, 4.00 mmol), DIEA (0.83 cm3, 
4.79 mmol) and (BOC)20 (0.87 g, 4.79 mmol) in dry DCM (20 cm3) under nitrogen and the 
solution was stirred for 2 h. The solvents were removed under reduced pressure to give the 
presumed Boc protected lactam (0.73 g, 91%). Vmax (NaCllcm· l ) 2982 (CH2), 1810 (C=O), 
1756 (C=O), 1372 (CMe3), 1213, 1120 (CO), 1071, 845 and 775 (Ar). OH (400MHz, 
MeOD) 1.56 (9 H, s, qCH3)3), 2.23 (2 H, m, CHCH2), 3.30 (2 H, m, CH2), 3.80 (I H, t, J 
6.2 Hz, CH). Oc (lOO MHz, MeOD) 22.2 (CH2), 28.3 (NCH2), 37.6 (CMe3), 53.2 (CH), 
114.5 (CMe3) 173.9,215.4 (C=O). 
N-Boc-Serine Methyl Ester.12o 
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jOH 
BocHN eOOMe 
To a dry round-bottomed flask was added serine methyl ester (1.00 g, 6.43 mmol), (Boc )20 
(1.40 g, 6.43 mmol) and DIEA (1.34 cm3, 7.71 mmol) in dry DCM (100 cm3). The reaction 
was then stirred for 2 h at room temperature. The solution was washed with H20 (20 cm3 
x 3), dried (MgS04)' filtered and the solvent removed under reduced pressure to give N-
Boc-serine methyl ester (1.24 g, 94%), m.p. DC (\it.,120 m.p. DC). Found: MH+ 220.1187; 
C9H17NOs requires: MH+ 220.1185. mlz: 164, 120. Vrnax (NaCl/cm-l) 3393 (OH), 2977 
(CH2), 1754, 1691 (C=O), 1531 (N-O), 1366 (OH), 1162 (C-O), 1063 (C-H), 849 and 779 
CH2),4.23 (1 H, br, CH), 5.59 (1 H, d, J 7.6 Hz, NH). Dc (100 MHz, CDCI) 27.4 (OMe), 
28.3 (CMe3), 52.6 (CH), 55.7 (CMe3), 63.3 (CH2), 155.8, 171.4 (C=O). 
N -Boc-Serine.l2l 
jOH 
BocHN eOOH 
To a dry round-bottomed flask was added serine (1.00 g, 9.52 mmol), (BOC)20 (2.08 g, 
9.52 mmol) and DIEA (1.99 cm3, 11.42 mmol) in dry DCM (100 cm3). The reaction was 
then stirred for 2 h at room temperature. The solution was washed with H20 (20 cm3 x 3), 
dried (MgS04), filtered and the solvent removed under reduced pressure to give N-Boc-
serine in quantitative yield (1.95 g), m.p. 98°C (1it.,121 m.p. 91-95DC). Found: MH+ 
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230.1030; CSHlSNOs requires: MH+ 230.1028. mlz: 128, 114. Vmax (NaCl/cm·1) 3405 
(OH), 2979 (CH2), 1807, 1731 (C=O), 1591 (N-O), 1371 (OH), 1117 (C-O), 951 (C-H), 
844, 775 and 666 (CH2). OH (400 MHz, CDCI3) 1.39 (9 H, s, QCH3)3), 3.02 (I H, br, 
OH), 3.82 (2 H, m.br, CH2), 4.23 (1 H, d, J 1.3 Hz, CH), 5.47 (1 H, d, J 6.9 Hz, NH). Oc 
(100 MHz, CDCh) 14.1 (CMeJ), 21.0 (CH), 56.3 (CMe3), 63.7 (CH2), 155.9,169.9 (C=O). 
Formation of Sulphur containing Heterocyclic Amino Acids 
N -Boc-cysteine-O-ethyl ester 
To a dry round-bottomed flask was added N-BOC-cysteine-O-ethyl ester (10.00 g, 53.86 
mmol), (BochO (11.76 g, 53.86 mmol) and DIEA (11.18 cm3, 64.63 mmol) in dry DCM 
(200 cm\ The reaction was then stirred for 2 h at room temperature. The solvent was then 
washed with I M HCI (100 cm3 x 2), 1 M NaHC03 (100 cm3 x 2), and H20 (100 cm3 x 2), 
dried (MgS04), and the solvent removed under reduced pressure. Work up gave the Boc-
cysteine methyl ester as off white oil (12.62 g, 94%). Found: MH+ 250.1108; ClOHl9N04 
requires: MW 250.1108. mlz: 211, 193,135. Vmax (NaCVcm·1) 3367, 2979,1712,1507, 
1368, 1165, 1029,861,737. OH (400 MHz, CDCI3) 1.22 (3 H, t, J7.1 Hz, CH2CHJ), 1.38 
(9 H, s, QCH3)3), 2.90 (2 H, br, CH2S), 4.17 (2 H, q, J 7.1 Hz, CH2CH3), 4.50 (I H, br, 
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CH), 5.43 (1 H, br, NH). Dc (100 MHz, CDCb) 14.1 (CH3), 27.2 (CH2S), 28.2 (CMe3), 
56.2 (CH), 68.9 (OCH2) 80.2 (CMe3)170.4 (C=O). 
N-Boc-S-[2-(benzimidazol-l-yl)ethyl]-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.1 0 g, 
0.20 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O°C. Dry THF (25 cm3) was added to the reaction vessel 
followed by N-Boc-(S)-cysteine ethyl ester (0.50 g, 2.01 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of20 min before the addition of NI-
(2-iodoethyl)benzimidazole (2.18 g, 8.02 mmol), after which the reaction mixture was 
heated at reflux for 16 h. The THF was then removed under reduced pressure and the 
residue taken up in DCMlH20 (lOO cm3, 1:1 v/v). The DCM layer was separated, washed 
with H20 (20 cm3), dried (MgS04)' and the solvent removed under reduced pressure (ethyl 
acetatelhexane). Purification was by column chromatography. The title product was 
formed as a yellow oil (0.44 g, 66%). Found C,58.2, H,6.8, N,IO.4%; Cl9H27N304S 
requires C,58.0, H,6.9, N,10.7%. Found: MH+ 394.1802; Cl9H27N304S requires: MH+ 
394.1801. mlz: 338, 279, 220, 192, 160, 146, 118. Vmax (NaClIcm·1) 3352, 3223 (CON-H), 
2976 (CH2), 1708 (C-C=O), 1494 (N-C=O) 1458 (C=N), 1366 (-C(CH3)J), 1250, 1165, 
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1024 (CH2-S-CH2), 744 and 721 (ArH). liH (400 MHz, CDCh) 1.18 (3 H, t, J 7.2 Hz, 
CH2CH3), 1.36 (9 H, s, CMe3), 2.88 (2 H, dd/dd, J 6.3, 6.6 Hz, SCH2), 2.91 (2 H, t, 
J7.0 Hz, SCH2), 4.11 (2 H, q,J7.2 Hz, CHzCH3), 4.29 (2 H, t, J7.0 Hz, NCH2), 4.41 (1 H, 
br, CH), 5.23 (1 H, br, NH), 7.20-7.75 (4 H, m, ArH), 7.88 (1 H, s, N=CH). lie (100 MHz, 
CDCh) 14.2 (CH2CH3), 28.3 (CMe3), 32.3, 34.8 (CH2SCH2), 42.9 (CMe3), 44.9 (CH2N), 
61.9 (CHzCH3), 109.4 (NCH), 120.5, 122.4, 123.1, 128.6, 132.1 (ArCH), 133.3 (ArC), 
143.7 (ArC), 155.2, 170.7 (C=O). 
N-BOC-S-(2-(lndol-l-yl)ethyl)-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.10 g, 
0.20 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O°C. Dry THF (25 cm3) was added to the reaction vessel and 
followed by N-Boc-(S)-cysteine ethyl ester (0.50 g, 2.01 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of IOmin before the addition ofN-(2-
iodoethyl)indole (2.17 g, 8.02 mmol), after which the reaction mixture was heated at reflux 
for 48 h. The THF was then removed under reduced pressure and the residue taken up in 
DCMlH20 (lOO cm3, 1:1 v/v). The DCM layer was separated off, washed with H20 
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(20 cm\ dried (MgS04), and the solvent removed under reduced pressure. Purification 
was by column chromatography (ethyl acetatelhexane). The title product was formed as a 
yellow oil (0.24 g, 31%). Found: M+ 347.1431; C2oH2SN204S requires ~ 392.1771; 
C1sH23N203S requires M+ 347.1431 (loss of ethyl ester). mlz: 291, 249, 232,203, 176, 
146. OH (400 MHz, CDCh) 1.23 (3 H, t, J 7.1 Hz, CH2CH3), 1.36 (9 H, s, CMe3), 1.73 
(2 H, br, SCH2), 2.92 (2 H, br, SCH2), 4.12 (2 H, br, NCH2), 4.14 (2 H, q, J 7.1 Hz, 
CH2CH3), 4.49 (1 H, br, CH), 5.29 (l H, br, NH), 7.09-7.26 (2 H, m, ArH), 7.37-7.51 (2 H, 
m, ArH) 7.58-7.63 (2 H, m, ArH). Oc (100 MHz, CDCh) 14.1 (CH2CH3), 28.3 (CMe3), 
29.7 (CH2SCH2), 30.3 (CMe3), 31.9 (CH2SCH2), 45.1 (CH2N), 61.8 (CH2CH3), 107.8 
(CH), 126.4 (ArC), 128.4, 128.6, 129.2, 131.9, 132.2 and 132.9 (ArCH), 143.1 (ArC), 
157.6, 179.9 (C=O). 
N-Boc-S-[2-(3-benzoyluracil-l-yl)ethyl]-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.10 g, 
0.20 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
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decanted, and then cooled to O·C. Dry THF (25 cm3) was added to the reaction vessel 
followed by N-Boc-(S)-cysteine ethyl ester (0.50 g, 2.01 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 15 min before the addition of N 1-
(2-iodoethyl)-3-benzoyluracil (2.98 g, 8.02 mmol), after which the reaction was then heated 
at reflux for 16 h. The THF was then removed under reduced pressure and the residue 
taken up in DCMlH20 (100 cm3, 1:1 v/v). The DCM layer was separated off, washed with 
H20 (20 cm\ dried (MgS04), and the solvent removed under reduced pressure. 
Purification was by column chromatography (ethyl acetatelhexane). The title product was 
formed as a yellow oil (0.62 g, 64%). Found (LCMS): MH+ 272.29; C23H29N307S requires: 
MH+ 493.19; ClIHI6N204S MH+ requires 272.08 (loss ofNHBOC and benzoyl protection). 
mlz: 243, 188. Found: C,56.8, H,5.8, N,9.3%; C23H29N307S requires C,56.2, H,5.9, 
N,8.5%. Vmax (NaCl/cm·l ) 3416 (CONH), 2930 2857 (CH2), 2357, 1713 (C-C=O), 1650 
(N-C=O), 1555(N-C=O), 1453 (CH2), 1249, 1162, 1047 and 667 (ArH). QH (400 MHz, 
CDCh) 1.19 (3 H, t,J7.1 Hz, CH2CH3), 1.95 (9 H, s, CMe3), 3.13 (1 H, t,J6.6 Hz, SCH2), 
3.35 (2 H, t, J 6.4 Hz, SCH2), 4.04 (2 H, q, J 7.1 Hz, CH2CH3), 4.86 (3 H, m, NCH2 and 
CH), 5.72 (1 H, d, J 8.0 Hz, COCH=CH), 7.19-7.62 (6 H, m, ArH, NCH=CH). Qc (100 
MHz, CDCh) 7.1 (CH2CH3), 20.7 (CMe3), 50.0, 52.4 (CH2SCH2), 59.2 (CH2CH3), 62.1 
(CH2N), 64.9 (CMe3), 68.3 (CH), 100.5 (NCH=CH), 127.2 (ArCH), 128.0 (CH=CHCO), 
130.5 (ArCH), 143.7 (ArC), 148.3, 155.4, 161.2, 167.4, 169.9 (C=O). 
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N-Boc-S-[2-(3-BenzoyIthymin-l-yl)ethyl)-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.1 0 g, 
0.20 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O°C. Dry THF (25 cm3) was added to the reaction vessel 
followed by N-Boc-(S)-cysteine ethyl ester (0.50 g, 2.01 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 20 min before the addition of Nl-
(2-iodoethyl)-3-benzoyIthymine (3.09 g, 8.02 mmol), after which the reaction was then 
heated at reflux for 16 h. The THF was then removed under reduced pressure and the 
residue taken up in DCMlH20 (100 cm3, 1:1 v/v). The DCM layer was separated off, 
washed with H20 (20 cm\ dried (MgS04), and the solvent removed under reduced 
pressure. Purification was by column chromatography (ethyl acetatelhexane). The title 
product was formed as a yellow oil (0.61 g, 62%). Found: ~ 388.16; C24H31N307S 
requires: M+ 506.20; Cl9H20N20SS requires 388.11. m1z: 185, 127. Found: C,56.8, H,6.4, 
N,9.0%; C24H31N307S requires C,57.0, H,6.2, N,8.3%. Vmax (NaCI/cm·1) 3284 (CONH), 
2978,2930 (CH2), 1745 (C-C=O), 1698, 1657 (N-C=O), 1454 (CH2), 1367, 1251, 1175, 
668 (ArH). OH (400 MHz, CDCh) 1.19 (3 H, t, J 6.6 Hz, CH2CH3), 1.75 (9 H, s, CMe3), 
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1.81 (3 H, s, CH3), 3.26 (I H, t, J7.8 Hz, SCH2), 3.39 (2 H, t,J7.1 Hz, SCH2), 4.11 (2 H, 
q,J6.6 Hz, CH2CH3), 4.16 (2 H, t,J7.1 Hz, NCHz), 4.68 (I H, t, J8.5 Hz, CH), 5.71 (I H, 
s, C=CH), 7.24-7.95 (5 H, m, ArH). Oc (100 MHz, CDCh) 11.2 (CH2CH3), 11.7 (COCH3) 
27.3 (CMe3), 40.9, 48.3 (CH2SCH2), 54.0 (CMe3), 56.8 (CH2N), 65.9 (CH2CH3), 99.0 
(CH), 106.5 (CH2CH3), 107.6 (CCH3=CH), 135.3 (CCH3=CH), 135.7, 140.3 (ArCH), 150.1 
(ArC), 160.0, 162.6, 163.1, 163.2, 163.4 (C=O). 
N-Boc-S-[2-(6-t-Butyloxycarbonylaminopurin-9-yl)ethyl)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.10 g, 
0.20 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O·C. 25 cm3 of dry THF was added to the reaction vessel 
followed by N-Boc-cysteine ethyl ester (0.50 g, 2.01 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 10 min before the addition of 
N-Boc-S-[2-(6-t-Butyloxycarbonylaminopurin-9-yl)ethyl]-cysteine ethyl ester (3.12 g, 
8.020mmol) after which the reaction mixture was then heated at reflux for 16 h. The THF 
was then removed under reduced pressure and the residue taken up in DCMlH20 (lOO cm3, 
I: I v/v). The DCM layer was separated, washed with H20 (20 cm3), dried (MgS04)' and 
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the solvent removed under reduced pressure. Purification was by column chromatography 
(ethyl acetatelhexane). The title product was formed as a yellow oil (0.42 g,41%). Vrnax 
(NaCl/cm-1) 3419,2979 (CH2), 1738 (C=O), 1701 (C=N), 1657 (C=C), 1455, 1367 (CH2), 
1252,1175,1026,807,764,734 and 668 (ArH). OH (250 MHz, CDCh) 1.14 (3 H, t, J7.2 
Hz, CH2CH3), 1.44 and 1.47 (18 H, 2 x s, 2 x CMe3), 1.69 to 1.81 (4 H, m, CH2SCH2), 4.14 
(2 H, q, J 7.2 Hz, CH2CH3), 4.24 (3 H, dd, J 2.5, 2.9 Hz, NCH2), 6.00 (1 H, m, CH), 6.48 
(2 H, br, 2 x NH), 7.50 and 7.58 (2 H, s, ArH). 
N-Boc-S-[2-(Benzotriazol-l-yl)ethyl]-(S)-cysteine ethyl ester and 
N-Boc-S-[2-(Benzotriazol-2-yl)ethyl]-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.04 g, 
0.08 mmol, 60% in mineral oil), which was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O°c. Dry THF (25 cm3) was added to the reaction vessel 
followed by N-Boc-S-cysteine ethyl ester (0.20 g, 0.80 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 10 min before the addition of a) Nl-
(2-iodoethyl)benzotriazole (0.88 g, 3.21 mmol) and b) N2-(2-iodoethyl)benzotriazole 
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(0.88 g, 3.21 mmol), the reaction mixture was then heated at reflux for 16 h. The THF was 
then removed under reduced pressure and the residue taken up in DCMlH20 (100 cm3, 
1:1 v/v). The DCM layer was separated off, washed with H20 (20 cm\ dried (MgS04), 
and the solvent removed under reduced pressure. Purification was by column 
chromatography (ethyl acetatelhexane). The title products were formed as an: a) yellow oil 
(0.25 g, 75%). Found: MH+ 395.1750; CIsH26N404S requires: MH+ 395.1752. rnIz: 360, 
338, 294,250, 191, 176. Vrnax (NaCl/cm'l) 3444, 2915 (CH2), 2065, 1634 (C=N), 1495 
(CH2), 1393, 1247, 1162,746 and 668 (ArH). OH (400 MHz, CDCh) 1.24 (3 H, t, J7.0 Hz, 
CH2CH3), 1.60 (9 H, s, CMe3), 3.09 (2 H, br t, J 6.9 Hz, SCH2), 3.22 (2 H, t, J 6.7 Hz, 
SCH2), 4.08 (2 H, q, J 7.0 Hz, CH2CH3), 4.74 (2 H, t, J 6.9 Hz, NCH2), 4.84 (1 H, t, J 6.7 
Hz, CH), 5.23 (1 H, br, NH), 7.26 to 7.48 (3 H, m, ArH), 7.98 (1 H, m, ArH). Oc (100 
MHz, CDCI3) 12.3 (CH2CH3), 29.9 (CMe3), 33.2 and 35.2 (CH2SCH2), 54.0 (NCH2), 58.5 
(CH2CH3), 64.0 (CMe3), 111.9 (NCH), 128.6, 130.6, 131.1, 139.1 (ArCH), 142.1, 146.9 
(ArC), 170.2, 184.6 (C=O); b) yellow oil (0.25 g, 74%). Found: MH+ 395.1751; 
CIsH26N404S requires: MH+ 395.1752. rnIz: 360, 338, 294, 250, 191, 176. Vrnax 
(NaCl/cm·l) 3368, 2976 (CH2), 1717, 1688 (C=N), 1506, 1455 (CH2), 1165, 1128, 1025, 
854 and 749 (ArH). OH (400 MHz, CDCI3) 1.29 (3 H, t, J7.1 Hz, CH2CH3), 1.47 (9 H, s, 
CMe3), 3.00 (2 H, br t, J 6.9 Hz, SCH2), 3.29 (2 H, t, J 7.1 Hz, SCH2), 4.23 (2 H, q, 
J7.1 Hz, CH2CH3), 4.55 (1 H, br, CH), 4.93 (2 H, t, J6.9 Hz, NCH2), 5.44 (1 H, br, NH), 
7.40 and 7.88 (4 H, 2 x m, ArH). Oc (100 MHz, CD Ch) 14.1 (CH2CH3), 28.3 (CMe3), 32.1 
and 34.7 (CH2SCH2), 44.9 (NCH2), 55.S (CH2CH3), 61.S (CMe3), l1S.0 (NCH), 126.5, 
133.3 (ArCH), 144.4 (ArC), 177.9, 180.2 (C=O); 
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N -Boc-S-[2-(Benzotriazol-l-yl)propyl]-(S)-cysteine ethyl ester and 
N -Boc-S-[2-(Benzotriazol-2-yl)propyl]-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.04 g, 
0.08 mmol, 60% in mineral oil), this was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O·C. Dry THF (25 cm3) was added to the reaction vessel and 
followed by N-Boc-S-cysteine ethyl ester (0.20 g, 0.88 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 10 min before the addition of a) Nl-
(3-iodopropyl)benzotriazole (0.92 g, 3.21 mmol) and b) N2-(3-iodopropyl)benzotriazole 
(0.921g, 3.208mmol), the reaction mixture was then heated at reflux for 16 h. The THF 
was then removed under reduced pressure and the residue taken up in DCMlH20 (100cm3, 
1:1 v/v). The DCM layer was separated off, washed with H20 (20 cm\ dried (MgS04)' 
and the solvent removed under reduced pressure. Purification was by column 
chromatography (ethyl acetate/hexane. The title products were formed as a: a) yellow oil 
(0.20 g, 59%). Found: M+ 408.1832; CI9H28N404S requires: M+ 408.1833. rnIz: 322,250, 
214, 198, 158, 144, 130, 118. Vrnax (NaCllcm-l ) 3447, 2990 (CH2), 1636, 1556 (C=N), 
1432 (CH2), 1102, 1014, 823 and 692 (ArH). OH (400 MHz, CDCh) 1.22 (3 H, m, 
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CH2CH3), 1.43 (9 H, s, CMe3), 1.76 (2 H, br, CH2), 2.31 (2 H, t, J 7.0 Hz, SCH2), 2.74 
(2 H, t, J7.0 Hz, SCH2), 4.22 (2 H, m, CH]CH3), 4.66 (2 H, t, J7.0 Hz, NCH2), 5.23 (1 H, 
br, CH), 5.97 (1 H, br, NH), 7.31 to 7.47 (3 H, m, ArH), 8.00 (1 H, m, ArH). Oc (100 MHz, 
CDCb) 12.5 (CH3), 16.9 (CH2), 26.1 (CH), 27.8 (CMe3), 32.1 and 37.1 (CH2SCH2),42.9 
(NCH2), 59.9 (CH2CH3), 65.3 (CMe3), 129.5, 130.2 (ArCH), 131.3 (ArC), 135.4, 143.3 
(ArCH), 150.0 (ArC), 162.9, 170.0 (C=O); b) yellow oil (0.235g, 68%). Found: MH+ 
409.1913; CI9H2SN404S requires: MH+ 409.1911. mlz: 322,250,214, 184, 158, 144, 130, 
118. vrnax (NaCI/cm· l ) 3447,2987 (CH2), 1653, 1559 (C=N), 1457 (CH2), 1372, 1164, 
1112, 1031, 807 and 668 (ArH). OH (400 MHz, CDCb) 1.24 (3 H, t, J 7.1 Hz, CH2CH3), 
1.38 (9 H, s, CMe3), 1.70 (2 H, br, CH2), 2.50 (2 H, t, J 6.5 Hz, SCH2), 3.09 (2 H, t, J 6.6 
Hz, SCH2), 4.12 (2 H, q, J 7.1 Hz, CH]CH3), 4.70 (2 H, t, J 6.5 Hz, NCH2), 4.78 (1 H, br, 
CH), 5.00 (1 H, br, NH), 7.32 and 8.00 (4 H, m, ArH). Oc (100 MHz, CDCb) 12.3 (CH3), 
25.6 (CMe3), 26.5 (CH), 27.9 (CH2), 28.5 (NCH2), 31.4 (SCH2), 35.4 (CMe3), 46.2 (SCH2), 
54.1 (CH2CH3), 118.3 (ArC), 122.3 and 125.8 (ArCH), 164.8 and 177.1 (C=O). 
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N-Boc-S-[2-(Benzotriazol-l-yl)butyl]-(S)-cysteine ethyl ester and 
N-Boc-S-[2-(Benzotriazol-2-yl)butyl]-(S)-cysteine ethyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.04 g, 
0.08 mmol, 60% in mineral oil), this was washed for 5min with hexane, the hexane 
decanted, and then cooled to O·C. Dry THF (25 cm3) was added to the reaction vessel and 
followed by N-Boc-S-cysteine ethyl ester (0.20 g, 0.88 mmol) in dry THF (25 cm3). The 
reaction mixture was allowed to warm over a period of 10 min before the addition of a) N1-
(2-iodobutyl)benzotriazole (0.97 g, 3.21 mmol) and b) N2-(2-iodobutyl)benzotriazole 
(0.97 g, 3.21 mmol), the reaction mixture was then heated at reflux for 16 h. The THF was 
then removed under reduced pressure and the residue taken up in DCMlH20 (100 cm3, 1:1 
v/v). The DCM layer was separated off, washed with H20 (20 cm3), dried (MgS04), and 
the solvent removed under reduced pressure. Purification was by column chromatography 
(ethyl acetatelhexane). The title products were formed as a: a) yellow oil (0.13 g, 39%). 
Found: M+ 422.2013; C2oH30N404S requires: M+ 422.1989. mlz: 340, 214, 198, 173, 158, 
130. Vrnax (NaCl/cm-1) 3425, 2928 (CH2), 1708 (C=N), 1495 (CH2), 1367, 1280, 1165, 
1025,729 and 667 (ArH). OH (400 MHz, CDCh) 1.24 (3 H, t, J 7.2 Hz, CH2CH3), 1.43 (9 
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H, s, CMe3), 1.68 (2 H, rn, CHz), 2.17 (2 H, rn, CHz), 2.58 (2 H, t, J 7.3 Hz, SCHz), 2.92 (2 
H, t, J 4.9 Hz, SCH2), 4.18 (2 H, q, J7.2 Hz CH2CH3), 4.67 (2 H, rn, NCHl and CH), 5.34 
(1 H, br, NH), 7.37 to 7.53 (2 H, rn, ArH), 7.85 and 8.04 (2 H, rn, ArH). Dc (100 MHz, 
CDCh) 11.8 (CH3), 19.6, 20.0 (CHzCH1), 25.2 (CMeJ), 28.2 (CH), 31.2 and 35.4 
(CH1SCH1), 46.8 (NCH1), 66.3 (CH2CH3), 67.2 (CMe3), 133.4, 133.9 (ArCH), 134.1,140.7 
(ArCH), 146.7, 150.0 (ArC), 168.8, 176.5 (C=O); b) yellow oil (0.20 g, 61%). Found: 
MH+ 423.2063, CloH30N404S requires: MH+ 423.2067. m1z: 340, 214,184,173,158,130. 
vrnax (NaCl/crn'I) 3418, 2928 (CH1), 1710 (C=N), 1510 (CH1), 1321, 1157, 1066, 747 and 
624 (ArH). DH (400 MHz, CDCh) 1.23 (3 H, t,J7.1 Hz, CHzCHJ), 1.43 (9 H, s, CMe3), 
1.66 (2 H, rn, CHz), 2.21 (2 H, rn, CH1), 2.49 (2 H, t, J 7.2 Hz, SCHz), 2.58 (2 H, br, 
SCH2), 4.15 (2 H, q, J7.1 Hz, CH2CH3), 4.47 (1 H, br, CH), 4.73 (2 H, t, J 6.2 Hz, NCHz), 
5.28 (1 H, br, NH), 7.35 and 7.84 (4 H, rn, ArH). Dc (100 MHz, CDCh) 9.9 (CH3), 24.9 
(CMeJ), 27.0 and 29.1 (CH2CH2), 30.3 (CH), 31.0, 40.2 (CH2SCH1), 45.4 (NCHz), 63.2 
(CH2CH3), 70.6 (CMe3), 122.7, 126.5 (ArCH), 133.1 (ArC), 171.4, 173.6 (C=O). 
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N-Boc-S-[2-(Benzimidazol-l-yl)ethyl]-(S)-homocysteine methyl ester 
To a flame-dried RBF under a positive atmosphere of nitrogen was added NaH (0.0 I g, 
0.10 mmol, 60% in mineral oil), this was washed for 5 min with hexane, the hexane 
decanted, and then cooled to O·C. Dry THF (15 cm3) was added to the reaction vessel and 
followed by N-Boc-S-homocysteine methyl ester (0.10 g, 0.4Ommol) in dry THF (15 cm3). 
The reaction was allowed to warm over a period of 20 min before the addition of NI-(2-
iodoethyl)benzimidazole (2.18 g, 8.02 mmol), the reaction mixture was then heated at 
reflux for 16 h. THF was then removed under reduced pressure and the residue taken up in 
DCMlH20 (100cm3, 1:1 v/v). The DCM layer was separated off, washed with H20 (20 
cm3), dried (MgS04), and the solvent removed under reduced pressure. Purification was by 
column chromatography (ethyl acetate/hexane). The title product was formed as a cream 
oil (0.090 g, 57%). Found: MH+ 363.16; C19H27N304S requires: MH+ 394.16; 
(CH2), 1710 (C=N), 1496 (CH2), 1367, 1250, 1165, 1024 and 744 (ArH). OH (400 MHz, 
CDCh) 1.38 (9 H, s, CMe3), 1.89 (2 H, br, CHCH2), 2.20 (2 H, br, SCH2), 2.66 (2 H, t, 
J 7.8 Hz, SCH2), 3.69 (3 H, s, CH3), 3.85 (I H, br, CH), 4.32 (2 H, br, NCH2), 5.06 (I H, 
br, NH), 7.32 (2 H, m, ArH), 7.73 (2 H, m, ArH), 8.37 (I H, s, N=CH). 
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Deprotection Of Heterocylic Amino Acids 
N -Boc-S-[2-(benzimidazol-l-yl)ethyl)-(S)-cysteine (Ester deprotection) 
(YN~ V-\ 
8
1 BocHN eOOH 
N-Boc-S-[2-(Benzimidazol-l-yl)ethyl]-(S)-cysteine ethyl ester (0.5 g, 1.27 mmol) was 
dissolved in THF/methanol (50 cm3, 3:1 v/v) and the solution cooled in an ice bath. 
LiOH(aq) (1 M sol, 200 mol%) was then added and the mixture stirred for 8 h after it had 
warmed to room temperature. The organics were removed under reduced pressure, the 
water layer acidified by dilute HCI to pH 4 and the product extracted by EtOAc (20 cm3 
x 3). After the extracts were dried (MgS04) and the solvent removed under reduced 
pressure, the deprotected product was obtained as a white solid (0.45 g, 97%). Found: 
1711 (C=O (acid», 1514 (NC=O), 1368, 1256, 1160 (C-O), 909 (CH), 734 and 647 (ArH). 
OH (250 MHz, CDCh) 1.43 (9 H, s, CMe3), 3.04-3.08 (4 H, m, CH2SCH2,), 4.52 (1 H, br, 
CH), 4.67 (2 H, t, J7.2 Hz, NCH2), 5.64 (1 H, br, NH), 7.50-7.52 (4 H, m, ArH), 7.96 (1 
H,s,N=CH). 
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S-[2-(benzimidazol-l-yl)ethyl]-(S)-cysteine ethyl ester (Amino deprotection) 
N-Boc-S-[2-(benzimidazol-l-yl)ethyl]-(S)-cysteine ethyl ester (0.5 g, 1.27 mmol) was 
added toTFAlDCM (50 cm3, 1:1 v/v) and the mixture stirred for 2 h. DIEAlDCM (50 cm3, 
5:95 v/v) was then added to neutralise the acid. The solvents were removed under reduced 
pressure to give the Boc deprotected product run through a short silica column to give the 
free amine (0.37g, 86%). Found: MH+ 294.47; C14H19N302S requires: MH+ 294.13. Vrnax 
(NaCl/cm·l) 3415, 2981 (O-CH2-)' 2356 (NH2l, 1766 (C=O(OC2HS», 1475 (CH2), 1371 
(CH3), 1118 (C-S-C), 844 (CH), 732 and 664 (ArH). OH (250 MHz, CDCh) 1.22 (3 H, t, J 
7.1 Hz, CH2CH3), 3.07-3.09 (4 H, m, CH2SCH2,), 4.18 (2 H, q,J7.1 Hz, CH2CH3) 4.35 (1 
H, t, J 5.6 Hz, NCH), 4.66 (1 H, t, J 6.5 Hz, NCH2), 6.11 (2 H, br, NH2), 7.49-7.63 (4 H, 
m, ArH), 7.95 (1 H, s, N=CH). 
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